IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene CDKN2A Ensembl ENSG00000147889 Chromosome 9 Start 21957751 End 21984490
Description Cyclin-dependent kinase inhibitor 2A, isoform 4 (p14ARF)(p19ARF) [Source:UniProtKB/Swiss-Prot;Acc:Q8N726]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1787
     Entrez Gene : 1029
     UCSC : uc003zpk.2
     GeneCards : 1787
     RefSeq : NM_000077
     CCDS : CCDS6510.1
     Uniprot : Q8N726
     Interpro : Q8N726
     OMIM : 600160
     GeneTests : CDKN2A
     CGAP : CDKN2A
     PMID : 8152487

< Top >


Somatic Mutaions        (help)
Lung cancer Adenocarcinoma Squamous Cell Carcinoma
Unique Mutated Samples % Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
267 12.95 2062 86 15.11 569 59 20.49 288
Sample datas
Sample Name Histology Subtype DNA Mutation Protein Mutation Mutation Description Zygosity Genomic Co-ordinates NCBI36 Pubmed
1126922 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18549475
1126923 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18549475
1126933 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18549475
1126988 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18549475
1127123 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
1127124 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
1127125 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
1127126 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
1127141 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
1127142 AD c.1_471del471 p.0? Whole gene deletion Homozygous 18559592
16660 AD c.154A>T p.M52L Substitution - Missense Heterozygous 9:21961204-2196120418948947
16668 AD c.202G>A p.A68T Substitution - Missense Heterozygous 9:21961156-2196115618948947
16825 AD c.167_168delGC p.A57fs*62 Deletion - Frameshift Heterozygous 9:21961190-2196119118948947
16953 AD c.330G>C p.W110C Substitution - Missense Heterozygous 9:21961028-2196102818948947
17170 AD c.301G>T p.G101W Substitution - Missense Heterozygous 9:21961057-2196105718948947
17190 AD c.250G>C p.D84H Substitution - Missense Heterozygous 9:21961108-2196110818948947
17242 AD c.199G>A p.G67S Substitution - Missense Heterozygous 9:21961159-2196115918948947
17262 AD c.241C>T p.P81S Substitution - Missense Heterozygous 9:21961117-2196111718948947
17739 AD c.155delT p.M52fs*2 Deletion - Frameshift Heterozygous 9:21961203-2196120318948947
4 AD c.376G>T p.V126F Substitution - Missense Unknown 9:21960982-219609829120722
902315 AD c.353_357CTGAG>A p.A118fs*27 Complex - frameshift Unknown 9:21961001-2196100511920642
917704 AD c.220G>T p.D74Y Substitution - Missense Unknown 9:21961138-219611389484839
917714 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917716 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917717 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917718 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
918356 AD c.376G>T p.V126F Substitution - Missense Unknown 9:21960982-219609829120722
929890 AD c.175_176insG p.V59fs*61 Insertion - Frameshift Unknown 9:21961182-219611837882351
929891 AD c.256_257insG p.A86fs*34 Insertion - Frameshift Unknown 9:21961101-219611027882351
931377 AD c.1_457del457 p.? Unknown Homozygous 7563154
931378 AD c.1_457del457 p.? Unknown Homozygous 7563154
931379 AD c.1_457del457 p.? Unknown Homozygous 7563154
931380 AD c.1_457del457 p.? Unknown Homozygous 7563154
931381 AD c.1_457del457 p.? Unknown Homozygous 7563154
931382 AD c.1_457del457 p.? Unknown Homozygous 7563154
931383 AD c.1_457del457 p.? Unknown Homozygous 7563154
931384 AD c.1_457del457 p.? Unknown Homozygous 7563154
931385 AD c.1_457del457 p.? Unknown Homozygous 7563154
931386 AD c.1_457del457 p.? Unknown Homozygous 7563154
933278 AD c.?_?del? p.? Unknown Homozygous 10557071
933279 AD c.?_?del? p.? Unknown Homozygous 10557071
933280 AD c.?_?del? p.? Unknown Homozygous 10557071
933281 AD c.? p.D116Y Substitution - Missense Homozygous 10557071
933292 AD c.?_?del? p.? Unknown Homozygous 10557071
933293 AD c.?_?del? p.? Unknown Homozygous 10557071
933294 AD c.?_?del? p.? Unknown Homozygous 10557071
933295 AD c.?_?del? p.? Unknown Homozygous 10557071
A2/82 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9673367
A2182 AD c.1_471del471 p.0? Whole gene deletion Homozygous 7882351
A427 AD c.1_457del457 p.? Unknown Homozygous 9624535
A427 AD c.1_471del471 p.0? Whole gene deletion Homozygous 7882351
A427 AD c.1_471del471 p.0? Whole gene deletion Homozygous 8521414
A549 AD c.1_457del457 p.? Unknown Homozygous 9624535
A549 AD c.1_471del471 p.0? Whole gene deletion Homozygous 7882351
A549 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9673367
Ad1 AD c.250G>A p.D84N Substitution - Missense Unknown 9:21961108-219611088060323
Ad12 AD c.359A>C p.E120A Substitution - Missense Unknown 9:21960999-219609998060323
Ad20 AD c.358G>A p.E120K Substitution - Missense Unknown 9:21961000-219610008060323
Ad22 AD c.394G>C p.A132P Substitution - Missense Unknown 9:21960964-219609648060323
Ad24 AD c.284T>C p.V95A Substitution - Missense Unknown 9:21961074-219610748060323
Ad27 AD c.424C>T p.H142Y Substitution - Missense Unknown 9:21960934-219609348060323
Ad28 AD c.277A>G p.T93A Substitution - Missense Unknown 9:21961081-219610818060323
Ad29 AD c.296G>A p.R99Q Substitution - Missense Unknown 9:21961062-219610628060323
Ad5 AD c.401C>T p.A134V Substitution - Missense Unknown 9:21960957-219609578060323
Ad8 AD c.250G>C p.D84H Substitution - Missense Unknown 9:21961108-219611088060323
Calu-3 AD c.247C>T p.H83Y Substitution - Missense Unknown 9:21961111-219611118521414
HOP-62 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-2196482617088437
LC-2-ad AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
LCMS AD c.?_?del? p.?del Deletion - In frame Homozygous 9624535
LCT-5 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9673367
LXF-289 AD c.216C>A p.C72* Substitution - Nonsense Homozygous 9:21961142-21961142 
Ma-1 AD c.200G>T p.G67V Substitution - Missense Homozygous 9:21961158-219611589624535
Ma-17 AD c.1_457del457 p.? Unknown Homozygous 9624535
Ma-24 AD c.1_457del457 p.? Unknown Homozygous 9624535
Ma-29 AD c.(258_261)del1 p.R87fs Deletion - Frameshift Homozygous 9624535
Ma-3 AD c.172C>T p.R58* Substitution - Nonsense Homozygous 9:21961186-219611869624535
NCI-H1563 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
NCI-H1648 AD c.1_457del457 p.? Unknown Homozygous 7563154
NCI-H1651 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
NCI-H1755 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
NCI-H1793 AD c.1_457del457 p.? Unknown Homozygous  
NCI-H1975 AD c.205G>T p.E69* Substitution - Nonsense Homozygous 9:21961153-21961153 
NCI-H2122 AD c.1_150del150 p.? Unknown Homozygous  
NCI-H322 AD c.1_457del457 p.? Unknown Homozygous 9624535
PC-3 AD c.1_457del457 p.? Unknown Homozygous 9624535
PC-3 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9673367
PC-9 AD c.200G>T p.G67V Substitution - Missense Homozygous 9:21961158-219611589624535
RERF-LC-OK AD c.1_457del457 p.? Unknown Homozygous 9624535
S48299 AD c.205G>T p.E69* Substitution - Nonsense Unknown 9:21961153-219611539816274
SK-LU-1 AD c.1_471del471 p.0? Whole gene deletion Homozygous 7882351
SK-LU-1 AD c.1_471del471 p.0? Whole gene deletion Homozygous 8521414
SK-LU-1 AD c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
VMRC-LCD AD c.1_457del457 p.? Unknown Homozygous 9624535
110 SCC c.249_250insTT p.D84fs*63 Insertion - Frameshift Unknown 9:21961108-219611099120722
1126971 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 18549475
262 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9120722
44 SCC c.251A>T p.D84V Substitution - Missense Unknown 9:21961107-219611079120722
51 SCC c.358G>A p.E120K Substitution - Missense Unknown 9:21961000-219610009120722
912853 SCC c.? p.? Unknown Unknown 11820618
917722 SCC c.65G>C p.R22P Substitution - Missense Unknown 9:21964762-219647629484839
917725 SCC c.248A>G p.H83R Substitution - Missense Unknown 9:21961110-219611109484839
917728 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917730 SCC c.170C>T p.A57V Substitution - Missense Unknown 9:21961188-219611889484839
917731 SCC c.313delG p.D105fs*41 Deletion - Frameshift Unknown 9:21961045-219610459484839
917732 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917734 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917735 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
917736 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9484839
918298 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918299 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918300 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918301 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918302 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918303 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8988029
918358 SCC c.251A>T p.D84V Substitution - Missense Unknown 9:21961107-219611079120722
918360 SCC c.358G>A p.E120K Substitution - Missense Unknown 9:21961000-219610009120722
918362 SCC c.249_250insTT p.D84fs*63 Insertion - Frameshift Unknown 9:21961108-219611099120722
918366 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9120722
922293 SCC c.151-1G>T p.? Unknown Unknown 9:21961208-219612088631583
922294 SCC c.172C>T p.R58* Substitution - Nonsense Unknown 9:21961186-219611868631583
922296 SCC c.262G>T p.E88* Substitution - Nonsense Unknown 9:21961096-219610968631583
922297 SCC c.307_308CG>A p.R103fs*43 Complex - frameshift Unknown 9:21961050-219610518631583
922298 SCC c.322G>T p.D108Y Substitution - Missense Unknown 9:21961036-219610368631583
925960 SCC c.57delC p.A20fs*6 Deletion - Frameshift Unknown 9:21964770-219647707591275
929393 SCC c.247C>A p.H83N Substitution - Missense Unknown 9:21961111-219611117606711
929394 SCC c.238C>T p.R80* Substitution - Nonsense Unknown 9:21961120-219611207606711
933273 SCC c.?_?del? p.? Unknown Homozygous 10557071
933274 SCC c.?_?del? p.? Unknown Homozygous 10557071
933275 SCC c.?_?del? p.? Unknown Homozygous 10557071
933276 SCC c.?_?del? p.? Unknown Homozygous 10557071
933277 SCC c.?_?del? p.? Unknown Homozygous 10557071
933296 SCC c.243_249delCGTGCAC p.V82fs*62 Deletion - Frameshift Homozygous 9:21961109-2196111510557071
KNS-62 SCC c.457+1G>A p.? Unknown Homozygous 9:21960900-21960900 
LC-1-sq SCC c.1_457del457 p.? Unknown Homozygous 9624535
LC-1-sq SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9673367
LC-1F SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
NCI-H125 SCC c.1_457del457 p.? Unknown Homozygous 7563154
NCI-H157 SCC c.205G>T p.E69* Substitution - Nonsense Homozygous 9:21961153-21961153 
NCI-H157 SCC c.205G>T p.E69* Substitution - Nonsense Homozygous 9:21961153-219611539624535
NCI-H157 SCC c.206A>T p.E69V Substitution - Missense Unknown 9:21961152-219611527882351
NCI-H226 SCC c.1_150del150 p.? Unknown Homozygous 7563154
NCI-H226 SCC c.1_150del150 p.? Unknown Homozygous 17088437
NCI-H520 SCC c.134delG p.G45fs*8 Deletion - Frameshift Homozygous 9:21964693-21964693 
NCI-H520 SCC c.?del? p.?fs Deletion - Frameshift Unknown 8521414
NCI-H520 SCC c.?del? p.?fs Deletion - Frameshift Unknown 9624535
S48310 SCC c.?_?del? p.?fs Deletion - Frameshift Unknown 9816274
SCC16 SCC c.166_167delAG p.S56fs*63 Deletion - Frameshift Unknown 9:21961191-219611928060323
SCC2 SCC c.363delG p.G122fs*24 Deletion - Frameshift Unknown 9:21960995-219609958060323
SCC20 SCC c.183_185delGCT p.L62del Deletion - In frame Unknown 9:21961173-219611758060323
SCC27 SCC c.274delG p.D92fs*54 Deletion - Frameshift Unknown 9:21961084-219610848060323
SCC33 SCC c.449G>T p.G150V Substitution - Missense Unknown 9:21960909-219609098060323
SCC5 SCC c.196C>T p.H66Y Substitution - Missense Unknown 9:21961162-219611628060323
SCC7 SCC c.363delG p.G122fs*24 Deletion - Frameshift Unknown 9:21960995-219609958060323
SCC8 SCC c.250G>T p.D84Y Substitution - Missense Unknown 9:21961108-219611088060323
SCC9 SCC c.358G>A p.E120K Substitution - Missense Unknown 9:21961000-219610008060323
SK-MES-1 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8521414
SK-MES-1 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 9:21958228-21964826 
SW1271 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 7882351
SW900 SCC c.1_471del471 p.0? Whole gene deletion Homozygous 8521414

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
down 25/101(25%) IHC- 9731504 Cancer Res. 1998 Sep 1;58(17):3926-31.
up 57/106(54%) IHCKaplanMeier survival curves(P=0.0016) 11679179 Lung Cancer. 2001 Nov;34(2):207-18.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1713_s_at  0.91  3.07e-3  8.42e-3  1.74  3.59e-4  1.24e-3
 HG_U133A  207039_at  0.76  6.43e-8  1.87e-7  2.13  6.98e-59  1.85e-58
 HG_U133A  209644_x_at  1.20  2.22e-16  1.33e-15  3.18  1.05e-58  2.77e-58
 HG_U133A  211156_at  0.13  2.40e-1  2.89e-1  4.55  2.54e-105  1.99e-104
 HG_U133_Plus2  207039_at  1.42  1.83e-9  1.23e-8  1.72  2.78e-6  7.69e-6
 HG_U133_Plus2  209644_x_at  1.46  3.99e-14  4.87e-13  2.37  3.68e-22  6.56e-21
 HG_U133_Plus2  211156_at  0.10  4.76e-1  5.64e-1  0.57  4.73e-4  9.59e-4
 Stanford  8109  0.73  1.75e-1  3.58e-1  -0.33  3.59e-1  5.97e-1
 Agilent_HS_21.6K  4468  0.29  1.99e-3  1.32e-2  0.35  3.12e-4  2.06e-3
 Agilent_HS_21.6K  6538  -0.02  7.77e-1  8.73e-1  0.00  9.50e-1  9.72e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  207039_at  0.66  1.27e-1  7.93e-1  0.36  4.21e-1  1.00e+0
 HG_U133A  209644_x_at  0.70  9.16e-2  7.65e-1  -0.11  8.29e-1  1.00e+0
 HG_U133A  211156_at  -0.32  4.12e-1  9.06e-1  -0.17  5.04e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1713_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 207039_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 209644_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211156_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 207039_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 209644_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211156_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 8109    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 4468    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 6538    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
p16 low grade dysplasia In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. 15328914 Human
p16 low grade dysplasia CDC6 may be a biomarker of high grade and invasive lesions of the cervix, with limited use in low grade dysplasia. p16(INK4A) was the most reliable marker of cervical dysplasia. 15858126 Human
p16 serrated adenomas In this study, 46 serrated adenomas from 39 patients, 32 conventional (nonserrated) adenomas from 31 patients, and 18 hyperplastic polyps from 16 patients were evaluated for loss of heterozygosity (LOH) of APC, p53, p16, and 3p and for K-ras mutations of 11823977 Human
p16 hyperplastic polyps In this study, 46 serrated adenomas from 39 patients, 32 conventional (nonserrated) adenomas from 31 patients, and 18 hyperplastic polyps from 16 patients were evaluated for loss of heterozygosity (LOH) of APC, p53, p16, and 3p and for K-ras mutations of 11823977 Human
cdkn2 tumor Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
mts1 tumor Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
ink4a tumor Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
p16 tumor Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
cdkn2a skin cancer Both of these genes have been identified as risk factors in skin cancer, MC1R variants are associated with increased risk to both melanoma and nonmelanoma skin cancers, and p16/CDKN2A with increased risk of melanoma. 11830546 Human
p16 skin cancer Both of these genes have been identified as risk factors in skin cancer, MC1R variants are associated with increased risk to both melanoma and nonmelanoma skin cancers, and p16/CDKN2A with increased risk of melanoma. 11830546 Human
p16 skin cancer This link between p16 and MC1R may provide a molecular basis for the increased skin cancer risk associated with MC1R polymorphisms. 11830546 Human
p16 polyposis Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo 11839573 Human
p16 serrated adenomas Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo 11839573 Human
p16 tubular adenomas Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo 11839573 Human
p16 idiopathic myelofibrosis Hypermethylation of p15 and p16 genes was determined in 32 patients with agnogenic myeloid metaplasia(AMM), also known as idiopathic myelofibrosis (MF). 11849214 Human
p16 mycosis fungoides and sezary syndrome Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. 11874489 Human
p16 mycosis fungoides and sezary syndrome This study suggests that abnormalities of the P15 and P16 genes are common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these genes may be inactivated by allelic loss and aberrant promoter methylation. 11874489 Human
p14arf benign melanocytic nevi P14ARF expression was investigated by immunohistochemical staining of 32 tissue samples of benign melanocytic nevi (n=14), melanomas (n=12) and melanoma metastases (n=6). 11876522 Human
p14arf benign melanocytic nevi In summary, we demonstrated a significant inverse correlation between p14ARF protein expression and progression of melanocytic tumors since the amount of p14ARF protein staining decreased from benign melanocytic nevi to metastatic melanoma in situ. 11876522 Human
arf tumor angiogenesis The latter finding raises the possibility that Arf may function as a tumor suppressor at least in part by regulating tumor angiogenesis. 11891301 Mouse
p16 colorectal adenocarcinomas In this study, seven components of cell-cycle control [cyclin D1, retinoblastoma (pRb), p21, p27, p16, p53, and proliferating cell nuclear antigen (PCNA)] were examined in a large series of well-characterized colorectal adenocarcinomas using immunohistoch 11920733 Human
p16 differentiated carcinomas The P16 positive rate was negatively correlated with the degree of tumor histological differentiation, and the rate difference between the high differentiated carcinomas was significant (P < 0.05). 11930651 Human
p16 epithelial-myoepithelial carcinoma Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 carcinoma ex-pleomorphic adenoma (cepa) Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 adenoid-cystic carcinoma (acc) Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 malignant myoepithelioma Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 pancreatic intraepithelial neoplasia Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. 12000709 Human
p16 hyperplastic polyps METHODS: Thirty-nine hyperplastic polyps from 26 CUC patients, 39 sporadic hyperplastic polyps from 29 age- and sex-matched patients without CUC, and 26 colonic mucosal biopsies from 22 patients with CUC but without hyperplastic polyps were analyzed by po 12014733 Human
p16 hyperplastic polyps Loss of heterozygosity of APC, 3p, p53, p16, and K-ras mutations were present in 21%, 40%, 27%, 20%, and 19% of CUC patients with hyperplastic polyps, respectively, and in 0%, 11%, 20%, 13%, and 13% of non-CUC patients with sporadic polyps, respectively. 12014733 Human
p16 b-cell acute lymphoblastic leukaemia We examined deletion and methylation of the p15INK4B (p15) and p16INK4A (p16) genes, using Southern blotting and methylation-specific polymerase chain reaction (PCR), in 70 untreated adult patients with precursor B-cell acute lymphoblastic leukaemia (PBC- 12028019 Human
ink4 relapsed childhood all These findings argue against an independent prognostic role of INK4 deletions in relapsed childhood ALL. 12036898 Human
p16 primary cutaneous b-cell lymphomas We analyzed DNA from 36 cases of primary cutaneous B cell lymphomas, four systemic B cell lymphomas, and six benign B cell lymphoproliferative infiltrates for abnormalities of p15 and p16 using microsatellite markers for 9p21, methylation specific polymer 12060387 Human
p16 primary cutaneous b-cell lymphomas In primary cutaneous B cell lymphomas with allelic loss or promotor hypermethylation of either p15 or p16, loss of expression in tumor cells was identified in 5 of 8 and 9 of 10 cases, respectively. 12060387 Human
cdkn2a yolk-sac tumor Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
p16 yolk-sac tumor Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
arf colon tumors A PCR-based analysis of ARF and p53 cDNAs in normal colon tissues and AOM-induced colon tumors failed to detect mutations in either of these two critical tumor suppressor genes. 12097273 Human
arf colon tumors A marked increase in ARF mRNA and protein levels was observed in colon tumors, indicating activation of the ARF-p53 pathway in these tumors. 12097273 Human
p16 differentiated cancer We report the establishment of a novel AVC cell line (AVC1) derived from a moderately differentiated cancer, having a mutated K- ras, wild-type p53, and methylated p16. 14677066 Human
p16 serous carcinoma In serous carcinoma, p53 mutation is the most frequent genetic alteration, followed by inactivation of p16 and e-cadherin and amplification of her2/neu. p53 mutation occurs in endometrial intraepithelial carcinoma, the putative precursor of serous carcino 14747944 Human
p16 pancreatoblastoma Although the cytomorphologic features alone were not specific, the presence of a markedly elevated serum lipase level, cutaneous lesions of fat necrosis, and loss of heterozygosity at 1p, 5q25 at the APC locus, 9p21 at the p16 locus, and 17p13 at the p53 12112815 Human
p16 endometrial polyps Cytological atypia in endometrial polyps and immunostaining for p16, p53 and Ki67. 12121245 Human
p16 superficial bladder cancers To study whether specific or bulk hypermethylation predicts intrabladder recurrence, we determined the frequency of aberrant promoter hypermethylation of seven genes, hMLH1, O(6)-methylguanine-DNA-methyltransferase (MGMT), p16, Von Hippel-Lindau (VHL), de 12124340 Human
p16 acute lymphoblastic leukemia Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. 12127556 Human
p16 spindle cell neoplasms Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. 12152785 Human
p16 metastatic human prostate cancer Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. 12169393 Human
p16 multiple myeloma These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re 12199782 Human
p16 tumour These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re 12199782 Human
p16 eccrine porocarcinoma Aberrant expression of p16 and RB protein in eccrine porocarcinoma. 12207741 Human
p16 eccrine porocarcinoma Furthermore, one case of eccrine porocarcinoma was analyzed for p16 gene mutation. 12207741 Human
p16 eccrine porocarcinoma Conversely, one case of eccrine porocarcinoma did not show immunoreactivity for p16 protein, whereas RB protein was positive in the scattered nuclei. 12207741 Human
p16 eccrine porocarcinoma No p16 gene mutation was detected in the investigated eccrine porocarcinoma case. 12207741 Human
p16 eccrine porocarcinoma CONCLUSIONS: These results indicate that detectable p16 protein and loss of RB protein are common occurrences in eccrine porocarcinoma lesions. 12207741 Human
p16 eccrine porocarcinoma Moreover, overexpression of p16 protein may be an additional, simple and useful diagnostic marker for eccrine porocarcinoma on routine laboratory screening. 12207741 Human
arf oral cancer These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation. 12234999 Human
ink4a oral cancer These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation. 12234999 Human
p16 cervical squamous cell carcinomas The cyclin-dependent kinase inhibitor p16(ink4) is expressed in cervical squamous cell carcinomas, their precursors, and cervical ACs, and there is a strong relationship between p16 expression and the presence of human papillomavirus (HPV)-encoded E6/E7 t 12378514 Human
p16 glandular neoplasms The diffuse distribution of p16 immunostaining in HPV16/18-positive glandular neoplasms supports a strong association with HPV infection and indicates that this biomarker may discriminate ACIS from its benign mimics. 12378514 Human
ink4a childhood cancer The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer. 12368906 Human
arf childhood cancer The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer. 12368906 Human
p16 squamous cell carcinoma in situ We hypothesized that there may be an appreciable difference in expression of p16 between normal skin, actinic keratoses, squamous cell carcinoma in situ, and invasive squamous cell carcinoma. 12429789 Human
p16 lymphoid leukemia To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. 12228235 Human
cdkn2a lymphoid leukemia To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. 12228235 Human
p16 head and neck squamous cell carcinoma Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression appears to be an independent prognostic factor, although loss of p16 protein may be used to predict overall patient survival in early-stage head and neck squamous cell carci 13679459 Human
p16 nodular melanomas Overall, 52 (48%) tumours expressed p16; nodular melanomas had significantly lower levels of p16 immunoreactivity than superficial spreading melanomas (P = 0.015). 12459643 Human
arf pituitary tumor ARF mutation accelerates pituitary tumor development in Rb+/- mice. 12486224 Mouse
p14arf intestinal-type cancers Whereas p14ARF methylation was found more frequently in intestinal type cancers in an early stage and in diffuse type cancers in an advanced stage, MSI tended to be related especially to p14ARF methylation in cancers of the intestinal type. 12608655 Human
cdkn2a plasma cell tumors Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. 11113205 Mouse
p14arf plexiform neurofibroma We have determined the methylation status of the CpG island of 11 tumour-related genes (RB1, p14ARF, p16INK4a, p73, TIMP-3, MGMT, DAPK, THBS1, caspase 8, TP53 and GSTP1) in 18 neurofibromas (including one plexiform neurofibroma) and three neurofibrosarcom 12883734 Human
ink4a marginal-zone lymphomas (mzl) Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. 11166833 Human
p16 bladder carcinomas Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. 11223676 Human
p16 acute promyelocytic leukemia Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. 11283136 Human
p16 therapy-related myelodysplastic syndrome During follow-up, p16 methylation was acquired in two patients, one during the third hematologic relapse, and the other during transformation into therapy-related myelodysplastic syndrome. 11283136 Human
ink4a mouse lymphomas The BMI-1 gene is a putative oncogene belonging to the Polycomb group family that cooperates with c-myc in the generation of mouse lymphomas and seems to participate in cell cycle regulation and senescence by acting as a transcriptional repressor of the I 11289106 Human
arf mouse lymphomas The BMI-1 gene is a putative oncogene belonging to the Polycomb group family that cooperates with c-myc in the generation of mouse lymphomas and seems to participate in cell cycle regulation and senescence by acting as a transcriptional repressor of the I 11289106 Human
p14arf endometrial neoplasms We also studied the profile of p14ARF promoter hypermethylation in an extensive collection of 559 human primary tumors of different cell types, observing that in colorectal, gastric, renal, esophageal, and endometrial neoplasms and gliomas, aberrant methy 11306450 Human
p16 metaplasia DAP-kinase was methylated at a similar frequency in all four stages, whereas hMLH1 and p16 were methylated in cancer samples (20.3% and 42.2%, respectively) more frequently than in intestinal metaplasia (6.3% and 2.1%, respectively) or adenomas (9.8% and 11306456 Human
p16 metaplasia The hMLH1, THBS1, and TIMP-3 hypermethylation frequencies were similar in both intestinal metaplasia and adenomas, but the p16 hypermethylation frequency tended to be higher in adenomas (11.5%) than in intestinal metaplasia (2.1%; P = 0.073). 11306456 Human
p14arf anaplasia In one tumor containing distinct areas with and without anaplasia, p14ARF hypermethylation was detected in the WHO grade II area, while homozygous co-deletion of p14ARF and p16INK4a was found in the region with anaplastic features (grade III). 11307615 Human
p14arf peritumoral vessel invasion The analysis of concomitant P14ARF and TP73 overexpression and clinicopathologic parameters of the tumors showed a statistically significant difference with respect to peritumoral vessel invasion (P = 0.01), lymph node metastasis (P = 0.03), negative ERBB 11319797 Human
cdkn2a melanoma in situ Among many gene alterations detected in human melanoma, defect of CDKN2A located at chromosome 9p21 seems to be most important in the earlier developmental phase, though significance of this gene in the evolution of melanoma in situ has not been confirmed 11323215 Human
ink4a enchondroma The correlation between INK4A/p16 protein expression and tumour grade, and the retention of expression in enchondromas, indicates that loss of INK4A/p16 protein expression may be an important event during tumour progression from enchondroma to conventiona 14991902 Human
p16 enchondroma The correlation between INK4A/p16 protein expression and tumour grade, and the retention of expression in enchondromas, indicates that loss of INK4A/p16 protein expression may be an important event during tumour progression from enchondroma to conventiona 14991902 Human
ink4a b16 melanoma In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. 14743208 Human
arf b16 melanoma In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. 14743208 Human
cdkn2 mesenchymal tumors We previously demonstrated that approximately one-half of soft-tissue sarcomas were devoid of either pRB, the product of the retinoblastoma gene, or 16, the product of the MTS1/CDKN2 gene, while a smaller subset of aggressive mesenchymal tumors without me 11341347 Human
mts1 mesenchymal tumors We previously demonstrated that approximately one-half of soft-tissue sarcomas were devoid of either pRB, the product of the retinoblastoma gene, or 16, the product of the MTS1/CDKN2 gene, while a smaller subset of aggressive mesenchymal tumors without me 11341347 Human
p14arf burkitt lymphoma p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. 11360201 Human
ink4a polycythemia vera Increased expression of the INK4a/ARF locus in polycythemia vera. 11369633 Human
arf polycythemia vera Increased expression of the INK4a/ARF locus in polycythemia vera. 11369633 Human
ink4a primary carcinomas Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. 11369056 Human
ink4a neurofibromatosis SUMMARY: Karyotypic complexities associated with frequent loss or rearrangement of a number of chromosome arms, deletions, and mutations affecting the TP53 region, and molecular alterations of the INK4A gene have been reported in sporadic and/or neurofibr 11406645 Human
p16 condylomas Limitations in specificity included minimal or no suprabasal staining for Ki-67 in immature condylomas and occasional suprabasal staining of reactive epithelial changes (10%), diffuse weak nuclear cyclin E staining in some normal or metaplastic epithelia, 11420459 Human
cdkn2a neurofibroma CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. 11433531 Human
ink4a leukaemia Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. 15029199 Human
cdkn2a leukaemia Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. 15029199 Human
arf leukaemia Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. 15029199 Human
p16 endometrial adenocarcinomas Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. 15043304 Human
p16 endometrial adenocarcinomas Most endocervical adenocarcinomas (ECAs) contain high-risk human papillomavirus (HPV) DNA, whereas endometrial adenocarcinomas (EMAs) rarely do. p16 is an inhibitor ofcyclin-dependent kinases, and overexpression of p16 has been observed in cervical intrae 15043304 Human
p16 insulinomas RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
cdkn2a insulinomas RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
p14 insulinomas RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
p16 pancreatic tumors RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
cdkn2a pancreatic tumors RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
p14 pancreatic tumors RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) 11479232 Human
cdkn2a atypical meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
cdkn2a benign meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
cdkn2a atypical meningioma Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14(ARF), and CDKN2B genes. 11485924 Human
cdkn2a benign meningioma One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. 11485924 Human
cdkn2a atypical meningiomas One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. 11485924 Human
p16 angiosarcoma of the liver This study was performed to determine whether alterations of p16 are involved in the development of angiosarcoma of the liver. 11495043 Human
mts1 mammary adenocarcinoma A composite enhancer that is active in murine mammary adenocarcinoma cells was previously identified in the first intron of the mts1/S100A4 gene. 11504871 Mouse
ink4a malignant pleural mesothelioma Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. 11507034 Human
arf malignant pleural mesothelioma Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. 11507034 Human
ink4a melanocytic nevi Here we evaluate 21 melanocytic lesions at various stages of malignant progression from common melanocytic nevi to metastatic melanomas and examine these lesions for Id1 and p16/Ink4a expression. 11507043 Human
p16 melanocytic nevi Here we evaluate 21 melanocytic lesions at various stages of malignant progression from common melanocytic nevi to metastatic melanomas and examine these lesions for Id1 and p16/Ink4a expression. 11507043 Human
ink4a melanoma in situ We demonstrate that Id1 expression correlates with loss of p16/Ink4a expression in melanoma in situ; however, more advanced stages of melanoma do not express Id1 except within perivascular regions, despite overall decreased p16/Ink4a expression in these l 11507043 Human
p16 melanoma in situ We demonstrate that Id1 expression correlates with loss of p16/Ink4a expression in melanoma in situ; however, more advanced stages of melanoma do not express Id1 except within perivascular regions, despite overall decreased p16/Ink4a expression in these l 11507043 Human
p16 metastatic bladder cancers DESIGN: The authors examined the pattern of allelic loss with polymorphic microsatellite markers on chromosome 9p21 (D9S161, D9S171, IFNA), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 locus, in matched primary an 11520271 Human
p16 metastatic carcinoma CONCLUSIONS: The pattern of allelic loss at chromosome 9p21 (p16) and 17p13 (p53) was generally maintained during cancer progression to metastasis, and identical allelic loss in primary cancer was conserved in paired metastatic carcinoma. 11520271 Human
ink4a melanoma CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. 11544530 Human
ink4a melanoma However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. 11544530 Mouse
arf melanoma However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. 11544530 Mouse
p 16 bone metastasis The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. 15015656 Human
cdkn2a bone metastasis The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. 15015656 Human
p 16 intracranial tumor The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. 15015656 Human
cdkn2a intracranial tumor The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. 15015656 Human
p16 breast adenocarcinomas ErbB2 was also a deciding factor in deregulation of cyclin D1-cdk4/6 in human tumors because no loss of pRb or p16 was found in tumors overexpressing erbB2, although erbB2-negative invasive breast adenocarcinomas frequently lacked expression of p16 or pRb 14982856 Human
p16 gallbladder adenomas STUDY DESIGN: Twenty-four gallbladder carcinomas, 20 gallbladder adenomas, and 18 chronic cholecystitis specimens were immunohistochemically and histopathologically investigated for the relation of p53, p16, and VEGF to Nevin staging and pathologic gradin 11584965 Human
p16 blastic nk-cell lymphoma In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. 11676855 Human
p14 blastic nk-cell lymphoma In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. 11676855 Human
ink4a primary central-nervous-system lymphoma Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. 11804283 Human
arf primary central-nervous-system lymphoma Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. 11804283 Human
p16 anaplastic tumors 7/26 (27%) benign, 3/12 (25%) atypical but 4/7 (57%) anaplastic tumors lacked both, p16 and p15 protein expression. 11859969 Human
p16 waldenstrom macroglobulinemia MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma 11920239 Human
p16 waldenstrom macroglobulinemia RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s 11920239 Human
p16 undifferentiated carcinoma The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 11819820 Human
p16 signet-ring-cell carcinoma The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 11819820 Human
p16 endometrial carcinomas Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. 10656444 Human
p16 endometrial carcinoma We therefore wanted to assess the pattern and prognostic impact of p16 protein expression and promoter region methylation in a population-based series of 316 endometrial carcinoma patients with long-term and complete follow-up. 10656444 Human
p16 intratumor microvessel density Loss of nuclear p16 staining was significantly associated with increased age, high FIGO (International Federation of Gynecology and Obstetrics) stage, serous papillary or clear cell histological types, high histological grade, aneuploidy, low estradiol an 10656444 Human
p16ink4 colorectal tumors Loss of p16INK4 tumor suppressor function in colorectal tumors was associated with proximal location in the gut. 12963980 Human
p14arf pediatric solid tumors Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. 12963998 Human
p16 polypoid adenomas We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dyspl 15064707 Human
ink4a parathyroid adenomas The aim of the present study was to evaluate the alterations in the components of the pRB pathway in parathyroid adenomas and parathyroid aggressive tumors, including patterns of expression of pRB, Cyc D1, and p16/INK4A. 10671696 Human
p16 parathyroid adenomas The aim of the present study was to evaluate the alterations in the components of the pRB pathway in parathyroid adenomas and parathyroid aggressive tumors, including patterns of expression of pRB, Cyc D1, and p16/INK4A. 10671696 Human
cdkn2 uterine cervical cancer Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines. 10675486 Human
p16 uterine cervical cancer Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines. 10675486 Human
p16 high-grade lymphoma With time, a fraction of follicular lymphoma accumulates mutations of p53 and of p16 and evolves into a high grade lymphoma. 10681729 Human
cdkn2a plasmacytoma In contrast, mutations of the murine CDKN2A gene predispose BALB/c mice to pristane-induced plasmacytoma. 10688850 Mouse
p16 acral-lentiginous melanoma An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. 10657449 Human
p16 acral-lentiginous melanomas These data suggest that p16 inactivation may play an important role in the development and progression of acral lentiginous melanomas. 10657449 Human
p16 mouse lymphomas Previously, we have reported frequent inactivation of the Cdkn2a/Cdkn2b loci encoding p16/p15 cyclin dependent kinase inhibitors in a subset of 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas (S.-M. Zhuang, A. Schippert, A. Hau 10773403 Mouse
cdkn2a mouse lymphomas Previously, we have reported frequent inactivation of the Cdkn2a/Cdkn2b loci encoding p16/p15 cyclin dependent kinase inhibitors in a subset of 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas (S.-M. Zhuang, A. Schippert, A. Hau 10773403 Mouse
p16 tubular adenomas We found that abnormal expression of p16 and p27 increased with the progression of tubular adenomas to advanced gastric cancers. 10779641 Human
ink4a germ-cell tumors Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. 10786670 Human
arf germ-cell tumors Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. 10786670 Human
ink4a nongerminomatous germ-cell tumors To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. 10786670 Human
arf nongerminomatous germ-cell tumors To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. 10786670 Human
ink4a germinoma These data suggested that INK4a/ARF gene abnormalities could play an important role in the genesis of ICGTs, especially in pure germinoma. 10786670 Human
arf germinoma These data suggested that INK4a/ARF gene abnormalities could play an important role in the genesis of ICGTs, especially in pure germinoma. 10786670 Human
ink4a high-grade lymphomas Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 10793069 Human
p16 high-grade lymphomas Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 10793069 Human
cyclin-dependent kinase inhibitor p16 high-grade lymphomas Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 10793069 Human
p14arf brain metastases Thus, in addition to these two genes, we determined the methylation status of the genes p16INK4a, glutathione S-transferase P1 (GSTP1), O6-methylguanine DNA methyltransferase (MGMT), thrombospondin-1 (THBS1), p14ARF, TP53, p73, and tissue inhibitor of met 14654977 Human
ink4a primary breast cancer INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. 10914724 Human
p16 marginal zone b-cell lymphoma Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study. 10913669 Human
p16 colorectal adenocarcinomas Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. 10919023 Human
ink4 colorectal adenocarcinomas Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. 10919023 Human
p16 colorectal adenocarcinomas CONCLUSIONS: pTS expression regulation in human gastric and colorectal adenocarcinomas in complex, and upregulated by p16/INK4. 10919023 Human
ink4 colorectal adenocarcinomas CONCLUSIONS: pTS expression regulation in human gastric and colorectal adenocarcinomas in complex, and upregulated by p16/INK4. 10919023 Human
cdkn2a tumor Taken together, our data indicate that mutations of the PTEN and TP53 tumor suppressor genes, homozygous deletion of the CDKN2A gene as well as overexpression of the EGFR, p53 and Mdm2 proteins lack prognostic significance for overall survival time in pat 11083071 Human
p16 squamous-cell lung carcinoma By increasing the sensitivity of a PCR approach to detect methylated DNA sequences, we now demonstrate that aberrant methylation of the p16 and/or O6-methyl-guanine-DNA methyltransferase promoters can be detected in DNA from sputum in 100% of patients wit 11085511 Human
p16 primary cutaneous large-cell lymphoma Here, we provide the first evidence of the involvement of the tumor suppressor gene p16 in primary cutaneous large cell lymphoma. 11121148 Human
cdkn2a regional cancer We screened 80 individuals with at least two primary cutaneous melanomas, who were identified mainly by a search of a regional cancer registry, for germ-line CDKN2A mutations. 11156381 Human
p16 mature teratoma Total resection was performed, and histogenetical findings led to the diagnosis of a mature teratoma with normal p16 gene, whereas analysis of intracranial tumor showed p16 deletion. 11155064 Human
p16 intracranial tumor Total resection was performed, and histogenetical findings led to the diagnosis of a mature teratoma with normal p16 gene, whereas analysis of intracranial tumor showed p16 deletion. 11155064 Human
p16 squamous cell carcinoma in situ A total of 33 cases were examined for evidence of death-associated protein kinase and p16 hypermethylation and these consist of 9 cases of spongiotic dermatitis as nonneoplastic skin control, 9 cases of actinic keratosis, 8 cases of squamous cell carcinom 12861061 Human
p16 squamous cell carcinoma in situ P16 promoter methylation was detected in 1 case of invasive squamous cell carcinoma and 1 case of nonneoplastic skin control but none of the cases of squamous cell carcinoma in situ or actinic keratosis. 12861061 Human
p16 breast and ovarian cancer At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
p16 medullary-thyroid carcinoma At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
p16 salivary-gland carcinomas Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. 10534174 Human
p16 salivary duct carcinoma In addition, another salivary duct carcinoma showed a homozygous deletion of p16 in differential polymerase chain reaction analysis. 10534174 Human
p16 salivary duct carcinomas These results suggest that inactivation of p16 is important in the development or progression of at least some salivary duct carcinomas, but we found no evidence that its alteration plays a role in the other subtypes examined. 10534174 Human
p16 invasive cancers Hypermethylation of p16 was localized only to the neoplastic cells in both in situ lesions and invasive cancers, and was associated with loss of p16 protein expression. 10535995 Human
p16 invasive cancer These data suggest that p16 inactivation is selected as the most effective mechanism of blocking the cyclin D-Rb pathway during the evolution of an invasive cancer from precursor lesions. 10535995 Human
p16 malignant brain tumors The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s 10536183 Human
p16 low-grade tumors The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s 10536183 Human
p16 neurofibromatosis 1 Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. 10595918 Human
cdkn2a neurofibromatosis 1 Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. 10595918 Human
p16 gastric adenosquamous carcinoma The expression of p53, p16 and RB proteins and their clinicopathologic correlation were investigated in 15 cases of primary gastric adenosquamous carcinoma and 2 cases of squamous cell carcinoma of the stomach. 10605694 Human
p16 squamous cell carcinoma of the stomach The expression of p53, p16 and RB proteins and their clinicopathologic correlation were investigated in 15 cases of primary gastric adenosquamous carcinoma and 2 cases of squamous cell carcinoma of the stomach. 10605694 Human
p16 angiomyolipoma In order to investigate a possible link between the two tumours, we investigated mutations in the p53-gene, loss of heterozygosity (LOH) at p53, Rb and p16, c-Myc expression, and the telomerase activity of the angiomyolipoma and the osteosarcoma. 10605697 Human
p16 angiomyolipoma Whilst the tibial osteosarcoma showed LOH at p16, no genetic alterations or increased telomerase activity were found in the angiomyolipoma. 10605697 Human
p16 small-bowel adenocarcinomas The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). 10613343 Human
p16 salivary gland neoplasm Quantitative study on expression of p16 multiple tumor suppressor gene in salivary gland neoplasm. 12840862 Human
p16 parotid neoplasm The PU of p16 gene was higher in deep lobe of recurrent parotid neoplasm with incomplete capsule than that in shallow lobe of primary parotid neoplasm with complete capsule. 12840862 Human
p16 salivary gland tumors The findings suggests that p16 gene plays an equally important role in the salivary gland tumors and tumors in other part of the body. 12840862 Human
ink4a adult soft tissue sarcomas Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. 9890173 Human
ink4a adult soft tissue sarcomas This study was undertaken to evaluate the frequency of INK4A and INK4B gene alterations in a cohort of adult soft tissue sarcomas. 9890173 Human
ink4a high-grade sarcomas The overall frequency of gene alteration (deletion or rearrangement) was approximately 15% for the INK4A and INK4B genes, with changes restricted to high-grade sarcomas. 9890173 Human
ink4a adult soft tissue sarcomas CONCLUSION/IMPLICATIONS: Coincident homozygous deletion of the INK4A and INK4B genes occurs frequently in adult soft tissue sarcomas. 9890173 Human
p16 female breast cancer We report the approximately tenfold increase in copy number of DNA from 9p23-24, which is far distal to P16/CDKN2A in female breast cancer cell line COLO 824, as revealed by fluorescence in situ hybridization, comparative genomic hybridization, and micros 9892114 Human
cdkn2a female breast cancer We report the approximately tenfold increase in copy number of DNA from 9p23-24, which is far distal to P16/CDKN2A in female breast cancer cell line COLO 824, as revealed by fluorescence in situ hybridization, comparative genomic hybridization, and micros 9892114 Human
p16 liver cancer Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. 9892188 Human
p16 ovarian epithelial tumor OBJECTIVE. The aim of this study was to test the hypothesis that DNA methylation is important for silencing the p16 tumor suppressor gene in ovarian epithelial tumors and to compare the prevalence of this mechanism among different ovarian epithelial tumor 9889036 Human
p16 ovarian epithelial tumors OBJECTIVE. The aim of this study was to test the hypothesis that DNA methylation is important for silencing the p16 tumor suppressor gene in ovarian epithelial tumors and to compare the prevalence of this mechanism among different ovarian epithelial tumor 9889036 Human
p16 non-small cell carcinoma p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. p16, an inhibitor of cell cycle machinery, is frequently inactivated in non-small cell carcinoma of the lung (NSCCL). 9988232 Human
p16 other cancers These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as R 10022125 Human
p16 bladder cancer These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as R 10022125 Human
ink4a papillomas The protein expression of cdk6 and ckis viz. p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in UVB exposed skin, but significant upregulation was observed both in papillomas and carcinomas. 10022811 Human
p16 papillomas The protein expression of cdk6 and ckis viz. p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in UVB exposed skin, but significant upregulation was observed both in papillomas and carcinomas. 10022811 Human
p16 acute leukemias Reports on homozygous deletion of p16 and p15 genes suggest the value of larger, prospective studies with standardized treatment protocols to definitively establish the prognostic utility of p15/p16 deletions in acute leukemias. 10073286 Human
p16 relapsed childhood all These findings indicate that loss of function of proteins encoded by p16 and/or p15 plays an important role in the biology of relapsed childhood ALL, and is associated with disease progression in a subset of cases. 10090949 Human
cdkn2a oropharyngeal squamous cell carcinomas DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. 10221335 Human
cdkn2a oropharyngeal squamous cell carcinomas Our data show that inactivation of the CDKN2A gene products is a near-universal step in the development of oral and oropharyngeal squamous cell carcinomas, and we suggest that homozygous deletion is the most common mechanism of inactivation. 10221335 Human
p16 verrucous carcinomas Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. 10226946 Human
p16 invasive ductal breast cancer Using methylation-specific PCR, aberrant hypermethylation of p16 and CDH1 in tumor and plasma was analyzed and correlated with levels of serum protein markers, carcinoembryonic antigen (CEA) and carcinoma antigen 15-3 (CA15.3), in 36 patients with invasiv 14534701 Human
ink4a gastric stromal tumors Thirty-eight c-kit-positive gastric stromal tumors were subjected to methylation-specific polymerase chain reaction (MSP) to detect promoter methylation associated with 11 candidate tumor suppressor genes (p16/INK4a, APC, MGMT, hMLH1, p73, E-cadherin, RAR 14675710 Human
p16 gastric stromal tumors Thirty-eight c-kit-positive gastric stromal tumors were subjected to methylation-specific polymerase chain reaction (MSP) to detect promoter methylation associated with 11 candidate tumor suppressor genes (p16/INK4a, APC, MGMT, hMLH1, p73, E-cadherin, RAR 14675710 Human
p16 adenomatous polyps EXPERIMENTAL DESIGN: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. 11801557 Human
p16 adenomatous polyps No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. 11801557 Human
ink4a extrahepatic bile duct cancers Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. 11802210 Human
arf extrahepatic bile duct cancers Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. 11802210 Human
ink4 spindle-cell tumor Gene deletion of the INK4 locus is associated with transformation to a highly invasive spindle cell tumor phenotype. 10341708 Human
p16 prostatic adenocarcinomas The purpose of the present study was to evaluate patterns of p16 expression in a well-characterized cohort of prostatic adenocarcinomas while exploring potential associations between alterations of p16 and clinicopathological variables. 10353729 Human
p16 metastatic prostate cancers Analysis of six independent lines from metastatic prostate cancers reveals a similar loss of either p16 or pRb. 10383161 Human
ink4 nervous system tumors BACKGROUND: A genetic syndrome of cutaneous malignant melanoma and nervous system tumors recently has been characterized and shown to be linked to the INK4 locus in the 9p21 region. 10388473 Human
cdkn2a plasma cell tumors The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. 10396076 Mouse
p16 sporadic colorectal cancers CIMP+ tumors also have a high incidence of p16 and THBS1 methylation, and they include the majority of sporadic colorectal cancers with microsatellite instability related to hMLH1 methylation. 10411935 Human
ink4a melanoma Here we show that melanoma genesis and maintenance are strictly dependent upon expression of H-RasV12G in a doxycycline-inducible H-Ras12G mouse melanoma model null for the tumour suppressor INK4a. 10440378 Mouse
p16 adrenocortical tumors Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. 10443678 Human
p16 adrenocortical tumors Inactivation of the p16 tumor suppressor gene (p16INK4A), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. 10443678 Human
p16 adrenocortical tumors Immunohistochemistry showed the absence of p16 nuclear staining in all adrenocortical tumors with LOH within 9p21, and positive staining in all remaining tumors without LOH. 10443678 Human
p16 tumor angiogenesis Infection with a recombinant replication-defective adenovirus vector containing the cDNA of wild-type p16 significantly reduced the expression of vascular endothelial growth factor, which is thought to be a pivotal mediator of tumor angiogenesis, in p16-d 10446996 Human
p16 common acute lymphoblastic leukemia There were two patients who had DNA abnormalities in both 9p and 12p, one with common acute lymphoblastic leukemia (ALL) showed 9p LOH and the TEL/AML1 fusion gene on 12p and the other with common ALL and 12p RER had diminished expression of both the p27( 10453181 Human
p16 liver metastases To evaluate the clinical value of occult micrometastatic disease detection in lymph nodes, we tested genetic (K-ras and p53 gene mutations) and epigenetic (p16 promoter hypermethylation) molecular markers in the perihepatic lymph nodes from colorectal can 10499618 Human
p16 liver metastases Sixteen of the 21 (76%) liver metastases harbored either gene point mutations or p16 promoter hypermethylation. 10499618 Human
p16 actinic keratosis We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. 10498902 Human
arf metastatic cancers In combination, KrasG12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. 14681207 Human
ink4a metastatic cancers In combination, KrasG12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. 14681207 Human
mts1 gastrinoma In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. 9443399 Human
p16 gastrinoma In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. 9443399 Human
p16 intradermal nevi We have searched the frequency of p16 and p53 deletion in nine dysplastic nevi and 13 benign intradermal nevi with five microsatellite markers. 9490270 Human
cdkn2a plasmacytoma Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 9482902 Mouse
p16 plasmacytoma When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all 9482902 Mouse
p16 invasive breast carcinoma The cell cycle-associated retinoblastoma protein (pRb) and p16 protein were demonstrated using immuno-histochemistry on paraffin sections from 192 cases of invasive breast carcinoma. 9495362 Human
cdkn2a thymic lymphomas We used this microsatellite to detect loss of heterozygosity of the Cdkn2A and Cdkn2B loci in gamma-irradiation-induced thymic lymphomas of C57BL/6J x RF/J F1 hybrids. 9501299 Human
mts1 atypical adenomatous hyperplasia Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. 9531999 Human
p16 atypical adenomatous hyperplasia Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. 9531999 Human
cdkn2a hepatoblastoma Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. 9537438 Human
cdkn2a hepatoblastoma Structural analysis of the CDKN2A, CDKN2B, and CDKN2C genes in hepatoblastoma cases showed the absence of deletions and/or point mutations. 9537438 Human
cdkn2a hepatoblastoma Messenger RNA (mRNA) analysis showed that CDKN2C is expressed in all hepatoblastoma samples studied, while both CDKN2A and CDKN2B genes are not transcribed in the cancer specimens as well as in the matched normal liver tissues. 9537438 Human
cdkn2a human hepatoblastoma Our findings demonstrated the following: 1) CDKN2A, CDKN2B, and CDKN2C genes are structurally unmodified in human hepatoblastoma, and 2) CDKN2A (alpha-transcript) and CDKN2B are transcriptionally silenced in normal liver whereas CDKN2A (beta-transcript) a 9537438 Human
cdkn2a hepatoblastoma These results show that CDKN2A gene family alterations are not involved in hepatoblastoma development, whereas changes in cyclin D types might play a role in this type of tumor. 9537438 Human
cdkn2a stage i lung cancer We tested five gene promoters [CDKN2A (p16), O(6)-methylguanine-DNA-methyltransferase, glutathione S-transferase P1 (GSTP1), adenomatous polyposis coli (APC), and death-associated protein kinase (DAPK)] by real-time methylation-specific PCR in primary tum 12684406 Human
p16 stage i lung cancer We tested five gene promoters [CDKN2A (p16), O(6)-methylguanine-DNA-methyltransferase, glutathione S-transferase P1 (GSTP1), adenomatous polyposis coli (APC), and death-associated protein kinase (DAPK)] by real-time methylation-specific PCR in primary tum 12684406 Human
p16 testicular cancer The aim of our study was to examine TGCT and testicular cancer cell lines for deletions and mutations of the p15 and p16 genes. 9554401 Human
p16 testicular cancer For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. 9554401 Human
p16 testicular tumors For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. 9554401 Human
cdkn2 large-cell lymphoma Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. 9591637 Human
p16 adrenal cortical carcinomas Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
p16 high-grade malignant lymphomas Paraffin sections of 9 reactive lymph nodes and 43 low-grade and 60 high-grade malignant lymphomas were reacted with antibodies against pRB and p16. 9620022 Human
p16 high-grade lymphomas Loss of p16 was identified in 14 of 55 evaluable high-grade lymphomas but not in any of the low-grade lesions. 9620022 Human
p16 diffuse large cell lymphomas While loss of RB function was a rare event in human lymphomagenesis, p16 was absent in some 25% of high-grade non-Hodgkin's lymphomas; diffuse large cell lymphomas were the primary target of tumor suppressor gene inactivation. 9620022 Human
ink4 nervous system tumors Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. 9622062 Human
p16 adenocarcinoma of the uterine cervix METHODS: In 40 cases of adenocarcinoma of the uterine cervix and 10 normal cervices, expression of estrogen receptor and cell cycle regulatory gene products (cyclin E, p16, p21WAF1/CIP1, p27, p53, and Ki-67) was studied using immunohistochemical technique 9635534 Human
p19 human leukemia-lymphoma Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. 9639410 Human
ink4 human leukemia-lymphoma Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. 9639410 Human
p16 human leukemia-lymphoma Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. 9639410 Human
p16 primary carcinoma The results revealed that nuclear expression of beta-catenin, p16 and c-myc was quantitatively increased from normal mucosa to premalignant adenoma, primary carcinoma and lymph node metastatic carcinoma; the frequency of nuclear overexpression of beta-cat 14601048 Human
p16 metastatic carcinoma The results revealed that nuclear expression of beta-catenin, p16 and c-myc was quantitatively increased from normal mucosa to premalignant adenoma, primary carcinoma and lymph node metastatic carcinoma; the frequency of nuclear overexpression of beta-cat 14601048 Human
cdkn2a soft-tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
mts1 soft-tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
p16 soft-tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
cdkn2a soft-tissue tumors Presumably, alterations of the CDKN2A gene do not contribute to the oncogenesis in the majority of soft tissue tumors. 9664128 Human
p16 t-cell childhood acute lymphoblastic leukaemias As a high proportion of T-cell childhood acute lymphoblastic leukaemias have deletions of both p15 and p16, our data suggest that inactivation of these genes makes it possible for leukemic cells to avoid senescence. 9704925 Human
ink4a low-grade lymphomas This loss of p16/INK4A was found more frequently in cases showing tumor progression from mucosa-associated lymphoid tissue low-grade lymphomas (31 of 37) or follicular lymphomas (4 of 4) into diffuse large B-cell lymphomas. 9736037 Human
p16 low-grade lymphomas This loss of p16/INK4A was found more frequently in cases showing tumor progression from mucosa-associated lymphoid tissue low-grade lymphomas (31 of 37) or follicular lymphomas (4 of 4) into diffuse large B-cell lymphomas. 9736037 Human
cdkn2a secondary tumors By comparing the genetic changes in the primary and corresponding secondary tumors, we found that additional loss of CDKN2A and/or RB1, encoding important components of the cell cycle regulatory pathway, was the most frequent genetic change in both types 9739018 Human
p16 adenomas In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions 9751761 Rat
p16 carcinoma in situ The timing for p16 methylation was recapitulated in human SCCs where the p16 gene was coordinately methylated in 75% of carcinoma in situ lesions adjacent to SCCs harboring this change. 9751761 Rat
p16 carcinosarcoma This loss associated with carcinosarcoma of the urinary bladder is in agreement with previous studies, suggesting a possible role for the tumor suppressor gene p16 in the pathogenesis of this tumor. 14692829 Human
cdkn2 esophageal tumors p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. 9808520 Human
p16 esophageal tumors p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. 9808520 Human
p16 inherited cancer syndromes Frequent allelic losses on chromosome 9 are seen in a wide variety of human tumors; moreover, two genes (P16 and PTC) whose mutant alleles confer predispositions to some inherited cancer syndromes have been identified on this chromosome. 9818027 Human
p16 undifferentiated carcinoma Undifferentiated carcinoma (FRO) cells had a nonsense point mutation at codon 72 (CGA-TGA, Arg-Stop) of p16, whereas the poorly differentiated papillary carcinoma (NPA) line harbored a point mutation at the exon 1-intron 1 boundary that altered the donor 9827724 Human
p16 condylomata acuminata Condylomata acuminata and low-grade squamous intraepithelial lesions with infection by low-risk HPV such as HPV-6/11 showed focal and weak immunohistochemical staining for p16. 9846965 Human
p16 leiomyosarcoma Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. 14595762 Human
p16 pleomorphic adenoma of the parotid gland Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. 9917133 Human
p16 carcinosarcoma Cyclin D1 gene amplification and p16 gene deletion in patients with esophageal carcinosarcoma. 9990483 Human
p16 carcinosarcoma Because inactivation of p16 gene (which is a putative tumor suppressor gene) is thought to have similar oncogenic effects with CD1 gene amplification, DPCR was used to examine whether p16 homozygous deletion occurs in esophageal carcinosarcoma. 9990483 Human
p16 carcinosarcoma These results suggest that homozygous deletion of the p16 gene occurs less frequently than CD1 gene amplification in esophageal carcinosarcoma. 9990483 Human
p16 esophageal tumors To determine the role and mode of inactivation of the p16 and p15 genes in human esophageal tumors, we examined alterations and expression of the alpha and beta forms of the p16 gene, 5' CpG island methylation of p16 exon 1 alpha, and alterations of 9033652 Human
p16 juvenile pilocytic astrocytoma We screened human primary and recurrent malignant glioma, juvenile pilocytic astrocytoma, medulloblastoma, and meningioma tissue specimens for alterations in p16 gene structure. 9049826 Human
cdkn2a ovarian adenocarcinomas To determine the role of the CDKN2A gene in the development of ovarian adenocarcinomas, we examined a large series of benign, low malignant potential (LMP) and invasive ovarian neoplasms for evidence of loss of heterozygosity (LOH), homozygous deletions, 9052747 Human
cdkn2a ovarian adenocarcinomas No evidence of hypermethylation of the CDKN2A gene was found in 50 primary ovarian adenocarcinomas nor in 3 ovarian cancer cell lines. 9052747 Human
p14arf salivary-gland carcinomas Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. 12684623 Human
p16 malt lymphomas These results indicate that p16 gene methylation is a frequent event in NHLs, mainly in MALT lymphomas, and suggest that it could be an important mechanism of inactivation of this gene. 9067584 Human
p16 plasmacytoma Moreover, hypermethylation of p16/p15 was associated with blastic disease and concomitant hypermethylation of both genes may be pathogenetically related to plasmacytoma development. 9116295 Human
p16 metastatic prostate cancer METHODS: Five metastatic prostate cancer cell lines were analyzed for p16 gene structure and its expression by Southern and Northern blot analyses. 9122044 Human
p16 low-grade tumors Aberrant expression of p16 protein, detected by immunohistochemistry, occurred in 22 of 60 tumors, more frequently in low-grade tumors, and had significant correlation with low p16 mRNA expression. 9133447 Human
p16 ovarian epithelial tumors We conclude that inactivation of p16, by loss of p16 mRNA and protein expression as a consequence of hypermethylation of the 5'-CpG island, rather than by gene deletion or point mutation, may play an important role in the genesis of human ovarian epi 9133447 Human
cdkn2 metastatic prostate cancer Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. 9171999 Human
mts1 metastatic prostate cancer Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. 9171999 Human
p16 metastatic prostate cancer Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. 9171999 Human
p16 lymph-node metastasis METHODS: p53 and p16 expression status, the Ki-67 LI, and int-2/cyclin D1 amplification were assessed by immunohistochemical staining and slot blot analysis in pretreatment endoscopic biopsy specimens of 41 patients with T4 or M1 Lym (distant lymph node m 12900371 Human
p16 barrett's adenocarcinomas Only a minority of Barrett's adenocarcinomas with 9p21 LOH have a somatic mutation in the remaining p16 allele, and none have been found to have homozygous deletions. 9205067 Human
p16 esophageal adenocarcinomas To determine whether p16 promoter hypermethylation may be an alternative mechanism for p16 inactivation in esophageal adenocarcinomas, we examined the methylation status of the p16 promoter in flow-sorted aneuploid cell populations from 21 patients with p 9205067 Human
mts1 pituitary adenomas Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. 9205080 Human
p16 barrett's adenocarcinomas The aim of our study was to determine, in 26 Barrett's adenocarcinomas and 20 squamous-cell carcinomas of the esophagus, the prevalence of loss of heterozygosity on chromosome 9 by typing of microsatellite loci and mutation of p16 by direct sequencin 9212218 Human
p16 benign melanocytic nevi To investigate the role of the alterations of p16 expression in melanoma, we evaluated by immunohistochemistry the p16 expression and cell proliferation in 79 primary CMM and 10 benign melanocytic nevi (BMN). 9221801 Human
p16 spindle cell neoplasms In contrast, no fibromatoses and other spindle cell neoplasms of low malignant potential displayed abnormal p16 expression, and only 4 of 23 cases showed loss of pRB expression. 9269824 Human
mts1 testicular germ-cell tumors Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. 9284835 Human
p16ink4 testicular germ-cell tumors Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. 9284835 Human
p16 hepatoblastoma Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. 12748249 Human
p16 hepatoblastoma Aberrant methylation of 5' CpG islands of p16 was present in 12 of 24 (50.0%) cases of hepatoblastoma. 12748249 Human
p16 hepatoblastoma Nine of 12 (75.0%) unmethylated cases of hepatoblastoma displayed diffuse immunoreactivity, whereas 3 cases of unmethylated hepatoblastoma were not immunostained for p16. 12748249 Human
p16ink4 bone sarcoma Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. 9309118 Human
p16ink4 bone sarcomas As the molecular events leading to the development of pediatric bone sarcomas remain unclear, we analyzed 75 osteosarcoma and Ewing sarcoma samples from 43 pediatric patients to search for alterations at the TP53 or p16INK4 tumor suppressor genes. 9309118 Human
cdkn2 thymic carcinoma p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. 9398039 Human
p16ink4 thymic carcinoma p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. 9398039 Human
cdkn2 thymic carcinomas Subsequently, we examined the 36 thymomas and 4 thymic carcinomas for mutations in p53 and CDKN2 genes, using PCR-SSCP and direct-sequencing analyses. 9398039 Human
cdkn2 thymic carcinoma We searched for hypermethylation in the promoter region of CDKN2, observing it in 4 thymomas and 1 thymic carcinoma. 9398039 Human
mts1 b16 melanoma Here we have examined the expression of CD44v6 in metastatic variants of the B16 melanoma with different levels of 18A2/mts1 expression. 9413186 Human
p16 lung adenomas Allelic loss of the p16 tumor suppressor gene also is a frequent event, occurring in about 50% of mouse lung adenocarcinomas, but rarely in lung adenomas, suggesting that it may play a role in malignant conversion or progression of lung tumors. 9589349 Mouse
cdkn2 benign prostatic hyperplasias Markedly reduced expression of CDKN2 mRNA was found in 43% (26 of 60) of untreated primary carcinomas, whereas no alteration was observed in 10 benign prostatic hyperplasias. 9815578 Human
cdkn2 primary carcinomas Markedly reduced expression of CDKN2 mRNA was found in 43% (26 of 60) of untreated primary carcinomas, whereas no alteration was observed in 10 benign prostatic hyperplasias. 9815578 Human
cdkn2 primary carcinomas Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas. 9815578 Human
cdkn2 primary carcinomas Analysis of genomic DNA indicated that altered CDKN2 expression in primary carcinomas of the prostate was more frequently due to down-regulation of transcription (five of seven) than deletion of the gene (two of seven). 9815578 Human
p16 plasma-cell leukemia (pcl) However, the frequency and significance of p16 abnormalities in multiple myeloma (MM) and the more aggressive phase of plasma cell leukemia (PCL) have not been well defined. 9815612 Human
cdkn2 differentiated thyroid cancers Infrequent CDKN2 mutation in human differentiated thyroid cancers. 8561866 Human
cdkn2 anaplastic thyroid cancers We examined the frequency of cyclin-dependent kinase (CDK) N2 alterations in differentiated and anaplastic thyroid cancers to assess the involvement of CDKN2 in the development of these cancers. 8561866 Human
cdkn2 papillary cancers LOH in the region of CDKN2 is seen in a significant proportion of follicular and anaplastic but not papillary cancers. 8561866 Human
cdkn2a ocular melanoma Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. 12883368 Human
cdkn2a ocular melanoma Our findings argue against an important predisposing effect of the MC1R and CDKN2A genes for ocular melanoma. 12883368 Human
p16 myxofibrosarcoma In this study, we evaluated the expression of p53, MDM2, MIB-1 (Ki-67), p21, p27, p16, cyclin A, cyclin D1, and cyclin E by immunohistochemistry in 45 cases of myxofibrosarcoma. 14608538 Human
p16 myxofibrosarcoma Among 43 cases of myxofibrosarcoma for which immunohistochemical findings were available, high MIB-1 labeling index (LI) (cutoffs of 10 and 22.5 on average), high cyclin A LI (cutoffs 10% and 13.8% on average), low p21 LI (cutoffs 10 and 20.7 on average), 14608538 Human
p16 meningiomas In this study, p15, p16, CDK4 and cyclin D1 genes were analyzed in 69 nonastrocytic human brain tumors, including 17 oligodendrogliomas, 16 medulloblastomas/primitive neuroectodermal tumors (PNETs), 14 ependymomas and 22 meningiomas. 8621248 Human
mts1 mouse adenocarcinoma The expression level of this gene correlates with the hypomethylation of the mts1 first intron sequence in mouse adenocarcinoma cells. 8622894 Mouse
cdkn2 undifferentiated carcinoma These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. 8625287 Human
p16 undifferentiated carcinoma These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. 8625287 Human
p16ink4 t-cell lymphoblastic lymphoma A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones. 8656689 Human
p16ink4 malignant brain tumor Alterations in P16ink4 or in the gene encoding one of its ligands, cyclin-dependent kinase 4 (CDK4), have been reported in human glioma cell lines and primary tumors but not in primitive neuroectodermal tumors (PNETs), the most common malignant brain tumo 8847566 Human
p16 compound nevi Surprisingly, p16 deletions were also detected in 8/8 benign compound nevi and in 1/3 normal human melanocyte isolates. 8649798 Human
cdkn2a childhood rhabdomyosarcoma Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. p16INK4A, p15INK4B, and p18 proteins are highly specific inhibitors of cyclin-dependent serine/threonine kinase (CDK) activities required for G 8703847 Human
p16 nasopharyngeal carcinoma Hypermethylation of the p16 gene in nasopharyngeal carcinoma. 8665502 Human
p16ink4 thyroid tumors Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. 8690521 Human
p16ink4 thyroid tumors We have examined the status of the p16INK4 gene in 31 thyroid tumors and 7 thyroid cell lines. 8690521 Human
cdkn2 myxoid chondrosarcoma Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. 8689636 Human
cdkn2 myxoid chondrosarcoma We have previously reported a similar 9p21 abnormality and deletions of the CDKN2 and MTS2 genes in a myxoid chondrosarcoma cell line and its subclones. 8689637 Human
p14arf low-grade tumors Some differences may be established regarding the methylation profiles of specific genes and tumor types: MGMT, THBS1, TIMP-3, and p16INK4A appear hypermethylated in low-grade tumors (at least in 45% of cases), whereas GSTP1, DAPK, and p14ARF are mostly c 12579314 Human
p16 recurrent tumors The primary and recurrent tumors in Group A did not show structural alterations in the p16, p15 or CDK4 genes, whereas homozygous codeletion of p16 and p15 was observed in both primary and recurrent tumors in Group B. 8760309 Human
cdkn2 meningothelial meningioma The 1 meningioma with a CDKN2/p16 deletion was a meningothelial meningioma, without atypical or malignant features. 8834533 Human
p16 meningothelial meningioma The 1 meningioma with a CDKN2/p16 deletion was a meningothelial meningioma, without atypical or malignant features. 8834533 Human
p16 gastric carcinomas To evaluate the preferential histological type of MI-associated mutations in the development of gastric carcinoma, mutations of TGF-beta RII, p53, and p16 were analyzed for the two types of primary gastric carcinomas showing MI. 8840981 Human
p16 gastric carcinoma To evaluate the preferential histological type of MI-associated mutations in the development of gastric carcinoma, mutations of TGF-beta RII, p53, and p16 were analyzed for the two types of primary gastric carcinomas showing MI. 8840981 Human
p16 parathyroid adenomas Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. 8855819 Human
p16 parathyroid adenomas Because inactivation of the p16 or p15 genes might be expected to result in oncogenic consequences similar to those from cyclin D1 overexpression, we examined 25 parathyroid adenomas for 1) allelic loss of polymorphic DNA loci on chromosome arm 9p, 2) hom 8855819 Human
p16 parathyroid tumors However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some h 8855819 Human
p16 parathyroid adenomas These observations indicate that inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas; however, loss of a different tumor suppressor gene (or genes) on 9p appears to contribute to the p 8855819 Human
cdkn2 ovarian adenocarcinomas To establish the frequency of CDKN2 gene abnormalities in ovarian tumour specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary and five metastatic ovarian adenocarcinomas. 8855976 Human
cdkn2 sporadic breast cancer Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. 8889502 Human
p16 esophageal tumors Alterations in the p16 and p15 cyclin kinase inhibitors, including point mutation and homozygous deletion, have been reported in primary esophageal tumors and/or tumor-derived cell lines. 8893331 Human
p16 thyroid carcinomas The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Waf1 is a downstream effector of p53. 8912526 Human
p16 inverted papillomas Cuboidal and squamous metaplasia in inverted papillomas showed increased p16 expression in surface cells compared to columnar epithelium in inverted papillomas (p < 0.05 between squamous metaplasia and columnar epithelium). 12507294 Human
p16 inverted papillomas Cuboidal and squamous metaplasia in inverted papillomas involves downregulation of pRb expression along with increased p16 expression in surface cells. 12507294 Human
p19 burkitt-like lymphoma Using Southern blot analysis, one homozygous deletion of the p19 gene was detected in a human immunodeficiency virus (HIV)-related Burkitt-like lymphoma sample. 8946928 Human
mts1 primary carcinomas The multiple tumor suppressor 1 (MTS1) and 2 (MTS2) genes, located on chromosome 9p21, have been reported to be deleted or mutated in many malignant cell lines and in a high percentage of some primary carcinomas. 8957063 Human
multiple tumor suppressor 1 primary carcinomas The multiple tumor suppressor 1 (MTS1) and 2 (MTS2) genes, located on chromosome 9p21, have been reported to be deleted or mutated in many malignant cell lines and in a high percentage of some primary carcinomas. 8957063 Human
mts-1 thyroid tumors RESULTS: We failed to demonstrate homozygous deletions of MTS-1 and MTS-2 in thyroid tumors, but we demonstrated a highly frequent base pair exchange of the MTS-2 gene 27 codons upstream the 5' end of exon 2. 8957499 Human
mts1 gallbladder carcinoma Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. 12532418 Human
mts1 malignant blue nevus We performed a molecular analysis for loss of heterozygosity on microdissected samples from the spectrum of benign to malignant blue nevus, using a panel of eight genes (MTS1, MXI1, CMM1, p53, NF1, L-myc hOGG1, and MCC), many of which are commonly associa 12544095 Human
cdkn2 squamous cancer MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 7845688 Human
mts-1 squamous cancer MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 7845688 Human
cdkn2 primary glioblastoma Using this probe, FISH analysis of primary glioblastoma tumors revealed homozygous deletions of the CDKN2 region in 6 of 9 tumors (67%) whereas a yeast artificial chromosome probe containing the interferon type I (IFN) gene cluster was deleted in only 4 c 7867008 Human
mts1 female breast carcinomas Analysis of MTS1/CDK4 in female breast carcinomas. 7889533 Human
mts1 breast adenocarcinomas Using PCR-SSCP, we analyzed exons one (126 bp) and two (307 bp) of the MTS1 gene to determine the incidence of mutation in a population of 50 primary breast adenocarcinomas and corresponding normal tissue. 7889533 Human
p16 blast crisis We have used a semiquantitative multiplex polymerase chain reaction assay to search for deletions of the p16 gene in 34 patients with chronic myeloid leukemia in blast crisis (CML BC), 19 patients with acute lymphoblastic leukemia (ALL), and 25 patients w 7718873 Human
mts1 metastatic cancers The mts1 gene codes for a 101 amino acid protein which belongs to the subfamily of S100 Ca(2+)-binding proteins and is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts. 7731714 Human
p16 nasopharyngeal carcinoma p16 gene alterations in nasopharyngeal carcinoma. 7743498 Human
p16 gastric adenoma For instance, p16 methylation was found in 2.7% of normal gastric epithelium (n = 36), 16.7% of chronic atrophy gastritis (n = 24), 37.5% of dysplasia (n = 24), 67.4% of gastric adenoma (n = 43), and 85.2% of gastric carcinoma (n = 27). 12547284 Human
p16 large-cell carcinoma METHODS: p16 and p53 expression were detected by immunohistochemical analysis of 90 paraffin specimens of resected NSCLC, including 35 squamous cell carcinoma, 47 adenocarcinoma, and eight large cell carcinoma, between stages I and IV. 12559346 Human
p16 gastric adenomas The significance of p16 mutations in gastric tumorigenesis was examined by assessing p16 mutations as well as loss of heterozygosity (LOH) on 9p in 13 gastric adenomas and 45 adenocarcinomas. 7775254 Human
p16 gastric adenomas Although we found a sequence polymorphism at the second position of codon 99 (CGC/CAC) of the p16 in one gastric adenoma patient, no somatic mutations were detected in any of the gastric adenomas or adenocarcinomas. 7775254 Human
p16 gastric adenoma Although we found a sequence polymorphism at the second position of codon 99 (CGC/CAC) of the p16 in one gastric adenoma patient, no somatic mutations were detected in any of the gastric adenomas or adenocarcinomas. 7775254 Human
cdkn2 central nervous system primitive neuroectodermal tumor To investigate the possible role of this gene in the genesis of the central nervous system primitive neuroectodermal tumor (PNET), four established PNET cell lines and 18 PNET surgical specimens were studied for deletions and mutations of the MTS1/CDKN2 g 7791990 Human
mts1 central nervous system primitive neuroectodermal tumor To investigate the possible role of this gene in the genesis of the central nervous system primitive neuroectodermal tumor (PNET), four established PNET cell lines and 18 PNET surgical specimens were studied for deletions and mutations of the MTS1/CDKN2 g 7791990 Human
mts1 secondary tumors Two out of 5 (40%) secondary tumors showed evidence of homozygous deletion of MTS1. 7794250 Human
cdkn2 biliary tract cancers Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. p16Ink4 and p15Ink4B are cyclin-dependent kinase 4 inhibitors and link to the regulation of cell cycle in mammalian cells. 7796400 Human
p16ink4 biliary tract cancers Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. p16Ink4 and p15Ink4B are cyclin-dependent kinase 4 inhibitors and link to the regulation of cell cycle in mammalian cells. 7796400 Human
cdkn2 gastric cancer We report a highly frequent homozygous deletion of the p16/CDKN2 gene in the esophageal cancer cell line and a relatively high frequency of homozygous deletion in gastric cancer cell lines. 7614482 Human
cdkn2 adult solid tumors Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. 7630190 Human
mts1 adult solid tumors Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. 7630190 Human
p16ink4 adult solid tumors Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. 7630190 Human
cdkn2 squamous cell carcinoma of the bladder High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. 7658499 Human
p16ink4 cutaneous malignant melanoma BACKGROUND. A gene on chromosome 9p, p16INK4, has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. 7666916 Human
cdkn2 colon tumors It was striking to find that this region was extensively methylated and the gene not expressed in the normal colonic mucosa of 6 of 10 (60%) patients with colon cancer, whereas 5 of the corresponding colon tumors showed no methylation and high levels of p 7553622 Human
p16 testicular tumor MATERIALS AND METHODS: We examined alterations of p16 in 78 primary genital tumors (42 testicular, 21 ovarian and 15 endometrial cancers) and mononuclear cells from 2 patients with Lynch syndrome II as well as 5 testicular tumor cell lines by single-stran 7563391 Human
p16 testicular tumors RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. 7563391 Human
p16 testicular tumor RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. 7563391 Human
p16 endometrial tumors CONCLUSIONS: Taken together, these results suggest that p16 alterations probably are not important for tumorigenesis of testicular, ovarian and endometrial tumors. 7563391 Human
p16 small-lymphocytic lymphoma We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f 7579381 Human
p16 borderline ovarian tumors Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. 7478544 Human
p16 acute promyelocytic leukemia Neither p16 mRNA nor its protein expression are regulated during the cell cycle of normal phytohemagglutinin-stimulated lymphocytes, retinoblastoma protein-negative cells, papilloma virus-transformed cells, and acute promyelocytic leukemia cells. p16 mRNA 7589458 Human
cdkn2 chronic phase cml Whereas none of 22 chronic phase CML cases examined showed alterations, we found that 3/17 total blast crisis examined (18%) showed a homozygous deletion of the CDKN2 gene. 8555065 Human
cdk4i common acute lymphoblastic leukaemias We found that none of acute myeloblastic leukaemias (four cases) showed the CDK4I alteration, whereas 6/13 (46%) common acute lymphoblastic leukaemias (ALLs) displayed homozygous deletions. 8555068 Human
mts1 metastatic cancers Mts1 is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, and although mts1 is known to be involved in the metastatic phenotype (Davies et al., 1993; Grigorian et al., 1993), the role mts1 plays in this process is not cl 7478526 Human
ink4a colon tumor Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. 12591718 Human
arf colon tumor Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. 12591718 Human
ink4a colon tumors Colon tumors in 3-month-old Min mice that were null for the Ink4a/Arf locus (-/-) were moderately larger than in Ink4a/Arf-wild-type (+/+) animals (P = 0.032). 12591718 Mouse
p14arf neurofibroma Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. 12920094 Human
p16ink4 dedifferentiated chondrosarcoma We found p16INK4 and E-cadherin promotor methylation in the low grade chondroid compartment of the dedifferentiated chondrosarcoma. 12924447 Human
cdkn2a conjunctival melanoma CONCLUSION: Evidence for comorbid OM and CM exists in patients with strong phenotypic expression of atypical nevi and conjunctival melanoma, although CDKN2A mutations have not been documented in patients with OM. 12925397 Human
p16 advanced prostate cancer Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. 12947069 Human
p16 small cell carcinoma of the uterine cervix P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. 14506638 Human
p16 gastric tubular adenomas Loss of p27kip1 and p16Ink4a (p16) expression, another CDI, has been reported during the progression of gastric tubular adenomas to advanced gastric cancer. 12603618 Human
p16 neuroendocrine tumors The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. 12612881 Human
p16 adenoid-cystic carcinoma Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. 12624503 Human
p16 adenoid-cystic carcinomas (acc) To explore the role of p16 in the biological behavior of adenoid cystic carcinomas (ACC), we investigated the immunohistochemical expression of p16 protein in 38 ACC tumors (32 primary, 3 recurrent, and 3 metastatic tumors) and the methylation status of i 12624503 Human
p14arf meningiomas Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. 12640680 Human
p14arf meningiomas We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. 12640680 Human
p16 human malignant mesothelioma To determine whether p16 is altered in human malignant mesothelioma (MM), molecular analysis of multiple 9p loci was performed on 40 cell lines and 23 primary tumors from 42 MM patients. 7923195 Human
mts1 esophageal tumors The MTS1 gene is frequently mutated in primary human esophageal tumors. 7970734 Human
p14arf intestinal-type adenocarcinoma TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. 12673679 Human
p14 mucinous cystic neoplasms In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c 14614047 Human
p16 mucinous cystic neoplasms In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c 14614047 Human
p14 mucinous cystic neoplasms There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. 14614047 Human
p16 mucinous cystic neoplasms There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. 14614047 Human
p16 non-small cell carcinomas The authors evaluated 5 noninvasive dysplasias and 33 invasive gallbladder carcinomas (6 small cell carcinomas, 27 non-small cell carcinomas, of which 16 were accompanied by an in situ carcinoma component) for expression of the protein products of the p16 12692194 Human
p16 squamous cervical cancer Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. 12694668 Human
p16 squamous cervical cancer OBJECTIVE: To examine the prognostic significance of the protein expression of the cyclin-dependent kinase (cdk) inhibitors p27, p21, and p16 in early squamous cervical cancer (SCC). 12694668 Human
p16 plasma cell tumors BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. 12700664 Mouse
p16 recurrent colorectal cancer Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. 12712439 Human
p14 duodenal carcinomas RESULTS: Duodenal carcinomas were methylated more frequently or had increased methylation densities than biliary carcinomas at p14 (P = 0.04), hMLH1 (P = 0.04), MGMT (P = 0.01), MINT1 (P = 0.01), MINT25 (P = 0.01), MINT27 (P = 0.001), RAR beta (P = 0.03), 12730870 Human
mts1 intraductal papillary-mucinous tumors P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. 12749268 Human
p16 intraductal papillary-mucinous tumors P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. 12749268 Human
p19 sezary syndrome Antibodies reactive with human T-cell leukemia virus type I (HTLV-I) proteins p19, p24, gp46, p56, and gp68 were detected in four of 27 patients with mycosis fungoides/Sezary syndrome (MF/SS) and one patient with Kaposi's sarcoma using radioimmunopre 1353704 Human
p16 hyperplastic polyps METHODOLOGY: To evaluate the possible p16 role in the development of colonic neoplasms, the authors studied p16 immunohistochemical expression of 84 lesions of colorectal cancers, 6 lesions of hyperplastic polyps, 59 lesions of adenomas and 8 lesions of c 14696398 Human
p16 hyperplastic polyps RESULTS: Compared with normal colonic mucosa, in which virtually no p16 expression was observed, p16 was overexpressed in hyperplastic polyps (33%:2/6) adenomas (46%:27/59), carcinoma in adenoma (88%:7/8) and in adenocarcinomas (98%:82/84). 14696398 Human
mts1 mouse tumor Structure of gene mts1, transcribed in metastatic mouse tumor cells. 2332170 Mouse
cdkn2a primary testicular lymphoma We studied the methylation status of E-cadherin, CDKN2B, CDKN2A, BRCA1, RB1, VHL, RASSF1A, RARB, and GSTP1 by use of TGCT tissues and testicular malignant lymphoma tissues (25 primary TGCT tissues and three primary testicular lymphoma tissues). 12874790 Human
cdkn2a testicular lymphoma In contrast, all three (100%) of the testicular lymphoma tissues demonstrated hypermethylation of E-cadherin, RASSF1A, and RARB, but not CDKN2B, CDKN2A, BRCA1, RB1, VHL, and GSTP1. 12874790 Human
p16 small bowel adenomas The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). 10613343 Human
p16 dcis Three of these proteins, cyclin D1, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relativ 9652762 Human
p16 dcis We therefore characterised the cell cycle regulators cyclin E, cyclin D1, p27 and p16 in a material of DCIS cases arranged in a tissue microarray. 14612904 Human
p16 ductal carcinoma in situ Three of these proteins, cyclin D1, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relativ 9652762 Human
p16 mucinous adenocarcinoma In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; 17365826 Human
p16 benign ovarian tumors METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ova 17177027 Human
p14 lynch syndrome We found MLH1 and p14(ARF) are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. 17278092 Human
p16 monoclonal gammopathy of undetermined significance In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), smoldering multiple myeloma (SMM; n=40), and MM (n=522) 16840723 Human
p16 mgus In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), smoldering multiple myeloma (SMM; n=40), and MM (n=522) 16840723 Human
ink4a figo stage iib ovarian carcinoma We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different pla 17242700 Human
p16ink4a recurrent respiratory papillomatosis Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 17277618 Human
p16 sporadic breast cancer MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic breast cancer patients was examined by methylation-specific PCR (MSP) assay. 17264521 Human
ink4a adenocarcinoma in situ of the uterine cervix IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. 17192788 Human
ink4a follicular lymphoma These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma. 17374722 Human
ink4a sarcoma Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spe 17360455 Mouse
p16 borderline ovarian tumors METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ova 17177027 Human
p16 adenocarcinoma in situ of the uterine cervix IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. 17192788 Human
p14 lynch syndrome Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu 17278092 Human
p16 lynch syndrome Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu 17278092 Human
p16 polyp Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu 17278092 Human
p16 oropharyngeal cancer Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. 17236202 Human
p14 polyp Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu 17278092 Human
arf polyp Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu 17278092 Human
p14arf papillary carcinomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14arf follicular adenomas These deregulations were statistically significant for pl6INK4a (P=0.006) in follicular adenomas and close to statistical significance for p14ARF in follicular adenomas (P=0.06) and in papillary carcinomas (P=0.05). 17117177 Human
p16 familial uveal melanoma Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). 8740697 Human
cdkn2 familial uveal melanoma CDKN2 gene, a cutaneous melanoma predisposition gene, is probably not a uveal melanoma predisposition gene as evidenced by the lack of somatic mutations involving this gene in uveal melanoma samples and the absence of germline mutations in familial uveal 8970601 Human
arf germ cell tumors Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. 10786670 Human
arf medulloblastoma Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. 11212243 Mouse
arf malignant ependymoma We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological 11585252 Human
arf ependymal neoplasms We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological 11585252 Human
arf asap Here predictions for these two mechanisms were tested for the Arf1 effector GGA and ASAP family Arf GAPs. 12376537 Human
arf cerebellar tumors Unlike p53, loss of the Arf tumor suppressor did not contribute to the appearance of vascular or cerebellar tumors. 14500377 Mouse
arf low-grade tumours For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. 14636164 Human
arf pediatric medulloblastomas We analyzed the TP53 and INK4A/ARF loci in 29 pediatric medulloblastomas. 14969745 Human
arf kidney cancer We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-beta2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. 15289362 Human
arf genitourinary cancer Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-beta2, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control sub 15289362 Human
arf alveolar rhabdomyosarcomas Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. 15489287 Mouse
arf high-grade prostatic intraepithelial neoplasias EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
arf myelofibrosis We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. 15755503 Human
arf mantle-cell lymphomas CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. 15781632 Human
arf amelanotic melanoma OBJECTIVE: To characterize a murine model of spontaneous amelanotic melanoma arising in the uvea of transgenic mice bearing a targeted deletion of the Ink4a/Arf tumor suppressor locus (exons 2 and 3) and expressing human H-ras controlled by the human tyro 16087843 Mouse
arf malignant mesotheliomas Human malignant mesotheliomas accumulate multiple somatic genetic alterations, including inactivation of the NF2 and CDKN2A/ARF tumor suppressor genes. 16166281 Human
arf malignant mesotheliomas Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice showed frequent homologous deletions of the Cdkn2a/Arf locus and adjacent Cdkn2b tumor suppressor gene, as well as reciprocal inactivation of Tp53 in a subset of tumors that 16166281 Mouse
arf genitourinary cancer Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels. 16170165 Human
cdk4i squamous cell carcinomas of the larynx We have examined the presence of p16MTS1/CDK4I gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplificat 9333020 Human
cdkn2 anaplastic astrocytomas Forty-six glioblastomas, 16 anaplastic astrocytomas, and 8 astrocytomas were studied for the loss of the CDKN2 (p16/MTS1) gene on 9p. 7987821 Human
cdkn2 cervical tumor In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. 7743516 Human
cdkn2 ovarian tumors In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. 7743516 Human
cdkn2 central nervous system pnet The genesis of the human central nervous system PNET does not involve deletion or mutation of the MTS1/CDKN2 gene. 7791990 Human
cdkn2 stage iv nsclc Homozygous CDKN2 deletion was detected in 13 (28%) of 46 tumor cell lines from patients with stage III or stage IV NSCLC, compared with zero of 10 tumor cell lines from patients with stage I or stage II NSCLC. 7563154 Human
cdkn2 anaplastic astrocytomas By using comparative multiplex PCR, homozygous deletions of the CDKN2/p16 gene were detected in 24 GBMs (57%) and in 2 anaplastic astrocytomas. 8548755 Human
cdkn2 hemangiopericytomas Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. 8834533 Human
cdkn2 bronchogenic carcinoma [Expression of CDKN2 gene product in human bronchogenic carcinoma] OBJECTIVE: To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic ca 9388844 Human
cdkn2 thymomas Subsequently, we examined the 36 thymomas and 4 thymic carcinomas for mutations in p53 and CDKN2 genes, using PCR-SSCP and direct-sequencing analyses. 9398039 Human
cdkn2 thymomas We searched for hypermethylation in the promoter region of CDKN2, observing it in 4 thymomas and 1 thymic carcinoma. 9398039 Human
cdkn2 prostate tumor Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas. 9815578 Human
cdkn2 head and neck carcinomas [Mutation and methylation of CDKN2 gene in human head and neck carcinomas] OBJECTIVE: To study mutations of CDKN2 gene in human head and neck carcinomas (HNC) and to elucidate the role of this gene in tumorigenesis. 10072856 Human
cdkn2 carcinoid DNA was extracted and polymerase chain reaction (PCR) was performed to evaluate loss of heterozygosity and microsatellite alterations using primers flanking 22 polymorphic microsatellite markers from 9 chromosomal regions, including genes associated with 10679642 Human
cdkn2 seminoma To assess whether the aberrant p16INK4A expression could be related to the alterations in CDKN2 regulatory sequence, we screened seminoma DNAs from 19 patients for the promoter mutations. 15734211 Human
cdkn2 seminoma These data suggest that in addition to previously characterized anomalies, the identified CDKN2 promoter mutation may be relevant for altered p16INK4A protein expressions in at least some seminoma. 15734211 Human
cdkn2a benign epithelial tumours Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). 9036870 Human
cdkn2a anaplastic oligodendrogliomas LOH for 9p and/or deletion of the CDKN2A gene occurred in 15 of these 55 tumors, and 11 of these cases were among the 24 (42%) anaplastic oligodendrogliomas. 10433931 Human
cdkn2a anaplastic oligodendrogliomas These findings demonstrate that oligodendroglial neoplasms usually have loss of 1p and 19q whereas astrocytomas of the progressive type frequently contain mutations of the TP53 gene, and that 9p loss and CDKN2A deletions are associated with progression fr 10433931 Human
cdkn2a head and neck tumors We tested 30 patients with primary head and neck tumors using methylation-specific PCR searching for promoter hypermethylation of the tumor suppressor gene p16 (CDKN2A), the DNA repair gene O6-methylguanine-DNA-methyltransferase (MGMT) and the putative me 11221887 Human
cdkn2a anaplastic meningiomas Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. 11485924 Human
cdkn2a anaplastic meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
cdkn2a anaplastic meningiomas Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14(ARF), and CDKN2B genes. 11485924 Human
cdkn2a anaplastic meningiomas Two anaplastic meningiomas carried somatic point mutations in CDKN2A (c.262G>T: E88X and c.262G>A: E88K) and p14(ARF) (c.305G>T: G102V and c.305G>A: G102E). 11485924 Human
cdkn2a anaplastic meningiomas However, the majority of anaplastic meningiomas either show homozygous deletions of CDKN2A, p14(ARF), and CDKN2B, mutations in CDKN2A and p14(ARF), or lack of expression of one or more of these genes. 11485924 Human
cdkn2a supratentorial primitive neuroectodermal tumours Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. 12175345 Human
cdkn2a myeloid tumors The effectiveness of large-scale insertional mutagenesis in a sensitized genetic background is demonstrated by the preference for activation of MAP kinase signaling, collaborating with Cdkn2a loss in generating the lymphoid and myeloid tumors. 12185367 Human
cdkn2a mammary tumor Differences in mammary tumor occurrence among genotypes for Prkdc and Cdkn2a in N2 mice were not statistically significant. 12750252 Human
cdkn2a ependymal tumours CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. 14636164 Human
cdkn2a low-grade tumours For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. 14636164 Human
cdkn2a kidney tumors Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six 14695183 Human
cdkn2a glioblastoma EXPERIMENTAL DESIGN: In this series of 140 consecutive cases of glioblastoma treated at a single center, we analyzed the frequency, age dependency and prognostic effects of TP53 mutation, CDKN2A/p16 deletion, EGFR amplification, as well as loss of chromos 14734474 Human
cdkn2a hereditary breast-ovarian cancer syndrome This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat 15264268 Human
cdkn2a barrett's esophagus We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (aneuploidy, tetraploidy) within each Barrett's esophagus segment o 15492292 Human
cdkn2a high-grade prostatic intraepithelial neoplasias EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
cdkn2a invasive cervical cancers Flow cytometry on primary CVX and NCK and immunohistochemical staining of formalin fixed paraffin-embedded tumor specimens from which primary CVX cultures were derived as well as from a separate set of invasive cervical cancers confirmed differential expr 15629771 Human
cdkn2a colon polyps Aberrantly Methylated CDKN2A, MGMT, and MLH1 in Colon Polyps and in Fecal DNA from Patients with Colorectal Polyps. 15709190 Human
cdkn2a hyperplastic polyps Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the pot 15709190 Human
cdkn2a colon adenomas Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the pot 15709190 Human
cdkn2a hyperplastic polyps We have found that methylated MGMT, CDKN2A, and MLH1 occur in 49%, 34%, and 7% of adenomas and in 5%, 10%, and 7% of hyperplastic polyps, respectively, and that they are more common in histologically advanced adenomas. 15709190 Human
cdkn2a invasive ductal carcinomas Expressions of DUSP6, CDKN2A, TP53, and SMAD4 were investigated by immunohistochemistry in a total of 206 lesions of dysplastic ductal precursors and carcinomas retrieved from 52 pancreata with invasive ductal carcinomas and 51 of those with intraductal p 15832194 Human
cdkn2a malignant mesotheliomas Human malignant mesotheliomas accumulate multiple somatic genetic alterations, including inactivation of the NF2 and CDKN2A/ARF tumor suppressor genes. 16166281 Human
cdkn2a malignant mesotheliomas Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice showed frequent homologous deletions of the Cdkn2a/Arf locus and adjacent Cdkn2b tumor suppressor gene, as well as reciprocal inactivation of Tp53 in a subset of tumors that 16166281 Mouse
cdkn2a gastrointestinal stromal tumors Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors. 16166437 Human
ink4 digestive tract tumor CONCLUSION: The role of DNA methylation in the silence of p16/INK4 may different between these two types of upper digestive tract tumor. 15612883 Human
ink4a liver tumors Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. 9667743 Mouse
ink4a liver tumors Approximately 12% (3/26) of the liver tumors exhibited point mutations in exon 1 of the INK4a gene, with each of the three tumors exhibiting two point mutations. 9667743 Mouse
ink4a lung tumor To provide further evidence that hypermethylation is involved in the loss of p16 (Ink4a) gene expression, three mouse lung tumor cell lines (C10, sp6c and CMT64) displaying complete methylation at seven promoter CpG sites and no p16 (Ink4a) expression wer 10964101 Mouse
ink4a liver tumors Using the transplacental carcinogenesis model, which results in the induction of both lung and liver tumors following in utero exposure to MC, the results of this and our previous studies show that alterations in the Ink4a locus occur in only 15 and 27% o 11595130 Human
ink4a liver tumors These results imply that damage to the Ink4a gene is not a frequent pathway to malignant progression in mouse lung and liver tumors following in utero exposure to environmental carcinogens. 11595130 Mouse
ink4a pediatric medulloblastomas We analyzed the TP53 and INK4A/ARF loci in 29 pediatric medulloblastomas. 14969745 Human
ink4a malignant ovarian germ cell tumours Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours: INK4A promoter CpG island methylation is associated with cell proliferation. 15476271 Human
ink4a barrett's esophagus We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (aneuploidy, tetraploidy) within each Barrett's esophagus segment o 15492292 Human
ink4a alveolar rhabdomyosarcomas Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. 15489287 Mouse
ink4a neurofibroma In Part I of this review, we discussed findings demonstrating that a loss of NF1 tumor suppressor gene function in neoplastic Schwann cells is a key early step in neurofibroma formation and that progression from neurofibroma to MPNST is associated with ab 15715079 Human
ink4a melanoma The mutation of genes associated with melanoma, such as INK4a or BRAF that would affect either Mitf cooperation with Rb1 or Mitf stability respectively, would impair Mitf-mediated cell cycle control. 15716956 Human
ink4a myelofibrosis We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. 15755503 Human
ink4a mantle-cell lymphomas CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. 15781632 Human
ink4a amelanotic melanoma OBJECTIVE: To characterize a murine model of spontaneous amelanotic melanoma arising in the uvea of transgenic mice bearing a targeted deletion of the Ink4a/Arf tumor suppressor locus (exons 2 and 3) and expressing human H-ras controlled by the human tyro 16087843 Mouse
mlm hamartomas To investigate the molecular mechanisms of tuberous sclerosis (TSC) histopathologic lesions, we have tested for loss of heterozygosity the two TSC loci (TSC1 and TSC2) and seven tumor suppressor gene-containing regions (TP53, NF1, NF2, BRCA1, APC, VHL, an 8824721 Human
mts1 metastatic tumors The mts1 gene is specifically expressed in certain metastatic tumors but not in their nonmetastatic counterparts. 1329089 Human
mts1 anaplastic astrocytomas After controlling for the contamination of tumor samples with normal cells, homozygous loss of MTS1 was found in 13 of 25 anaplastic astrocytomas (WHO grade III) and in 27 of 46 cases of glioblastomas (WHO grade IV) but in none of seven astrocytomas (WHO 7805033 Human
mts1 central nervous system pnet The genesis of the human central nervous system PNET does not involve deletion or mutation of the MTS1/CDKN2 gene. 7791990 Human
mts1 tumors of the central nervous system In this study we have examined the status of the MTS1 gene in a variety of non-astrocytic tumors of the central nervous system. 7794250 Human
mts1 t-cell neoplasms We observed a higher frequency of MTS1 deletions in ALL than in NHL (P < 0.001) and in T-cell neoplasms compared to B-cell neoplasms (67% v 6%; P = 0.001). 8547074 Human
mts1 common tumor The genes p16 (or MTS1) and TEL/AML1 are now respectively recognized as the most common tumor suppressor and fusion genes in childhood acute lymphoblastic leukemia. 9372085 Human
mts1 testicular germ cell tumors Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. 9284835 Human
mts1 mesenchymal neoplasms BACKGROUND AND OBJECTIVES: Tumor suppressor gene MTS1/p16 (cyclin-dependent kinase-4 inhibitor) and a putative tumor metastasis suppressor gene nm23 (nucleoside diphosphate A kinase) have been identified in a variety of human tumors but have not been well 11223831 Human
mts1 minimal residual disease We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi 12127556 Human
mts1 mrd We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi 12127556 Human
mts1 adenocarcinomas of the uterine cervix The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with internati 14584070 Human
mts1 rectal carcinomas [The expression of MTS1 gene product in transitional mucosa adjacent to rectal carcinomas and its clinical significance] OBJECTIVE: To study the property of transitional mucosa (TM) adjacent to rectal carcinoma and the clinical significance of MTS1 gene d 11829899 Human
mts1 rectal carcinoma METHODS: We used the immunohistochemical methods to observe the range of TM adjacent to rectal carcinoma, and the immunohistochemical method to observe the expression of MTS1 gene product on TM, using normal mucosa and carcinoma tissue as control. 11829899 Human
mts1 rectal carcinoma TM is related to MTS1 gene expression deficit of rectal carcinoma, showing that MTS1 gene expression deficit or mutation may be a factor inducing transitional change adjacent to carcinoma. 11829899 Human
mts1 pulmonary metastasis Microarray Analysis of Metastasis-Associated Gene Expression Profiling in a Murine Model of Thyroid Carcinoma Pulmonary Metastasis: Identification of S100A4 (Mts1) Gene Overexpression as a Poor Prognostic Marker for Thyroid Carcinoma. 15579771 Human
p14 prostate tumors RESULTS: Overexpression of p16 mRNA was found in 6/9 (67) of prostate tumors compared to the adjacent normal prostate, whereas elevated p14 and p15 levels were only observed in 2/9 (22) and 1/6 (17) of prostate cases, respectively. 10797499 Human
p14 prostate tumors Exon 2 of p16/p14 is methylated in a majority of prostate tumors compared to the unmethylated upstream 5' region, and may be a potential tumor marker for human prostate cancer. 10797499 Human
p14 malignant ependymoma We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological 11585252 Human
p14 ependymal neoplasms We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological 11585252 Human
p14 advanced cancers Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity. 12716465 Human
p14 carcinoid tumors Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. 12584572 Human
p14 carcinoid tumors Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, p = 0.03), THBS1 (44 versus 9%, p = 0.04), p14 (44 versus 9%, p = 0.04) and RARbeta (25 versus 0%, p = 0.03). 12584572 Human
p14 low-grade tumours For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. 14636164 Human
p14 colon adenoma To address changes in the methylation profiles of multiple genes during colorectal carcinogenesis, we investigated the methylation of 12 genes (APC, COX-2, DAP-kinase, E-cadherin, GSTP1, hMLH1, MGMT, p14, p16, RASSF1A, THBS1, and TIMP3) in normal colon (n 15122305 Human
p14 relapsed childhood acute lymphoblastic leukemia Methylation profile was analyzed in nine cases of relapsed childhood acute lymphoblastic leukemia (ALL) for p14, p15, p16, Rb, MGMT, APC, hMLH1, RARbeta, RIZ, DAPK, and FHIT genes by using methylation specific polymerase chain reaction (MSP) analysis. 15201966 Human
p14 nodular melanomas Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. 15547691 Human
p14 nodular melanomas Strong staining of p14 was found in 63% of nodular melanomas and was associated with strong p53 expression (p=0.014), and with high levels of CDK4 (p<0.0001). 15547691 Human
p14 uterine cervical cancer METHODS: We analyzed CpG island hypermethylation in 15 genes (APC, CDH1, COX2, DAPK, FHIT, GSTP1, HLTF1, hMLH1, MGMT, p14, p16, RASSF1A, RUNX3, THBS1, and TIMP3) and its association with the methylene-tetrahydrofolate reductase (MTHFR) C677T and A1298C an 15589597 Human
p14 high-grade prostatic intraepithelial neoplasias EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
p14 myelofibrosis We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. 15755503 Human
p14arf pediatric astrocytomas Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. 10665922 Human
p14arf stage i adenocarcinomas of the lung Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. 11940214 Human
p14arf laryngeal tumor [Effect of p14ARF gene on cell growth of human laryngeal tumor cells and expression of endogenous p53 protein] OBJECTIVE: To explore the inhibitory effect of p14ARF on the cell growth of laryngeal carcinoma and the expression on endogenous p53. 12761983 Human
p14arf familial cancers They are "classical" tumor suppressor genes with associated familial cancers (BRCA1, hMLH1, p16INK4a, VHL, etc.) and putative new tumor suppressor genes which loss may contribute to the transformed phenotype (MGMT, p14ARF, GSTP1, RARB2, etc.). 12908548 Human
p14arf neurofibromatosis p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. 14519636 Human
p14arf diffuse astrocytomas Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. 14581362 Human
p14arf ependymal tumours CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. 14636164 Human
p14arf kidney tumors Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six 14695183 Human
p14arf well-differentiated liposarcomas Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas. 14695989 Human
p14arf clear cell sarcoma Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. 15298727 Human
p14arf melanocytic neoplasm Alterations in the p16INK4a/p14ARF gene are common in malignant melanoma, which is the prototypical melanocytic neoplasm. 15298727 Human
p14arf barrett's adenocarcinoma To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease. 15185075 Human
p14arf invasive breast cancers p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. 15318938 Human
p14arf nsclc Using genetic and epigenetic analyses, we examined various molecular alterations including the loss of protein and mRNA expression, and 5'CpG hypermethylation, allelic imbalance, and mutation of the p14ARF gene in a series of 102 NSCLC samples, in pa 15269146 Human
p14arf occupational bladder cancer An analysis of the effects of lifestyle and occupational bladder cancer risk factors revealed that TCC of smokers showed a 2-fold elevated expression of MDM2 mRNA and an approximately 2-fold lower expression of P14ARF mRNA, whereas the activity of the p73 15492852 Human
p14arf aggressive nk-cell leukemia We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. 15813917 Human
p14arf aggressive nk-cell leukemia It has been reported that tumor suppressor genes are inactivated by DNA methylation of the promoter region and/or first exon of the genes in a variety of human cancers. 15813917 Human
p14arf squamous cell carcinoma of the anterior tongue p14ARF Protein Expression Is a Predictor of Both Relapse and Survival in Squamous Cell Carcinoma of the Anterior Tongue. 15930346 Human
p16 brain tumors Deletion of p16 and p15 genes in brain tumors. 7987828 Human
p16 medulloblastomas We found that p16 and a neighboring gene, p15, were often homozygously deleted in glioblastoma multiformes but not in medulloblastomas or ependymomas. 7987828 Human
p16 primary tumours Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear. 7777061 Human
p16 melanomas in situ Our results suggest that loss of p16 protein expression is (a) not necessary for tumor initiation in malignant melanoma because all melanomas in situ and the majority of primary invasive melanomas retain expression of this protein; and (b) potentially mor 7796391 Human
p16 hodgkin's disease We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f 7579381 Human
p16 anaplastic astrocytomas By using comparative multiplex PCR, homozygous deletions of the CDKN2/p16 gene were detected in 24 GBMs (57%) and in 2 anaplastic astrocytomas. 8548755 Human
p16 hemangiopericytomas Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. 8834533 Human
p16 common tumor The genes p16 (or MTS1) and TEL/AML1 are now respectively recognized as the most common tumor suppressor and fusion genes in childhood acute lymphoblastic leukemia. 9372085 Human
p16 trophoblastic tumors [The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors] OBJECTIVE: To evaluate the relationship between the regulatory factors in G1 phase of cell cycle and the cacrinogenesis of the trophoblastic cells. 10681785 Human
p16 trophoblastic tumors RESULTS: The expressions of p16 protein between malignant trophoblastic tumors and normal villi were significantly different (P < 0.05). 10681785 Human
p16 ovarian serous cystadenocarcinoma [A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden 10683958 Human
p16 cll Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. 9018124 Human
p16 benign epithelial tumours Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). 9036870 Human
p16 benign tumours Most benign tumours showed no p16 expression in the tumour cells, whereas only 11% of malignant cancers were p16 negative. 9036870 Human
p16 gastric tumors Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript pl6beta in esophageal and gastric tumors. p16 gene expression was undetectable in 13 of 25 esophageal squamous 9333024 Human
p16 neck tumors Expression of p16 protein was negative or weak in 9% of the cases, and this tended to be less frequent in head/neck tumors compared with the others (0% vs. 12%). 9355977 Human
p16 prostate tumor Results of the study show that whereas universal promoters, such as Cytomegalovirus (CMV) and Rous Sarcoma Virus (RSV) promoter-driven tumor suppressors (e.g. p53, p21, and p16), were effective in inhibiting prostate tumor growth, the advantages of drivin 9436028 Human
p16 benign testicular tumors For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. 9554401 Human
p16 b-cell non-hodgkin's lymphomas Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. 9573674 Human
p16 low-grade squamous intraepithelial lesions Condylomata acuminata and low-grade squamous intraepithelial lesions with infection by low-risk HPV such as HPV-6/11 showed focal and weak immunohistochemical staining for p16. 9846965 Human
p16 cystadenomas All six cases of normal pancreas and all but 1 of 20 cases of chronic pancreatitis expressed p16 protein, whereas 37.5% (3 of 8) of cystadenomas and 41. 9% (26 of 62) of PCs lost p16 expression. 9815833 Human
p16 cervical tumor MSP-ISH reveals that p16 hypermethylation occurs heterogeneously within early cervical tumor cell populations that are separate from those expressing viral E7 transcripts. 10535995 Human
p16 gliomas Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. 10587703 Human
p16 premalignant condition Loss of heterozygosity (LOH) at 9p21 and 17p13 chromosomes (locations for p16 and p53 genes, respectively) is frequently observed in the premalignant condition, Barrett's esophagus. 10601379 Human
p16 adenocarcinomas of the prostate METHODS: The levels of p16 and CDK4 proteins were quantitated by immunofluorescence flow cytometry, using paraffin embedded material, in 104 adenocarcinomas of the prostate after radical prostatectomy. 10640976 Human
p16 bph RESULTS: In prostatic carcinoma specimens, p16 protein was elevated significantly compared with BPH, with a median fluorescence index (FI) of 15.4 versus 10.7, respectively (P = 0.010). 10640976 Human
p16 bph This was not the case for CDK4 protein, although p16 protein expression correlated significantly with CDK4 protein expression in BPH (Spearman rank correlation [R(S)] = 0.63) and carcinoma (R(S) = 0.78). 10640976 Human
p16 secondary glioblastomas Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or ana 10666371 Human
p16 cartilaginous tumour The role of two important tumour suppressor genes, p16 and p53, was evaluated in cartilaginous tumour tissues. 10709095 Human
p16 prostate tumor Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. 10713671 Human
p16 prostate tumors RESULTS: Overexpression of p16 mRNA was found in 6/9 (67) of prostate tumors compared to the adjacent normal prostate, whereas elevated p14 and p15 levels were only observed in 2/9 (22) and 1/6 (17) of prostate cases, respectively. 10797499 Human
p16 prostate tumors Diminished RB levels in prostate tumors that had upregulated p16 mRNA were found, although absent RB was also detected in tumors without elevated p16 levels. 10797499 Human
p16 prostate tumors Exon 2 of p16/p14 is methylated in a majority of prostate tumors compared to the unmethylated upstream 5' region, and may be a potential tumor marker for human prostate cancer. 10797499 Human
p16 prostate tumors Moreover, prostate tumors injected with Adp16 expressed p16 and the adenoviral vector expressed the transgene for up to 14 days. 10854145 Human
p16 astrocytomas Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. 10896207 Human
p16 lung tumor To provide further evidence that hypermethylation is involved in the loss of p16 (Ink4a) gene expression, three mouse lung tumor cell lines (C10, sp6c and CMT64) displaying complete methylation at seven promoter CpG sites and no p16 (Ink4a) expression wer 10964101 Mouse
p16 adrenocortical neoplasms While the mechanisms of tumorigenesis for adrenocortical neoplasms remain unknown, several genes, such as Gsalpha, ACTH receptor (MC2-R), p53, and p16 tumor suppressor genes, are considered to be candidates for adrenocortical neoplasms. 11075727 Human
p16 hereditary breast and ovarian cancer At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
p16 transitional cell carcinoma of urinary bladder [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. 11831985 Human
p16 cystadenomas Lack of p16 expression was present in 7 of 16 cystadenomas, 4 of 13 LMP tumors, and 22 of 29 carcinomas (P [LMPs versus carcinomas] = 0. 01) and correlated with methylation changes in LMP tumors (P = 0.05). p16 expression was correlated with mucinous diff 9889036 Human
p16 cystadenomas Changes in DNA methylation may be more important for inactivation of this gene (and perhaps other tumor suppressor genes) in LMP tumors, which lack many of the alternative mechanisms present in carcinomas. p16 expression is primarily related to mucinous d 9889036 Human
p16 uterine tumours Alteration of p16 and p15 genes in human uterine tumours. 10408854 Human
p16 endometrial tumours Reduced expression of p16 protein, detected by immunohistochemistry, occurred even more frequently, in nine of 33 (27%) cervical and seven of 37 (19%) endometrial tumours. 10408854 Human
p16 pediatric all These results confirm and extend the authors' previous findings that homozygous deletion of p16 in pediatric ALL patients is an independent prognostic indicator of outcome from therapy. 11154239 Human
p16 mzbcl DESIGN AND METHODS: Fourteen cases of MZBCL diagnosed according to the REAL classification were studied by conventional chromosome analysis (CCA) and by interphase fluorescence in situ hybridization (FISH) using the following probes: 3q27/BCL6, 6q21, 7q31 11146573 Human
p16 head and neck tumors We tested 30 patients with primary head and neck tumors using methylation-specific PCR searching for promoter hypermethylation of the tumor suppressor gene p16 (CDKN2A), the DNA repair gene O6-methylguanine-DNA-methyltransferase (MGMT) and the putative me 11221887 Human
p16 mesenchymal neoplasms BACKGROUND AND OBJECTIVES: Tumor suppressor gene MTS1/p16 (cyclin-dependent kinase-4 inhibitor) and a putative tumor metastasis suppressor gene nm23 (nucleoside diphosphate A kinase) have been identified in a variety of human tumors but have not been well 11223831 Human
p16 minimal residual disease PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. 11283136 Human
p16 mrd PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. 11283136 Human
p16 apl CONCLUSION: In APL, p15 but not p16 gene methylation is frequent. 11283136 Human
p16 ptcl Fifty-seven cases of T-cell lymphomas (TCL) including 5 lymphoblastic (T-LBL) and 52 peripheral TCL (PTCL) were analyzed by immunohistochemistry for the expression of p53, mdm2, p21, Rb, cyclin D1, cyclin A, cyclin B1, and Ki67/MIB1 proteins and 39/52 PTC 11332692 Human
p16 basal cell nevus syndrome Expression of cyclin D1 and p16 protein was detected in the basal and parabasal cells in lining epithelium of OKCs and was found more frequently in basal cell nevus syndrome (BCNS)-associated OKCs than in primary or recurrent OKCs. 11488422 Human
p16 pnet Given that EWS/FLI1 is only able to transform immortalized 3T3 fibroblasts and that 30% of ES/PNET tumors contain a homozygous deletion of the p16 locus, it is likely that other genetic events are required for EWS/FLI1 oncogenesis. 11709708 Human
p16 mucoepidermoid carcinoma of salivary glands [Detection of proteins and mRNA of p16, p53 and nm23 in mucoepidermoid carcinoma of salivary glands and their prognostic significance] OBJECTIVE: To disclose the relationship between the expression of p16, p53 and nm23 and the significant morphologic char 11758216 Human
p16 parotid tumor [A qualititative study on p16 mutiple tumor suppressor gene, ras oncogene p21 and DNA content in parotid tumor and its' contiguous acini] OBJECTIVE: To determine the biologic characteristics of tumor's contiguous acini and the relationship of re 11769651 Human
p16 gastric malt lymphoma We performed a prospective study to evaluate the outcome of patients with low-grade gastric MALT lymphoma and the expression of p16 hypermethylation. 11824795 Human
p16 nsclc To identify the molecular basis for this p16 immunohistochemical negativity further, we performed a genetic and epigenetic study of p16(INK4a) status in a series of 115 NSCLC samples parallel to the clinicopathologic and prognostic analyses. 11920642 Human
p16 malignant eyelid tumors Expression of P16 protein and Bcl-2 protein in malignant eyelid tumors. 11930651 Human
p16 malignant eyelid tumors OBJECTIVE: To investigate the relationship between P16 gene (the tumor suppressor gene) and the bcl-2 gene (the apoptosis inhibitor gene) and the incidence and development of malignant eyelid tumors. 11930651 Human
p16 malignant eyelid tumors METHODS: The streptavidin-biotin-peroxidase complex immunohistochemistry method was used to study the expression of P16 gene and the bcl-2 gene in 96 cases of malignant eyelid tumors. 11930651 Human
p16 mucoid carcinoma The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 11819820 Human
p16 stage i adenocarcinomas of the lung Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. 11940214 Human
p16 minimal residual disease Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. 12127556 Human
p16 minimal residual disease We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi 12127556 Human
p16 mrd We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi 12127556 Human
p16 mrd A slower response to the induction treatment (MRD) was associated with LOH of p16 and worse clinical outcome. 12127556 Human
p16 familial cancers Based on our observations, the spectrum of familial cancers associated with p16 mutations should include a new clinical entity, familial HNSCC. 12352668 Human
p16 cin 3 Expression of p16 was restricted to CIN 2/CIN 3, CIN 1 associated with high-risk human papillomavirus, or cervical cancer. p16 immunostaining allowed precise identification of even small CIN or cervical cancer lesions in biopsy sections and helped to redu 12409715 Human
p16 advanced cancers Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity. 12716465 Human
p16 laryngeal papilloma [Human papilloma virus infection and expression of p16 protein in laryngeal papilloma and laryngeal carcinoma] OBJECTIVE: To evaluate the role of human papilloma virus (HPV) infection and inactivation of p16 gene in laryngeal papilloma (LP) and laryngeal 12761910 Human
p16 carcinoid tumors Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. 12584572 Human
p16 carcinoid tumors Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (p = 0.006). 12584572 Human
p16 neuroendocrine tumors of the lung The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. 12612881 Human
p16 apl In this study, methylation-specific polymerase chain reaction (MSP) was used to define the methylation status of a panel of nine genes, comprising p15, p16, RARbeta, oestrogen receptor (ER), E-cadherin (E-CAD), p73, caspase 8 (CASP8), VHL and MGMT, in 29 12899712 Human
p16 apl In APL, p15, p16, ER and RARbeta were most frequently methylated. 12899712 Human
p16 tongue squamous cell carcinoma [Expression of p15 and p16 proteins in tongue squamous cell carcinoma and their significances] BACKGROUND & OBJECTIVE: Abnormal expression of p15 and p16 were commonly found in many kinds of primary tumors, but the possible correlation between p15 and p16 14613656 Human
p16 ganglioglioma The present case is unusual in four aspects: (i) it arose from a low-grade ganglioglioma in the absence of previous radiation or chemotherapy, which is the fourth reported case; (ii) the original tumor showed a high proliferative index on flow cytometry b 14629754 Human
p16 skin metastasis In contrast, all cells of melanoma metastases, except one skin metastasis, lacked nuclear staining for p16. 14576937 Human
p16 mmmt Three consecutive cases of primary peritoneal MMMT were examined by paraffin immunohistochemistry for expression of p53, p16, BCL2, CerbB2, and classical cadherins E-cadherin, P-cadherin, and N-cadherin. 14675326 Human
p16 mmmt We conclude that p16 may be a common tumor suppressor gene expressed in peritoneal MMMT. 14675326 Human
p16 common tumor We conclude that p16 may be a common tumor suppressor gene expressed in peritoneal MMMT. 14675326 Human
p16 pancreatic adenocarcinoma A pancreatic adenocarcinoma cell line (PaCa44), which contains, among other alterations, a methylated p16 promoter, was treated with a chemoterapeutic agent, 5-aza-2'-deoxycytidine (DAC), in order to evaluate the effect of this drug on cell growth an 14679576 Human
p16 oral tumor The incidence of hypermethylation in oral tumor and adjacent mucosa for p16 gene was 66.7 and 50%, for DAPK was 68.3 and 60%, and MGMT gene was 51.7 and 26.7%, respectively. 14693237 Human
p16 kidney tumors Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six 14695183 Human
p16 oropharyngeal tumors P16 expression in the node metastases also correlated with site of tumor origin: 24 of 31 oropharyngeal tumors were p16 positive, whereas only 1 of 37 nonoropharyngeal tumors was p16 positive (77% versus 3%; P < 0.001; Fisher's exact). 14695150 Human
p16 glioblastoma EXPERIMENTAL DESIGN: In this series of 140 consecutive cases of glioblastoma treated at a single center, we analyzed the frequency, age dependency and prognostic effects of TP53 mutation, CDKN2A/p16 deletion, EGFR amplification, as well as loss of chromos 14734474 Human
p16 cin grade 3 Immunohistochemistry revealed that all HSIL and invasive carcinoma cases contained p16-positive cells in the liquid-based Pap smears and diffuse p16 staining was observed in all high-grade lesions with greater than CIN Grade 3 cervical intraepithelial neo 15098254 Human
p16 cervical tumor RESULTS: Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA; and in 40%, 10%, and 7.5% of cases of patients' plasma DNA. 15099958 Human
p16 spitz nevus An analysis of cell-cycle inhibitory proteins including p16, p21, and p27 showed that the majority of Spitz nevus cells expressed high levels of p16, with cells of the cases that had increased copy number of 11p expressing significantly higher levels than 15111324 Human
p16 barrett's esophagus Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. 15150093 Human
p16 salivary gland tumors [Expression of p16 and nm23 genes in salivary gland tumors] OBJECTIVE: To study the expression of p16 and nm23 genes in salivary gland tumors and the relation of P16 and nm23 proteins with fumorigenesis of salivary gland tumors. 15190803 Human
p16 salivary gland tumors METHODS: Expression of P16 and nm23 proteins was examined by SABC immunohistochemical method in 39 cases of paraffin blocks of normal salivary gland tissues and salivary gland tumors. 15190803 Human
p16 colon adenoma To address changes in the methylation profiles of multiple genes during colorectal carcinogenesis, we investigated the methylation of 12 genes (APC, COX-2, DAP-kinase, E-cadherin, GSTP1, hMLH1, MGMT, p14, p16, RASSF1A, THBS1, and TIMP3) in normal colon (n 15122305 Human
p16 small cell carcinoma of the uterine cervix In this study, 22 cases of primary small cell carcinoma of the uterine cervix were subjected to broad-spectrum HPV DNA amplification and typing, and immunohistochemically examined for the expression of p16, Rb, and p53 proteins. 15223960 Human
p16 cervical tumors While similar p16 and Rb expression patterns were observed in these HPV-negative tumors, a different expression pattern for p53 was noted where strong nuclear staining was seen in 8 cases (47%; P = 0.0004 compared with cervical tumors). 15223960 Human
p16 endometrial adenocarcinomas Re: Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection. 15223971 Human
p16 hereditary breast-ovarian cancer syndrome This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat 15264268 Human
p16 kidney cancer We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-beta2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. 15289362 Human
p16 genitourinary cancer Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-beta2, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control sub 15289362 Human
p16 vulvar squamous cell carcinomas METHODS: A total of 224 vulvar squamous cell carcinomas were immunohistochemically investigated for expression of p16, p21, and p27 using the biotin-streptavidin-peroxidase method and the OptiMax Plus automated cell staining system. 15385108 Human
p16 colorectal carcinomas This study aimed to identify potential abnormalities of retinoblastoma protein (pRb) and p16(INK4a) (p16) expression in resectable colorectal carcinomas (CRCs) and to assess the prognostic significance of pRb and p16 levels in patients with CRC. 15492985 Human
p16 eyelid tumors [A study on the expression of p16 protein and bcl-2 protein in cutaneous eyelid tumors] OBJECTIVE: To investigate the relationship between p16 (tumor suppressor) and bcl-2 (apoptosis inhibitor) gene expression and the incidence and development of eyelid m 11853608 Human
p16 skin carcinoma Monitoring of the expression of p16, p21(WAF1/CIP1) and Cyclin D1 proteins may be valuable for early detection and early treatment and prognostic assessment of skin carcinoma caused by coal-burning. 11860939 Human
p16 hepatitis b virus-related hepatocellular carcinoma [Effect of p16 gene on carcinogenesis of hepatitis B virus related hepatocellular carcinoma] OBJECTIVE: To investigate the relation between p16 gene expression and the carcinogenesis and progress of hepatitis B virus (HBV) related hepatocellular carcinoma 12921565 Human
p16 invasive carcinomas RARbeta, p16, and MGMT genes showed the highest incidences of methylation in premalignant and invasive carcinomas. 15173091 Human
p16 relapsed childhood acute lymphoblastic leukemia Methylation profile was analyzed in nine cases of relapsed childhood acute lymphoblastic leukemia (ALL) for p14, p15, p16, Rb, MGMT, APC, hMLH1, RARbeta, RIZ, DAPK, and FHIT genes by using methylation specific polymerase chain reaction (MSP) analysis. 15201966 Human
p16 hpv-related carcinomas Recently, the tumor suppressor protein p16 has been shown to be specifically overexpressed in HPV-related carcinomas and premalignant lesions of the uterine cervix, oral cavity, and anus, but the presence of p16 vulvar squamous lesions has not been examin 15213596 Human
p16 ameloblastic carcinoma There were 12 ameloblastomas (two peripheral, eight solid, and two unicystic) and three ameloblastic carcinoma studied for loss of heterozygosity of tumor suppressor genes on chromosomes 1p, 3p, 9p,10q, and 17p (L-myc, hOGG1, p16, pten, and p53). 15133474 Human
p16 oropharyngeal squamous cell carcinoma In this study, we sought to determine whether p16 expression is of prognostic importance in oropharyngeal squamous cell carcinoma. 15355894 Human
p16 oropharyngeal squamous cell carcinoma CONCLUSIONS: In patients with oropharyngeal squamous cell carcinoma, overexpression of p16 as determined by immunohistochemistry is associated with significantly improved prognosis and lower local recurrence rates. 15355894 Human
p16 large-cell neuroendocrine carcinomas Loss of Rb and p16 expression, respectively, was observed in no and 14% typical carcinoids, no and 40% atypical carcinoids, 49 and 18% large-cell neuroendocrine carcinomas, 84 and 8% small-cell carcinomas. 15154011 Human
p16 carcinoid tumors Rb pathway aberration was mostly attributed to Rb loss in small-cell carcinomas, while p16 loss and/or cyclin D1 overexpression besides Rb loss also played an important role in large-cell neuroendocrine carcinomas, while cyclin D1 overexpression was the o 15154011 Human
p16 large-cell neuroendocrine carcinomas Rb pathway aberration was mostly attributed to Rb loss in small-cell carcinomas, while p16 loss and/or cyclin D1 overexpression besides Rb loss also played an important role in large-cell neuroendocrine carcinomas, while cyclin D1 overexpression was the o 15154011 Human
p16 malignant germ cell tumours of the ovary To clarify the mechanisms underlying cell cycle promotion in malignant germ cell tumours of the ovary (MGCTOs), beta-catenin and components of the pRB pathway, cyclin D1 and p16, were analysed in relation to cell proliferation. 15476271 Human
p16 esophageal adenocarcinoma The size of a clone with a p16 lesion is not a significant predictor of esophageal adenocarcinoma when we controlled for p53 loss of heterozygosity status. 15492292 Human
p16 hydatidiform moles We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-s 15507671 Human
p16 choriocarcinomas We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-s 15507671 Human
p16 choriocarcinoma Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal plac 15507671 Human
p16 gestational trophoblastic neoplasia Hypermethylation of multiple genes, especially p16, might be related to the subsequent development of gestational trophoblastic neoplasia. 15507671 Human
p16 nodular melanomas Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. 15547691 Human
p16 smooth muscle tumors Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. 15589581 Human
p16 smooth muscle tumor In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS). 15589581 Human
p16 leiomyoma In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS). 15589581 Human
p16 leiomyoma METHODS: P16 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 patients with STUMP, and in 21 patients with LMS. 15589581 Human
p16 leiomyoma A statistically significant difference regarding the frequency of p16 protein expression was observed between LMS and STUMP (P < 0.05) as well as between LMS and leiomyoma (P < 0.05), but not between STUMP and leiomyoma (P > 0.05). 15589581 Human
p16 leiomyoma CONCLUSIONS: We found that p16 was more frequently and more strongly expressed in LMS compared to STUMP and leiomyoma. 15589581 Human
p16 smooth muscle tumors Furthermore, p16 might be a useful immunohistochemical marker, which could help to distinguish cases of smooth muscle tumors in which histologic features are ambiguous or borderline, but the use of p16 in a diagnostic setting should await further clinical 15589581 Human
p16 uterine cervical cancer METHODS: We analyzed CpG island hypermethylation in 15 genes (APC, CDH1, COX2, DAPK, FHIT, GSTP1, HLTF1, hMLH1, MGMT, p14, p16, RASSF1A, RUNX3, THBS1, and TIMP3) and its association with the methylene-tetrahydrofolate reductase (MTHFR) C677T and A1298C an 15589597 Human
p16 digestive tract tumor CONCLUSION: The role of DNA methylation in the silence of p16/INK4 may different between these two types of upper digestive tract tumor. 15612883 Human
p16 vin 3 Ninety-five percent of VIN 3 and basaloid or warty SCCs (76/80) and 4% of keratinizing SCC (2/48) were moderately to strongly immunopositive for p16, which localized to nucleus and cytoplasm; 52/58 analyzed (90%) contained HPV 16 transcripts. 15619206 Human
p16 vin 3 The positive predictive value (PPV) of moderate to strong diffuse p16 immunostaining and HPV positivity for the diagnosis of VIN 3 and of basaloid or warty SCC was 97% and 95%, respectively. 15619206 Human
p16 vulvar carcinomas These disparate patterns of p16 expression underscore 2 different mechanisms for p16 expression in HPV-related and HPV-unrelated vulvar carcinomas. 15619206 Human
p16 papillary neoplasm Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. 15619210 Human
p16 oropharyngeal tumors Loss of P16 protein was less common in oropharyngeal tumors than at other HNSCC locations (P = 0.02). 15623629 Human
p16 high-grade prostatic intraepithelial neoplasias EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
p16 invasive cervical cancers Flow cytometry on primary CVX and NCK and immunohistochemical staining of formalin fixed paraffin-embedded tumor specimens from which primary CVX cultures were derived as well as from a separate set of invasive cervical cancers confirmed differential expr 15629771 Human
p16 gallbladder adenoma METHODS: Forty-one gallbladder carcinoma, 7 gallbladder adenoma and 14 chronic cholecystitis specimens were immunohistochemically and histopathologically investigated for the relation of cyclin D1, p16 and Rb with Nevin staging and pathologic grading. 15655836 Human
p16 squamous papillomas Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: Association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression. 15668901 Human
p16 gastrointestinal stromal tumors Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study. 15701851 Human
p16 epithelioma Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: Clinicopathologic features, human papillomavirus DNA detection, and P16 expression. 15712186 Human
p16 liposarcomas In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur 15551306 Human
p16 soft-tissue sarcomas (stss) In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur 15551306 Human
p16 fibroadenoma Conversely, protein p16 expression, although heterogeneously distributed within the section, is considerably higher in breast carcinoma as compared to fibroadenoma in both tumoral and non-tumoral epithelia and stroma. 15578730 Human
p16 fibroadenoma Furthermore, in a subset of fibroadenoma with higher proliferative activity, p16 protein expression was substantially decreased as compared to those showing lower proliferation. 15578730 Human
p16 papillary tumors Low-grade superficial papillary tumors induced by activated H-ras had no detectable Rb family proteins (Rb, p107, and p130) and late cell cycle cyclins and kinases (cyclin A, E, and CDK1), but had increased level of p16, p53, and MDM2. 15734997 Human
p16 bronchioloalveolar carcinomas Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. 15753637 Human
p16 juvenile myelomonocytic leukaemia Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. 15755284 Human
p16 juvenile myelomonocytic leukaemia This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. 15755284 Human
p16 jmml This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. 15755284 Human
p16 jmml Aberrant methylation of p16 was not detected in children with either MDS or JMML. 15755284 Human
p16 jmml Since p15 and p16 genes were unmethylated in two children with JMML, in whom the disease had progressed with an increased number of blasts, a condition referred to as blastic crisis, we infer that the aberrant methylation of these genes is not responsible 15755284 Human
p16 myelofibrosis We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. 15755503 Human
p16 mucoid carcinoma The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 Human
p16 undifferentiated carcinoma The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 Human
p16 signet-ring-cell carcinoma The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 Human
p16 endocrine tumours AIMS: p16 and p27, the inhibitors of cyclin-dependent kinases, have been reportedly decreased in certain human tumours, including a few endocrine tumours. 15841692 Human
p16 glucagonoma Insulinomas, glucagonoma, PP-omas and non-functioning tumours were weakly stained for cdk6 and p16. 15841692 Human
p16 endocrine tumours This decreased cdk6 and p16 in pancreatic endocrine neoplasms may be a part of the cell cycle event in tumour transformation and progression, and the same process may involve other endocrine tumours. 15841692 Human
p16 leukoplakia METHODS: 20 patients of leukoplakia with hyperplasia, 11 patients of leukoplakia with mild dysplasia, 10 patients of leukoplakia with moderate dysplasia, 9 patients of leukoplakia with severe dysplasia, 10 patients with OSCC in low grade, 12 patients with 15842853 Human
p16 leukoplakia RESULTS: Rates of p16 methylation were 0 for normal individuals, 5% for patients of leukoplakia with hyperplasia, 18% for patients of leukoplakia with mild dysplasia, 10% for patients of leukoplakia with moderate dysplasia, 22% for patients of leukoplakia 15842853 Human
p16 leukoplakia CONCLUSIONS: It was first reported that p16 methylation occurred in every stage of leukoplakia cancerization and OSCC progression. p16 can be one of the important molecular biological markers for leukoplakia cancerization and OSCC progression. p16 methyla 15842853 Human
p16 peritoneal malignant mesothelioma P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. 15867227 Human
p16 peritoneal malignant mesothelioma CONCLUSIONS: Biphasic histology, increased mitotic rate, and p16 loss were independently associated with poorer survival in peritoneal malignant mesothelioma. 15867227 Human
p16 melanoma BRAF mutation and p16 inactivation accompanied MITF amplification in melanoma cell lines. 16001072 Human
p16 malignant thyroid tumors Design: Quantitative hypermethylation of Rassf1A, TSHR, RAR-beta2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-beta, and GSTpi was tested on a cohort of 82 benign and malignant thyroid tumors and five thyroid cancer cell lines. 15840741 Human
p16 ovarian adenocarcinoma We have evaluated the use of Ad5/3-Delta24, a serotype 3 receptor targeted Rb/p16 pathway selective CRAd, in combination with gemcitabine against human ovarian adenocarcinoma. 15800658 Human
p16 cystadenomas The mean methylation index was highest in invasive tumors [0.20 versus 0.065 (LMP) and 0.033 (cystadenomas); P = 0.001]. 16061849 Human
p16 invasive carcinomas LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%). 16061849 Human
p16 cystadenomas LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%). 16061849 Human
p16 cystadenomas All eight genes were hypermethylated in invasive cancers at a frequency of 9% to 30%. 16061849 Human
p16 de novo myelodysplastic syndromes Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. 16104874 Human
p16 genitourinary cancer Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels. 16170165 Human
p16ink4 esophageal cancer [Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer] To evaluate the prognostic significance of gene amplification and overexpression of cyclin D1 in the patients of esophageal squamous cancer, 8920671 Human
p16ink4 testicular germ cell tumors Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. 9284835 Human
p16ink4 bone tumors These data support the hypothesis that TP53 alterations may play a role in the development of pediatric bone tumors and that the primary mechanism of inactivation of p16INK4 seems to be homozygous deletion rather than point mutation. 9309118 Human
p16ink4 bone tumours [Analysis of the involvement of the tumour suppressor genes TP53, p16INK4, p21WAF1, RB1 and the drugs metabolizing enzymes in the development of bone tumours in children] BACKGROUND: Several tumor suppressor genes such as p16INK4, TP53, RB1 y p21WAF1 are 12886318 Human
p16ink4 adenocarcinomas of the uterine cervix The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with internati 14584070 Human
p16ink4 bronchioloalveolar carcinomas Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. 15753637 Human
p16ink4a hairy-cell leukemia (hcl) We analyzed p16INK4A and p15INK4B genes in 178 cases of primary leukemias including 81 cases of chronic lymphocytic leukemia (CLL), seven of hairy cell leukemia (HCL), seven of chronic myelogenous leukemia (CML), 43 of acute myelogenous leukemia (AML), 27 7795238 Human
p16ink4a skin tumors Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. p16INK4a and p15INK4b are cell cycle regulators that specifically bind to and inhibit the cyclin D-dependent kinases, cdk4 and cdk6. 7585567 Mouse
p16ink4a papillary tumors Fine mapping at 9p21 demonstrated that CIS also displayed a high frequency of homozygous deletion surrounding the p16INK4A locus, like superficial papillary tumors, the other form of noninvasive lesion found in the bladder. 7585577 Human
p16ink4a tumor syndrome Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. 8841025 Human
p16ink4a benign epithelial tumours Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). 9036870 Human
p16ink4a hematological malignancies Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. 9041182 Human
p16ink4a hematological malignancies We have analyzed both modes of inactivation of p15INK4B and p16INK4A in the major types of adult and pediatric hematological malignancies. 9041182 Human
p16ink4a adult acute myelogenous leukemia Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy 9041182 Human
p16ink4a pediatric acute myelogenous leukemia Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy 9041182 Human
p16ink4a adult acute lymphocytic leukemia Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy 9041182 Human
p16ink4a non-hodgkin's lymphoma Hypermethylation of p16INK4A, often without alterations of p15INK4B, was found in non-Hodgkin's lymphoma and was much more frequent in cases with high-grade than low-grade histology. 9041182 Human
p16ink4a hematological malignancies Remarkably distinct patterns of inactivation of p15INK4B and p16INK4A characterize different types of hematological malignancy, and alterations in these tumor suppressor genes are one of the most common alterations in hematological malignancies. 9041182 Human
p16ink4a thymomas To investigate the expression of p16INK4A, RB, p53 and cyclin D1 in thymomas, we first examined 36 thymomas (non-invasive type, 16 cases; invasive type, 20 cases) and 3 thymic carcinomas, using immunohistochemistry. 9398039 Human
p16ink4a thymic carcinomas To investigate the expression of p16INK4A, RB, p53 and cyclin D1 in thymomas, we first examined 36 thymomas (non-invasive type, 16 cases; invasive type, 20 cases) and 3 thymic carcinomas, using immunohistochemistry. 9398039 Human
p16ink4a invasive thymomas Only a subgroup of invasive thymomas and thymic carcinomas showed an inverse correlation between p16INK4A and RB expression. 9398039 Human
p16ink4a thymic carcinomas Only a subgroup of invasive thymomas and thymic carcinomas showed an inverse correlation between p16INK4A and RB expression. 9398039 Human
p16ink4a thymic carcinoma However, inactivation of p16INK4A and RB may play a role in the progression of thymoma and thymic carcinoma. 9398039 Human
p16ink4a mouse lymphomas The p16INK4a (alpha and beta form) and p15INK4b genes were analysed for homozygous deletion, hypermethylation and point mutation in B6C3F1 mouse lymphomas induced by 2',3'-dideoxycytidine or 1,3-butadiene. 9488045 Human
p16ink4a plasmacytoma Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 9482902 Mouse
p16ink4a mesenchymal tumours This study investigates p16INK4A gene status and expression in mesenchymal tumours, in particular soft tissue sarcomas (STSs). 9582521 Human
p16ink4a histiocytic lymphoma Human histiocytic lymphoma U937 cells were treated with onconase and expression of cyclins D3 and E, as well as of the cyclin-dependent kinase inhibitors (CKIs) p16INK4A, p21WAF1/CIP1 and p27KIP1 (all detected immunocytochemically) was measured by multipa 9697879 Human
p16ink4a sporadic colon cancer Recent evidence shows that transcriptional silencing as a consequence of hypermethylation of CpG islands is the predominant mechanism of p16INK4a gene inactivation in sporadic colon cancer. 9731506 Human
p16ink4a thyroid neoplasms METHODS: The authors examined 20 thyroid neoplasms (12 papillary carcinomas and 8 follicular adenomas) and 4 human thyroid carcinoma cell lines for gene mutations and epigenetic modifications of the p15INK4b and p16INK4a genes by Southern blot analysis, s 9827724 Human
p16ink4a undifferentiated carcinoma Undifferentiated carcinoma (FRO) cells had a nonsense point mutation at codon 72 (CGA-TGA, Arg-Stop) of p16, whereas the poorly differentiated papillary carcinoma (NPA) line harbored a point mutation at the exon 1-intron 1 boundary that altered the donor 9827724 Human
p16ink4a oral squamous-cell carcinoma Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16ink4a in response to treatment with a demethylating agent. 10030668 Human
p16ink4a carcinoma of the anterior tongue Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. 10537346 Human
p16ink4a squamous cell carcinoma of the anterior tongue Thus, we sought to determine the relationship between cyclin D1 and/or p16INK4A expression and disease outcome in squamous cell carcinoma of the anterior tongue. 10537346 Human
p16ink4a tongue cancers Immunohistochemical detection of nuclear proteins cyclin D1, p53, and p16INK4A, and the Ki-67 labeling index was undertaken in tissue sections from 148 tongue cancers treated by surgical resection. 10537346 Human
p16ink4a tongue cancer Multivariate analysis confirmed that in addition to pathological stage and regional lymph node status, cyclin D1 overexpression and loss of p16INK4A expression are independent predictors of death from tongue cancer. 10537346 Human
p16ink4a anaplastic ependymomas P16INK4a mRNA was found in all pilocytic astrocytomas (7/7), in all grade II and III astrocytomas (7/7 and 4/4, respectively), in 4/12 glioblastomas, 8/8 oligodendrogliomas, 10/11 anaplastic oligodendrogliomas, 4/7 ependymomas and 3/3 anaplastic ependymom 10564531 Human
p16ink4a acute adult t-cell lymphoma leukemia Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines. 10826477 Human
p16ink4a primary breast cancer INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. 10914724 Human
p16ink4a adenoid-cystic carcinomas (acc) In this study, the expressions of Rb, p16INK4A, and cyclin D1 alternations were analyzed by immunohistochemical assay in 5 specimens of normal salivary glands and twenty-two cases of adenoid cystic carcinomas (ACC). 10928172 Human
p16ink4a aggressive non-hodgkin's lymphoma Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. 11021747 Human
p16ink4a gastrinoma The presence or absence of methylation of the p16INK4a gene did not correlate with clinical characteristics of the gastrinoma, biological behavior (gastrin release and basal or maximal acid output), the presence or absence of known prognostic factors (tum 11095446 Human
p16ink4a gastrinoma Furthermore, because it is independent of disease stage it is probably an early event in the pathogenesis and because it is independent of the primary gastrinoma location, which is now thought to have different origins, methylation of the p16INK4a gene is 11095446 Human
p16ink4a glomus tumor p53 and p16INK4A mutations during the progression of glomus tumor. 10079377 Human
p16ink4a glomus tumors In spite of this possibility, the missense point mutations in conserved region of p53 and p16INK4A genes may indicate the role of p53 and p16INK4A in tumor progression of glomus tumors. 10079377 Human
p16ink4a scrotal cancer Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer. 10087941 Human
p16ink4a scrotal carcinoma Here, the mutation pattern of TP53, p16INK4A, and p15INK4B genes and the homo/hemizygous deletion patterns of p16INK4A/p15INK4B genes are presented in four scrotal carcinoma cases. 10087941 Human
p16ink4a scrotal carcinoma Homozygous deletion in p16INK4A/p15INK4B genes and a codon 259 missense point mutation (GAC-->TAC; Asp-->Tyr) in the TP53 gene were observed in one human papilloma positive scrotal carcinoma case. 10087941 Human
p16ink4a scrotal carcinoma The homozygous deletion in p16INK4A/p15INK4B genes was observed in another human papilloma positive scrotal carcinoma case. 10087941 Human
p16ink4a scrotal carcinoma The cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal carcinoma cases indicate that the alterations of TP53, p16INK4A, and p15INK4B genes have an important role in the progression of 10087941 Human
p16ink4a scrotal cancers The cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal carcinoma cases indicate that the alterations of TP53, p16INK4A, and p15INK4B genes have an important role in the progression of 10087941 Human
p16ink4a scrotal cancer The molecular alteration of TP53, p16INK4A, and p15INK4B genes may be useful as a prognostic marker in scrotal cancer. 10087941 Human
p16ink4a plasma cell tumors The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. 10396076 Mouse
p16ink4a adrenocortical tumors Inactivation of the p16 tumor suppressor gene (p16INK4A), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. 10443678 Human
p16ink4a seminoma Existence of the P16INK4A mutation and the hereditary TP53 mutation with or without loss of heterozygosity in the TP53 gene (seminoma/medulloblastoma) may be evidence for a common mechanism involved in tumorogenesis. 10484981 Human
p16ink4a primary mediastinal b-cell lymphoma Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. 10520030 Human
p16ink4a aggressive lymphomas Based on reports that p16INK4A gene, located on this chromosomal arm, is frequently altered in aggressive lymphomas, we analysed for alterations of this gene in 27 cases of PMBL, which were part of a series of 32 PMBL cases that have been characterized fo 10520030 Human
p16ink4a plasma cell dyscrasia Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. 11243384 Human
p16ink4a extramedullary plasmacytoma Many patients whose BM-MNC showed dense methylation of the p16INK4A gene had extramedullary plasmacytoma (extra-PC), and all available extra-PC samples showed alterations of the p16INK4A gene (4; dense methylation, 1; homozygous deletion). 11243384 Human
p16ink4a liver tumors p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK. 11238187 Rat
p16ink4a high-grade prostatic intraepithelial neoplasia Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. 11297246 Human
p16ink4a anaplasia In one tumor containing distinct areas with and without anaplasia, p14ARF hypermethylation was detected in the WHO grade II area, while homozygous co-deletion of p14ARF and p16INK4a was found in the region with anaplastic features (grade III). 11307615 Human
p16ink4a metastatic melanoma Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. 11544530 Mouse
p16ink4a hyperplasia Mice lacking p16Ink4a were born with the expected mendelian distribution and exhibited normal development except for thymic hyperplasia. 11544531 Mouse
p16ink4a smzl The mean proliferative index (MIB1 staining) in initial SMZL specimens of cases with LBCL transformation was 28.6%, higher than that of MIB1 staining in the overall SMZL series (21.8%), although not statistically significantly so. p53 or p16INK4a inactiva 11688461 Human
p16ink4a smzl It seems that progression in SMZL is mainly independent of p53 or p16INK4a inactivation. 11688461 Human
p16ink4a colorectal adenocarcinomas The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. 11696421 Human
p16ink4a colorectal adenocarcinomas However, invasion front of well-differentiated colorectal adenocarcinomas are known to be zones of low proliferation and express the cell cycle inhibitor p16INK4A. 11696421 Human
p16ink4a colorectal adenocarcinomas Therefore, we investigated the expression profiles of nuclear beta-catenin, cyclin D1, p16INK4A, and the Ki-67 antigen, a marker for proliferation, in serial sections of well-differentiated colorectal adenocarcinomas. 11696421 Human
p16ink4a primary-effusion lymphoma p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. 11896614 Human
p16ink4a primary-effusion lymphoma (pel) To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. 11896614 Human
p16ink4a pel Importantly, endogenous p16INK4a expression is not detected in six PEL derived cell lines and four primary PEL samples and examination of the p16INK4a locus shows deletion in two out of six and hypermethylation in four out of six PEL lines. 11896614 Human
p16ink4a pel Taken together these results suggest that p16INK4a loss may be a cellular change frequently associated with PEL. 11896614 Human
p16ink4a vin Co-incident methylation, accompanied by loss of expression, of sigma and p16INK4a was commonly detected in both SCC and VIN III, suggesting that epigenetic silencing of these two genes is an early and important event in vulval neoplasia. 11896620 Human
p16ink4a b-cell acute lymphoblastic leukaemia We examined deletion and methylation of the p15INK4B (p15) and p16INK4A (p16) genes, using Southern blotting and methylation-specific polymerase chain reaction (PCR), in 70 untreated adult patients with precursor B-cell acute lymphoblastic leukaemia (PBC- 12028019 Human
p16ink4a pediatric tumor Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. 12149641 Human
p16ink4a large-cell lymphoma We investigated the response of SUDHL-1 and L428 cells, derived from t(2;5)-anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD), respectively, to recombinant adenoviruses expressing cyclin-dependent kinase inhibitors (CDKIs) p27Kip1 (Adp 12153002 Human
p16ink4a xeroderma pigmentosum After characterization of the xeroderma pigmentosum C complementation group, we found unexpectedly that this patient also carried a germline mutation of the INK4a-ARF locus affecting the p16INK4A reading frame. 12485439 Human
p16ink4a mucinous cystadenocarcinomas METHODOLOGY: Seven serous cystadenomas (SCA) and seven malignant mucinous cystadenocarcinomas (MCC) were analyzed for alterations in the tumor suppressor genes p16INK4a, p53, and DPC4 by single-strand conformational variant analysis, direct sequencing, an 12499916 Human
p16ink4a serous cystadenomas METHODOLOGY: Seven serous cystadenomas (SCA) and seven malignant mucinous cystadenocarcinomas (MCC) were analyzed for alterations in the tumor suppressor genes p16INK4a, p53, and DPC4 by single-strand conformational variant analysis, direct sequencing, an 12499916 Human
p16ink4a low-grade tumors Some differences may be established regarding the methylation profiles of specific genes and tumor types: MGMT, THBS1, TIMP-3, and p16INK4A appear hypermethylated in low-grade tumors (at least in 45% of cases), whereas GSTP1, DAPK, and p14ARF are mostly c 12579314 Human
p16ink4a gastric tubular adenomas Loss of p27kip1 and p16Ink4a (p16) expression, another CDI, has been reported during the progression of gastric tubular adenomas to advanced gastric cancer. 12603618 Human
p16ink4a cin 3 The control HSIL case with a CIN 3 biopsy was diffusely positive for P16INK4A, and the control negative case with biopsy diagnosis of squamous metaplasia was negative. 12630076 Human
p16ink4a meningiomas Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. 12640680 Human
p16ink4a meningiomas We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. 12640680 Human
p16ink4a intestinal-type adenocarcinoma TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. 12673679 Human
p16ink4a salivary-gland carcinomas Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. 12684623 Human
p16ink4a adenoid-cystic carcinomas A total of 5 (14%) SGCs demonstrated homozygous deletion (1 case) or methylation (4 cases) of p16INK4a, all but one being adenoid cystic carcinomas. 12684623 Human
p16ink4a neurofibromatosis 1 We found that loss of p16INK4A coincided with transformation of neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis 1 patients. 12812137 Human
p16ink4a plexiform neurofibroma We have determined the methylation status of the CpG island of 11 tumour-related genes (RB1, p14ARF, p16INK4a, p73, TIMP-3, MGMT, DAPK, THBS1, caspase 8, TP53 and GSTP1) in 18 neurofibromas (including one plexiform neurofibroma) and three neurofibrosarcom 12883734 Human
p16ink4a familial cancers They are "classical" tumor suppressor genes with associated familial cancers (BRCA1, hMLH1, p16INK4a, VHL, etc.) and putative new tumor suppressor genes which loss may contribute to the transformed phenotype (MGMT, p14ARF, GSTP1, RARB2, etc.). 12908548 Human
p16ink4a neurofibroma Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. 12920094 Human
p16ink4a penile carcinoma Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. 12950023 Human
p16ink4a pediatric solid tumors Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. 12963998 Human
p16ink4a glandular neoplasms Approximately 80% of glandular neoplasms showed overexpression of p16INK4a. 14501820 Human
p16ink4a neurofibromatosis p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. 14519636 Human
p16ink4a leiomyosarcoma Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. 14595762 Human
p16ink4a adenocarcinoma in situ The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. 14648656 Human
p16ink4a brain metastases Thus, in addition to these two genes, we determined the methylation status of the genes p16INK4a, glutathione S-transferase P1 (GSTP1), O6-methylguanine DNA methyltransferase (MGMT), thrombospondin-1 (THBS1), p14ARF, TP53, p73, and tissue inhibitor of met 14654977 Human
p16ink4a brain metastases Our data suggest an important role for gene methylation in the development of brain metastases, primarily involving epigenetic silencing of DAP-kinase, THBS1 and the cell-cycle regulators RB1/p16INK4a. 14654977 Human
p16ink4a oropharyngeal squamous cell carcinomas Mutations of the cell cycle regulatory genes p16INK4A and p21WAF1 and the metastasis-inducing gene S100A4 are infrequent and unrelated to p53 tumour suppressor gene status and data on survival in oropharyngeal squamous cell carcinomas. 14981901 Human
p16ink4a b16 melanoma In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. 14743208 Human
p16ink4a clear cell sarcoma Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. 15298727 Human
p16ink4a melanocytic neoplasm Alterations in the p16INK4a/p14ARF gene are common in malignant melanoma, which is the prototypical melanocytic neoplasm. 15298727 Human
p16ink4a barrett's adenocarcinoma To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease. 15185075 Human
p16ink4a barrett's adenocarcinomas RESULTS: We detected 9p21 LOH, p16INK4a methylation and p16INK4a mutations in Barrett's adenocarcinomas in 5 of 15 (33%), 8 of 15 (53%) and 1 of 15 (7%) patients, respectively. 15185075 Human
p16ink4a mfh The growth inhibition rate was the greatest for lung adenocarcinoma cells, lacking p16INK4a expression associated with methylation-mediated gene silencing; 83% at a concentration of 300 nM for 72-h treatment; while the growth of osteosarcoma and MFH cells 15069542 Human
p16ink4a cin 3 When the time interval for disease progression from initial biopsy to CIN 3 or invasive cancer was compared with states of p16INK4A expression, cases stained positive for p16INK4A progressed within 64.2 months as compared with 122.3 months among those sta 15073118 Human
p16ink4a colorectal tumours Furthermore, p16INK4a promoter hypermethylation leading to gene silencing has been shown to occur in advanced colorectal tumours and has been associated with patient survival. p16INK4a is polymorphic, with variant alleles being associated with tumour prog 15492837 Human
p16ink4a squamous cell carcinoma in situ Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. p16INK4a is involved in many im 15257310 Human
p16ink4a papillary neoplasm Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. 15619210 Human
p16ink4a cervical squamous intraepithelial lesions Immunohistochemical Expression of p16INK4a and bcl-2 According to HPV Type and to the Progression of Cervical Squamous Intraepithelial Lesions. 15805425 Human
p16ink4a seminoma Human male germ-cell tumors of seminoma type display aberrant expression of INK4-family inhibitors of the cell cycle including CDKN2-encoded p16INK4A. 15734211 Human
p16ink4a seminoma To assess whether the aberrant p16INK4A expression could be related to the alterations in CDKN2 regulatory sequence, we screened seminoma DNAs from 19 patients for the promoter mutations. 15734211 Human
p16ink4a seminoma These data suggest that in addition to previously characterized anomalies, the identified CDKN2 promoter mutation may be relevant for altered p16INK4A protein expressions in at least some seminoma. 15734211 Human
p16ink4a aggressive nk-cell leukemia We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. 15813917 Human
p16ink4a aggressive nk-cell leukemia It has been reported that tumor suppressor genes are inactivated by DNA methylation of the promoter region and/or first exon of the genes in a variety of human cancers. 15813917 Human
p16ink4a phyllodes tumor We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 2 15981808 Human
p16ink4a ovarian cancer Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer. 16000597 Human
the p16 gene blast crisis We have used a semiquantitative multiplex polymerase chain reaction assay to search for deletions of the p16 gene in 34 patients with chronic myeloid leukemia in blast crisis (CML BC), 19 patients with acute lymphoblastic leukemia (ALL), and 25 patients w 7718873 Human
the p16 gene myeloid tumors Loss of the p16 gene is frequent in and highly specific to lymphoid malignancies (54 of 183 [30%] in lymphoid tumor v2 of 219 [1%] in myeloid tumors; P < .0001). 7632963 Human
the p16 gene testicular tumors RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. 7563391 Human
the p16 gene testicular tumor RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. 7563391 Human
the p16 gene borderline ovarian tumors Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. 7478544 Human
the p16 gene nasopharyngeal carcinoma Hypermethylation of the p16 gene in nasopharyngeal carcinoma. 8665502 Human
the p16 gene parathyroid tumors However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some h 8855819 Human
the p16 gene esophageal tumors To determine the role and mode of inactivation of the p16 and p15 genes in human esophageal tumors, we examined alterations and expression of the alpha and beta forms of the p16 gene, 5' CpG island methylation of p16 exon 1 alpha, and alterations of 9033652 Human
the p16 gene adrenal cortical carcinomas Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
the p16 gene adrenal cortical hyperplasia Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
the p16 gene malignant tumors of the adrenal cortex Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
the p16 gene adenomas In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions 9751761 Rat
the p16 gene carcinoma in situ The timing for p16 methylation was recapitulated in human SCCs where the p16 gene was coordinately methylated in 75% of carcinoma in situ lesions adjacent to SCCs harboring this change. 9751761 Rat
the p16 gene neuroblastoma We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. 9872329 Human
the p16 gene pleomorphic adenoma of the parotid gland Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. 9917133 Human
the p16 gene carcinoma in pleomorphic adenoma Results of this study suggest that two different genetic alterations, the inactivation of the p16 gene and genetic instability, play roles in the malignant transformation of carcinoma in pleomorphic adenoma. 9917133 Human
the p16 gene carcinosarcoma These results suggest that homozygous deletion of the p16 gene occurs less frequently than CD1 gene amplification in esophageal carcinosarcoma. 9990483 Human
the p16 gene malignant brain tumors The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s 10536183 Human
the p16 gene low-grade tumors The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s 10536183 Human
the p16 gene ovarian cystadenomas METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys 9889036 Human
the p16 gene endometrial tumours Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. 10408854 Human
the p16 gene cervical tumours Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. 10408854 Human
the p16 gene uterine tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
the p16 gene endometrial tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
the p16 gene cervical tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
the p16 gene uterine tumours These observations suggest that inactivation of the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours. 10408854 Human
the p16 gene common acute lymphoblastic leukemia There were two patients who had DNA abnormalities in both 9p and 12p, one with common acute lymphoblastic leukemia (ALL) showed 9p LOH and the TEL/AML1 fusion gene on 12p and the other with common ALL and 12p RER had diminished expression of both the p27( 10453181 Human
the p16 gene extrahepatic bile duct cancers In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. 11802210 Human
the p16 gene macroglobulinemia MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma 11920239 Human
the p16 gene macroglobulinemia RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s 11920239 Human
the p16 gene tumour These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re 12199782 Human
the p16 gene multiple myeloma These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re 12199782 Human
the p16 gene hepatoblastoma Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. 12748249 Human
the p16 gene corticotroph adenomas EXPERIMENTAL DESIGN: Tissue from 31 corticotroph adenomas and 16 nonadenomatous pituitaries were subject to methylation-sensitive PCR to determine the methylation status of the p16 gene CpG island. 15014032 Human
the p16 gene primary gastric lymphomas Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. 14976529 Human
the p16 gene primary gastric lymphomas In this study, we characterize protein expression and promoter hypermethylation of the p16 gene in B-cell primary gastric lymphomas from China. 14976529 Human
the p16 gene metastatic cancers Homozygous deletions of the p16 gene were observed in 2 of the 5 primary colorectal carcinomas and in 1 of the matching liver metastatic cancers. 11677769 Human
the p16 gene lung adenocarcinoma CONCLUSIONS: Aberrant methylation of the promoter region of the p16 gene and loss of expression of its product were in accord with the multistep progression of peripheral-type lung adenocarcinoma, and these alterations were associated closely with poor pr 15612080 Human
the p16 gene polyposis BRAF mutation status in patients with multiple/large HPs and/or hyperplastic polyposis correlated with HPs from the same patient (odds ratio, 5.8; P = 0.0002) but associated with younger age (odds ratio, 0.83; P = 0.006 compared to older age), with a larg 15793287 Human
the p16 mrna aml The p16 mRNA expression in 12 AML at diagnosis or relapse was significantly lower than that in 4 long term remission cases and normal controls. p16 mRNA expression was significantly higher in a case of AML with p53 mutation. 10921094 Human
the p16 protein intraductal carcinomas In 33 (9%) invasive and two (4%) intraductal carcinomas, a cytoplasmic accumulation of the p16 protein was seen. 9862580 Human
the p16 protein malignant eyelid tumors CONCLUSIONS: The expression of the P16 protein was related to the occurrence and degree of differentiation of malignant eyelid tumors. 11930651 Human
the p16 protein primary gastric lymphoma However, the p16 protein expression in primary gastric lymphoma has not been studied. 14976529 Human
the p19 gene burkitt-like lymphoma Using Southern blot analysis, one homozygous deletion of the p19 gene was detected in a human immunodeficiency virus (HIV)-related Burkitt-like lymphoma sample. 8946928 Human
p16ink4a high grade cervical intraepithelial neoplasia [The p16INK4a protein: a cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix] The identification of a small percentage of high grade cervical intraepithelial neoplasia (HGCIN) among patients with a diagnosis of atyp 17255929 Human
p16ink4a squamous papillomas DESIGN: Immunohistochemistry of p16INK4A and p53 was performed on biopsies of recurrent squamous papillomas and invasive lesions in nine patients. 17277618 Human
p16 figo stage iib ovarian carcinoma We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different pla 17242700 Human
p16ink4a high grade intraepithelial neoplasia [The p16INK4a protein: a cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix] The identification of a small percentage of high grade cervical intraepithelial neoplasia (HGCIN) among patients with a diagnosis of atyp 17255929 Human
p14arf follicular adenomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14arf oncocytic adenomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14 tumour infiltrating lymphocytes Methylation of the MLH1, P16, TIMP3 and P14 genes was associated with tumour infiltrating lymphocytes (p < 0.05), microsatellite instability (p < 0.001), BRAF mutation (p < 0.0001) and elevated concentrations of the methyl group carriers tetrahydrofolate 16981189 Human
cdkn2a familial atypical multiple mole melanoma Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. 11815963 Human
p19 thymoma Quantitative measurements of cultured human and murine thymic, and human thymoma reticuloepithelial cells (REC), immunolabeled by different antibodies (Ab) (TE3, TE4, anti-HTLV p19(p19), lu5, K11 and Aks) and by thymic hormones (thymulin and thymosin alph 2649289 Human
cdkn2a penile intraepithelial neoplasia OBJECTIVES: To investigate the role of CDKN2A and p53 in the pathogenesis of EGCs and their precursor lesions vulval intraepithelial neoplasia (VIN3), penile intraepithelial neoplasia and lichen sclerosus (LS). 17300232 Human
p16ink4a thyroid tumour The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. 17117177 Human
p16 head and neck carcinomas The main aim of this study was to investigate the relationship between HPV presence and p16 expression in a representative collection of 60 head and neck carcinomas by tissue microarrays. 17352245 Human
cdkn2a egc BACKGROUND: p53 has been extensively studied in external genital carcinoma (EGC), and is frequently inactivated, but little is known about the role of the CDKN2A tumour suppressor gene in the oncogenesis of EGC. 17300232 Human
p16 oligodendrogliomas Therefore, in oligodendrogliomas, the absence of the combined deletion of 1p and 19q and the aberrant expression of p53 or loss of p16 could be used as poor prognostic markers. 17319279 Human
p16 ameloblastoma [Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma] OBJECTIVE: To investigate the expression of human telomerase reverse transcripase (hTERT), cyclin D1 mRNA, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (ABs) 17334067 Human
arf sarcoma Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spe 17360455 Mouse
p16ink4a solid carcinomas BACKGROUND: BMI-1 is involved in the maintenance of stem cells and functions as an oncogene in both lymphomas and solid carcinomas, acting by downregulation of p16ink4a. 17244030 Human
ink4 ameloblastoma [Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma] OBJECTIVE: To investigate the expression of human telomerase reverse transcripase (hTERT), cyclin D1 mRNA, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (ABs) 17334067 Human
p16ink4a mucoepidermoid carcinoma of the salivary glands Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands. 17223311 Human
p14arf follicular carcinomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14arf papillary carcinomas These deregulations were statistically significant for pl6INK4a (P=0.006) in follicular adenomas and close to statistical significance for p14ARF in follicular adenomas (P=0.06) and in papillary carcinomas (P=0.05). 17117177 Human
ink4a low grade dysplasia CDC6 may be a biomarker of high grade and invasive lesions of the cervix, with limited use in low grade dysplasia. p16(INK4A) was the most reliable marker of cervical dysplasia. 15858126 Human
p14arf colorectal adenomas In primary colorectal carcinomas, p14ARF promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. p14ARF methylation appears in the context of an adj 10646864 Human
p14arf anaplastic astrocytomas To investigate the roles of the G1-S transition control system and the p14ARF/MDM2/p53 pathway in the development of astrocytic gliomas, we examined abnormalities of genes involved in these regulatory pathways in a total of 190 primary human astrocytic gl 10667596 Human
p14arf meningiomas Immunoreactivity of p14ARF, p27KIP1 and p73 did not show any differences between meningiomas of various histology and clinical outcomes. 12640680 Human
p14arf salivary gland carcinomas Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. 12684623 Human
p14arf tumors Our results suggest that abnormal expression of the p16 and/or p14ARF may be associated with a poor prognosis in these 3 tumors. 12963998 Human
p14arf invasive cervical cancer Serial consecutive biopsies representing normal cervical epithelium to cervical intraepithelial neoplasia and/or invasive cervical cancer were stained with immunohistochemistry for p16INK4A, p14ARF and proliferating cell nuclear antigen. 15502810 Human
p14arf nk cell leukemia We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. 15813917 Human
p19 hepatic tumor Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). 11568971 Mouse
p19 breast tumors Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. 12000749 Human
p19 neurofibromatosis The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. 12118376 Mouse
p19 mouse tumor Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. 12573439 Mouse
p14 aggressive lymphomas Aggressive lymphomas with p14(ARF) inactivation and p53 wild type showed a significantly lower p53 protein expression than tumors with no alteration in any of these genes. 10854221 Human
p14 neurofibroma CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. 11433531 Human
p14 chondrosarcoma Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues. 11477582 Human
p14 chondrosarcoma In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. 11477582 Human
p14 chondrosarcoma This indicates that genetic changes of p14(ARF) are a rare event in chondrosarcoma. 11477582 Human
p14 anaplastic meningiomas Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. 11485924 Human
p14 atypical meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
p14 benign meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
p14 benign meningioma One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. 11485924 Human
p14 malignant pleural mesothelioma Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. 11507034 Human
p14 common tumor p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t 11830494 Human
p14 myeloproliferative disorders A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr 12032783 Human
p14 primary carcinomas RESULTS: Altogether inactivation (methylation, loss of heterozygosity and mutation of exon 1beta) of p14(ARF) was found in 29 of all 68 (43%) carcinomas, with a significant difference in primary [8 of 29 (28%)] relative to second primary carcinomas [21 of 12189502 Human
p14 recurrent carcinomas Mutations of p53 were found in 32 of 68 HNSCCs (44%), evenly distributed among primary and recurrent carcinomas. p14(ARF) alterations showed no relationship to p53 mutations. 12189502 Human
p14 recurrent carcinomas The significantly higher rate of p14(ARF) alterations in recurrent (respective second primary) carcinomas suggests a further acquired genetic aberration during the development of the recurrent carcinomas. 12189502 Human
p14 pleomorphic adenomas To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. 12375265 Human
p14 pleomorphic adenomas Methylation of p14(ARF) was found in 1/42 cases and alterations of p16(INK4a) occurred in 12/42 of pleomorphic adenomas, which correlated with loss of mRNA transcription. 12375265 Human
p14 pleomorphic adenoma The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to ca 12375265 Human
p14 liver angiosarcoma Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D 12378512 Human
p14 gastric adenoma (ga) Five different classes of methylation behaviors were found: (a). genes methylated in GC only (GSTP1 and RASSF1A), (b). genes showing low methylation frequency (<12%) in CG, IM, and gastric adenoma (GA) but significantly higher methylation frequency in GC 12695555 Human
p14 sporadic breast cancer [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter 12942643 Human
p14 schwannomas EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific 14654541 Human
p14 mec Late-passage hTERT-immortalized MEC express p53 but down-regulate p14(ARF). 14966292 Human
p14 gallbladder tumors RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, 15014024 Human
p14 benign meningiomas We found methylation of p14(ARF) gene in five of 58 cases of benign meningiomas (8.6%), two of 10 cases of atypical meningiomas (20%), and two of four cases of anaplastic meningiomas (50%). 15073599 Human
p14 odontogenic tumors BACKGROUND: To clarify the roles of the p53-MDM2-p14(ARF) cell cycle regulation system in oncogenesis and cytodifferentiation of odontogenic tumors, p53 gene status and expression of p53, MDM2, and p14(ARF) proteins was analyzed in ameloblastomas as well 15078490 Human
p14 ameloblastoma Markedly decreased reactivity for p53, MDM2, and p14(ARF) was detected in keratinizing and granular cells in ameloblastoma subtypes. 15078490 Human
p14 ameloblastoma Basal cell ameloblastoma showed slightly higher reactivity for p53, MDM2, and p14(ARF) as compared with other subtypes. 15078490 Human
p14 ameloblastoma Immunoreactivity for p53, MDM2, and p14(ARF) in ameloblastoma variants suggests that these factors might be associated with tissue structuring and cytodifferentiation of ameloblastomas. 15078490 Human
p14 endometrial hyperplasias Thus expression levels of p14 were higher in G1 tumors than in normal endometria or endometrial hyperplasias, and the frequency of its staining in endometrioid carcinomas was inversely correlated with histologic grade. 15213599 Human
p14 endometrioid adenocarcinoma In conclusion, p14 expression correlated with histologic grade and Ki-67, but not other prognostic factors in endometrioid adenocarcinoma. 15213599 Human
p14 fundic gland polyps (fgps) We studied methylation of 2 tumor suppressor genes (p14, p16) and 4 MINT (methylated in tumor) clones (MINT1, MINT2, MINT25, MINT31) among 51 fundic gland polyps (FGPs) and 27 normal gastric body biopsy samples using bisulfite treatment of genomic DNA fol 15491970 Human
p14 b-cell lymphoblastic leukemia [Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands 15612580 Human
p14 b-cell lymphoblastic leukemia High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. 15612580 Human
p14 benign prostatic hyperplasias (bph) EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
p14 scc of the tongue CONCLUSIONS: These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers. 15930346 Human
p14 immunoblastic lymphoma Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r 16053658 Human
cyclin-dependent kinase inhibitor p16 t-cell acute lymphoblastic leukemia The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. 11278393 Human
cyclin-dependent kinase inhibitor p16 t-cell acute lymphoblastic leukemia The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. 11441822 Human
mts1 mucinous tumors p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. 9495360 Human
mts1 atypical adenomatous hyperplasia An immunohistochemical analysis. To clarify the events leading to the disruption of cell growth control that occurs during the development of pulmonary adenocarcinoma (AC), we used immunohistochemistry to evaluate the expression of G1 cycle regulators, cy 9531999 Human
mts1 soft tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
mts1 mouse adenocarcinoma Here we present a detailed analysis of the structure and function of this enhancer in the Mts1/S100A4-expressing CSML100 and non-expressing CSML0 mouse adenocarcinoma cell lines. 11504871 Human
mts1 transitional cell carcinoma of bladder [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. 11831985 Human
mts1 transitional cell carcinoma of urinary bladder [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. 11831985 Human
mts1 bladder cancer CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
mts1 transitional cell carcinoma of urinary bladder CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
mts1 transitional cell carcinomas (tcc) Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
ink4a megakaryoblastic leukemia In a human megakaryoblastic leukemia cell line, CMK, that showed some degree of megakaryocytic differentiation after culture with TPO, the cyclin-dependent kinase (Cdk) inhibitor p21(WAF1/Cip1), but not p27(Kip1), p16(INK4A), p15(INK4B), or p18(INK4C), wa 9111365 Human
ink4a plasmacytoma When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all 9482902 Mouse
ink4a plasmacytoma When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all 9482902 Mouse
ink4a indolent lymphomas Hypermethylation of the gene was also examined in a subset of tumors with lack of protein expression but without mutations or deletions of the gene. p16(INK4a) gene alterations were detected in 3 out of 64 (5%) indolent lymphomas but in 16 out of 48 (33%) 9531609 Human
ink4a low-grade tumors In the low-grade tumors, p16(INK4a) alterations were detected in 1 (4%) chronic lymphocytic leukemia (hemizygous missense mutation), 1 (6%) follicular lymphoma (homozygous deletion), and 1 (5%) typical mantle cell lymphoma (homozygous deletion). 9531609 Human
ink4a anaplastic large cell lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
ink4a large-cell lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
ink4a lymphoblastic lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
ink4a large-cell lymphoma Sequential samples of the indolent and transformed phase of three cases showed the presence of p16(INK4a) deletions in the Richter's syndrome but not in the CLL component of two cases, whereas in a follicular lymphoma the deletion was present in both 9531609 Human
ink4a plasma cell leukemia Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. 9815612 Human
ink4a advanced carcinomas PATIENTS AND METHODS: The expression patterns and their possible prognostic relevance of the cell cycle regulatory proteins p53, p21(WAF/CIP1), Rb, p16(INK4A), CDK4 and Cyclin D1, MIB1 (Ki-67) and BCL-2 were analysed in pretreatment tumor biopsies from 43 10525606 Human
ink4a neuroendocrine tumors of the lung Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. 10649246 Human
ink4a adult t-cell leukemia The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development of adult T-cell leukemia probably through modulation of growth regulatory molecules including p16(INK4a). 10753922 Human
ink4a human t-cell leukemia The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development of adult T-cell leukemia probably through modulation of growth regulatory molecules including p16(INK4a). 10753922 Human
ink4a indolent lymphomas To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 10854221 Human
ink4a leukoplakia Immunohistochemical analysis of Rb, p16(INK4A) and cyclin D1 expression was performed on 78 oral squamous cell carcinoma (SCC), 46 leukoplakia, and 20 normal mucosa. 11098077 Human
ink4a leukoplakia Rb and p16(INK4A) expression were observed in all normal mucosa and most of leukoplakia. 11098077 Human
ink4a marginal zone lymphomas Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. 11166833 Human
ink4a mzl Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. 11166833 Human
ink4a pediatric osteosarcomas Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. 11241308 Human
ink4a pediatric osteosarcomas We examined a series of 38 pediatric osteosarcomas for abnormal expression of pRB, p16(INK4a) and cyclin D1 by immunohistochemical analysis of archival biopsy specimens. 11241308 Human
ink4a metastasis There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen 11241308 Human
ink4a tumor necrosis There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen 11241308 Human
ink4a pediatric osteosarcomas Immunohistochemical analysis of p16(INK4a) expression in pediatric osteosarcomas may be a useful adjunctive marker of prognosis. 11241308 Human
ink4a t-cell acute lymphoblastic leukemia The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. 11278393 Human
ink4a t-cell acute lymphoblastic leukemia To investigate possible consequences of this genetic alteration for tumor development, we conditionally expressed p16(INK4A) in the T-cell acute lymphoblastic leukemia line CCRF-CEM, which carries a homozygous deletion of this gene. 11278393 Human
ink4a cin ii In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
ink4a intraepithelial neoplasm In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
ink4a invasive cervical cancers In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
ink4a monoclonal gammopathy of undetermined significance p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. p15(INK4b) and p16(INK4a) proteins are cell cycle regulators involved in the inhibition of G1 phase progression. 11418489 Human
ink4a uveal melanoma Treatment of uveal melanoma cell lines with 5-aza-2'-deoxycytidine results in demethylation of p16(INK4a) and in reexpression of p16(INK4a) mRNA, which is maintained upon withdrawal of the 5-aza-2'-deoxycytidine. 11431374 Human
ink4a t-cell acute lymphoblastic leukemia To investigate possible consequences of this genetic alteration for tumor development, we conditionally expressed p16(INK4A) in the T-cell acute lymphoblastic leukemia line CCRF-CEM, which carries a homozygous deletion of this gene. 11441822 Human
ink4a hcl The latter DNA probes and probes hybridizing to chromosomal regions, which are frequently deleted in other subtypes of non-Hodgkin lymphomas (NHL), namely 9p21/ P16(INK4A), 13q14/D13S25, and 17p13/P53 were subsequently applied to all 14 cases of HCL, but 11463458 Human
ink4a lymphoid tumors Interestingly, whereas p53 mutations or loss of heterozygosity did not account for the accelerated development of lymphoid tumors in UV-irradiated p53(+/-) mice, deletions in the p16(INK4a) gene were quite common. 11481437 Mouse
ink4a hepatic tumor Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). 11568971 Mouse
ink4a vulvar epidermoid carcinoma To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and 11593424 Human
ink4a barrett's esophagus Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the 11719461 Human
ink4a esophageal adenocarcinoma Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the 11719461 Human
ink4a primary central nervous system lymphoma Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. 11804283 Human
ink4a endometrial hyperplasia Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. 11818530 Mouse
ink4a pheochromocytoma Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. 11818530 Mouse
ink4a prostatic intraepithelial neoplasia Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. 11818530 Mouse
ink4a pheochromocytoma Functional synergy between Ink4a/Arf and Pten manifested most prominently in the development of pheochromocytoma, prompting an analysis of genes and loci implicated in this rare human neoplasm. 11818530 Mouse
ink4a pheochromocytoma The classical pheochromocytoma genes Ret, Vhl, and Nf-1 remained intact, a finding consistent with the intersection of these genes with pathways engaged by Pten and Ink4a/Arf. 11818530 Mouse
ink4a common tumor p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t 11830494 Human
ink4a nsclc To identify the molecular basis for this p16 immunohistochemical negativity further, we performed a genetic and epigenetic study of p16(INK4a) status in a series of 115 NSCLC samples parallel to the clinicopathologic and prognostic analyses. 11920642 Human
ink4a invasive ductal adenocarcinoma Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. 12010891 Human
ink4a angiosarcomas In vivo, mice doubly deficient for p16(INK4a) and p53 showed an increased rate of tumor formation with particular susceptibility to aggressive angiosarcomas. 12019151 Mouse
ink4a myeloproliferative disorders A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr 12032783 Human
ink4a thyroid tumors Additionally, we analyzed the methylation frequency of the CpG island of cell cycle inhibitor p16(INK4a) in the same thyroid tumors. 12097277 Human
ink4a oral cancer We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and t 12183435 Human
ink4a pleomorphic adenomas To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. 12375265 Human
ink4a pleomorphic adenomas Methylation of p14(ARF) was found in 1/42 cases and alterations of p16(INK4a) occurred in 12/42 of pleomorphic adenomas, which correlated with loss of mRNA transcription. 12375265 Human
ink4a pleomorphic adenoma The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to ca 12375265 Human
ink4a common neoplasms Loss of p16(INK4a) expression has also been frequently observed in more common neoplasms such as lung cancer as well. 12399123 Human
ink4a mesothelioma This methylation in these mesothelioma cells could be reversed, resulting in re-expression of p16(INK4a) protein, following the treatment of the cells with cytidine analogs, which are known inhibitors of DNA methylation. 12399123 Human
ink4a lobular carcinomas Oestrogen and progesterone receptors, tumour proliferative activity, the expression of cyclin A, p16(ink4A), p27(kip1), p21(waf1), p53, bcl-2, and levels of vascular endothelial growth factor and hypoxia-inducible factor-1alpha (HIF-1alpha) were evaluated 12402149 Human
ink4a oral cancer In an attempt to model oral cancer in a human cell-based system, we analyzed normal oral epithelial keratinocytes with the pRB pathway dysregulated by loss of expression of the cyclin-dependent kinase (cdk) 4/cdk6 inhibitor p16(INK4A) and/or ectopic expre 12543805 Human
ink4a mouse tumor Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. 12573439 Mouse
ink4a aggressive fibromatosis Importantly, exogenous p16(INK4a) introduced by cotransfection is sufficient to reduce GR activity in FS cells, without affecting GR activity in p16-positive aggressive fibromatosis cells. 12624188 Human
ink4a liver tumors Additionally, we analysed the methylation status of p16(INK4a) and other cancer-related genes in the same liver tumors. 12660822 Human
ink4a hca In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic ba 12660822 Human
ink4a plasma cell tumors BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. 12700664 Mouse
ink4a basal cell carcinoma Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. 12702553 Human
ink4a basal cell carcinomas Using immunohistochemistry and Western blotting of microdissected parts of basal cell carcinomas, we showed that p16(INK4a) was up-regulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, followed by ceas 12702553 Human
ink4a neuroendocrine tumors Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancrea 12802288 Human
ink4a tonsil cancers In our study 86 tonsil cancers were analysed for HPV status by sequence analysis of polymerase chain reaction products and for the expression of cell cycle proteins (p53, p21(CIP1/WAF1), pRb, p16(INK4A), cyclin D1 and p27(KIP1)) by immunohistochemistry. 12845651 Human
ink4a squamous cell carcinoma of the cervix Carcinogenesis of cervical cancer has been investigated, and p16(INK4a) overexpression in squamous cell carcinoma of the cervix has been reported as a result of infection by human papillomavirus (HPV) (eg, HPV 16), and the consequence of the retinoblastom 14506638 Human
ink4a small cell carcinoma of the cervix However, to our knowledge, there have been no studies on the relation between p16(INK4a) overexpression associated with HPV and small cell carcinoma of the cervix, which behaves more aggressively clinically than squamous cell carcinoma. 14506638 Human
ink4a small cell carcinoma The purpose of this study was to determine whether p16(INK4a) is overexpressed in small cell carcinoma, and if p16(INK4a) is overexpressed, the types of HPV that are related to this cancer. 14506638 Human
ink4a small cell carcinoma We reviewed 10 cases of small cell carcinoma and examined them for p16(INK4a) overexpression by immunohistochemistry. 14506638 Human
ink4a small cell carcinoma In conclusion, p16(INK4a) was overexpressed and HPV 18 was frequently detected in an integrated form in small cell carcinoma. 14506638 Human
ink4a schwannomas EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific 14654541 Human
ink4a hsil Comparison of the number of p16(INK4a) immunoreactive cells/1,000 cells exhibited a significantly higher mean count in HSIL (8.80 +/- 1.13) than other cytological groups. 14712490 Human
ink4a transitional cell carcinomas (tcc) Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
ink4a cysts Immunohistochemical staining was performed for p16(INK4a) and pRb in formalin-fixed, paraffin-embedded tissue sections of the uterine cervix using an indirect immunoperoxidase method. p16(INK4a) staining was detected in 7 of 108 sections (6.5%) of normal 15188135 Human
ink4a non-small cell carcinomas In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and non-small cell carcinomas. p16(INK4A) express 15309021 Human
ink4a cervical cancer The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C 15381905 Human
ink4a cin The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C 15381905 Human
ink4a colorectal carcinomas This study aimed to identify potential abnormalities of retinoblastoma protein (pRb) and p16(INK4a) (p16) expression in resectable colorectal carcinomas (CRCs) and to assess the prognostic significance of pRb and p16 levels in patients with CRC. 15492985 Human
ink4a fibroadenoma The potential role of p16(INK4a) methylation in breast cancer is controversial whereas there are no data on fibroadenoma. 15578730 Human
ink4a fibroadenoma To assess if inactivation of p16(INK4a) by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 15578730 Human
ink4a salivary gland carcinomas (sgcs) As combinations of genetic and/or epigenetic alterations occurring during salivary gland carcinogenesis are largely unknown, we here analyzed 36 salivary gland carcinomas (SGCs) for changes in INK4a/ARF, RB1, p21, p27, PTEN, p53, MDM2 and O6-MGMT genes us 15695118 Human
ink4a mantle cell lymphomas CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. 15781632 Human
ink4a mcl To determine the role of these genes in MCL, we have examined their gene status and expression and their relationship to INK4a/ARF and p53 gene aberrations in 69 tumors. 15781632 Human
ink4a oligodendroglial tumors Remarkably, 9 of 10 murine oligodendroglial tumors (from p53+/- or ink4a/arf+/- animals transgenic for S100beta-v-erbB) showed a similar tumor-specific down-regulation of mSLC5A8, the highly conserved mouse homologue. 15867356 Mouse
ink4a vin 3 RESULTS: p16(INK4a) immunoreactivity was different in VIN 1, VIN 2, VIN 3, and squamous cell carcinoma. 15870532 Human
ink4a vin 3 Strong expression of p16(INK4a) protein was observed in 92% (22 of 24) of VIN 2 and VIN 3 lesions and 100% (4 of 4) of invasive SCCs. 15870532 Human
ink4a condyloma acuminatum No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions. 15870532 Human
ink4a condyloma acuminatum CONCLUSIONS: Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) neg 15870532 Human
ink4a cervical polyp METHODS: A total of 188 consecutive and unselected colposcopically directed cervical biopsies and a single contemporaneous cervical polyp were accessioned prospectively over a 3-month period, step-serially sectioned and examined by H&E and immunostained f 16028838 Human
ink4a cervical polyp Diffuse strong parabasal immunostaining for p16(INK4a), suggestive of integrated high-risk HPV DNA into the host genome, was observed in 81 biopsies (42.9%, including the cervical polyp) and correlated (>90%) with HGSIL in the H&E sections. 16028838 Human
ink4a immunoblastic lymphoma Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r 16053658 Human
ink4a amelanotic melanoma Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. 16087843 Mouse
mts-1 ductal adenocarcinomas Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. 8640773 Human
cdkn2 biliary tract cancers Twenty-five primary biliary tract cancers were examined for somatic mutations in p16Ink4/CDKN2, p15Ink4B/MTS2, p53, and K-ras genes and allelic loss of 9p21 by microsatellite analysis. 7796400 Human
cdkn2 biliary tract cancer We found frequent homozygous deletions in p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in the biliary tract cancer cell lines. 7796400 Human
cdkn2 ampullary cancers One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. 7796400 Human
cdkn2 bile duct cancers One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. 7796400 Human
cdkn2 lymphoblastic lymphoma In the primary tumors, homozygous deletions of both CDKN2 and MTS2 were found in 35% of the T-ALL/lymphoblastic lymphoma (8 of 23). 7882348 Human
cdkn2 lymphoblastic lymphoma These results are consistent with a role for CDKN2 and/or MTS2 in the pathogenesis of some lymphoid leukemia/lymphomas, particularly in T-ALL/lymphoblastic lymphoma. 7882348 Human
cdkn2 bronchogenic carcinoma CONCLUSIONS: The results suggested that CDKN2 gene was a tumor suppressor gene, the inactivation of which were involved in the carcinogenesis of bronchogenic carcinoma and implicated in tumor differentiation. 9388844 Human
cdkn2 thymoma p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. 9398039 Human
cdkn2 thymoma A polymorphism in the 3' untranslated region of exon 3 of CDKN2 was detected in 5 cases of thymoma. 9398039 Human
cdkn2 neurofibromatosis Mutations of p16 (CDKN2), p53, ras, neurofibromatosis type I gene (NF-1), bcl2 and the retinoblastoma gene have been described, but none are common. 10427507 Human
cdkn2 transitional cell carcinomas (tcc) Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
p16 small lymphocytic lymphoma We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f 7579381 Human
p16 myeloid tumors Loss of the p16 gene is frequent in and highly specific to lymphoid malignancies (54 of 183 [30%] in lymphoid tumor v2 of 219 [1%] in myeloid tumors; P < .0001). 7632963 Human
p16 lymphoblastic lymphomas None of the lymphoid tumors studied possessed deletions of p18, including a group of lymphoblastic lymphomas which we previously reported to have deletions of p16 and p15. 8637248 Human
p16 ductal adenocarcinomas Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. 8640773 Human
p16 papillary cancer Homozygous deletion of the entire p16 coding sequence was observed in two of three follicular and two of four papillary cancer cell lines, but not in normal tissue or normal cells immortalised by SV40 T antigen. 8822272 Human
p16 differentiated thyroid cancer Given the co-existence of p16 abnormalities in primary tumours and cell lines observed in other tumour types, this high frequency of deletion suggests that p16 is a key tumour suppressor gene in the genesis of differentiated thyroid cancer. 8822272 Human
p16 advanced cancer In cancer in adenoma pRB and cdk2 were overexpressed with high frequency, and cdk4 overexpression was detected in advanced cancer. p16 overexpression was detected in almost all cancers, but in contrast p21 overexpression was rare event. 8920658 Human
p16 liposarcoma Using one microsatellite marker distal to p16(D9S171) and one intragenic sequence-tagged site (STS) marker (c5.1), we observed LOH in only one liposarcoma and one malignant schwannoma (2.6%). 9049181 Human
p16 megakaryoblastic leukemia In a human megakaryoblastic leukemia cell line, CMK, that showed some degree of megakaryocytic differentiation after culture with TPO, the cyclin-dependent kinase (Cdk) inhibitor p21(WAF1/Cip1), but not p27(Kip1), p16(INK4A), p15(INK4B), or p18(INK4C), wa 9111365 Human
p16 pancreatic neoplasms In half of the patients, two or more unique K-ras mutations were identified among distinct PILs, which is evidence for the separate clonal evolution of multiple pancreatic neoplasms within individual patients. p16 alterations (one homozygous deletion and 9187111 Human
p16 gastric adenocarcinomas Among 34 esophageal adenocarcinomas and 11 gastric adenocarcinomas, only one tumor lacked p16 expression and all tumors expressed p16beta. p16 sequences were not detectable by PCR in genomic DNA from tumors lacking both p16 and p16beta mRNA, suggesting th 9333024 Human
p16 bronchogenic carcinoma [Expression of CDKN2 gene product in human bronchogenic carcinoma] OBJECTIVE: To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic ca 9388844 Human
p16 ewing tumors Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far. 9393981 Human
p16 bladder tumor The remaining tumor lines expressed p16 at constant levels before and after 5-Aza-CdR treatment and showed minimal p16 promoter methylation, suggesting that other growth-regulatory genes may have been silenced by de novo methylation in these cells. p16 ex 9426064 Human
p16 plasmacytoma When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all 9482902 Mouse
p16 mucinous tumors p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. 9495360 Human
p16 oral tumors In this paper, we present results of our examination of a series of 80 oral squamous cell carcinomas for p53 exons 5-9 and p16 exons 1-2 mutations, and the potential association of these mutations with specific genotyping patterns. p53 mutation prevalence 9525287 Human
p16 oral tumors A significant association was not observed between the prevalence of p16 mutations in oral tumors and tobacco use, or CYP1A1 [val] or GSTM1 (0/0) genotypes. 9525287 Human
p16 indolent lymphomas Hypermethylation of the gene was also examined in a subset of tumors with lack of protein expression but without mutations or deletions of the gene. p16(INK4a) gene alterations were detected in 3 out of 64 (5%) indolent lymphomas but in 16 out of 48 (33%) 9531609 Human
p16 low-grade tumors In the low-grade tumors, p16(INK4a) alterations were detected in 1 (4%) chronic lymphocytic leukemia (hemizygous missense mutation), 1 (6%) follicular lymphoma (homozygous deletion), and 1 (5%) typical mantle cell lymphoma (homozygous deletion). 9531609 Human
p16 anaplastic large cell lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
p16 large-cell lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
p16 lymphoblastic lymphomas In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph 9531609 Human
p16 large-cell lymphoma Sequential samples of the indolent and transformed phase of three cases showed the presence of p16(INK4a) deletions in the Richter's syndrome but not in the CLL component of two cases, whereas in a follicular lymphoma the deletion was present in both 9531609 Human
p16 atypical adenomatous hyperplasia An immunohistochemical analysis. To clarify the events leading to the disruption of cell growth control that occurs during the development of pulmonary adenocarcinoma (AC), we used immunohistochemistry to evaluate the expression of G1 cycle regulators, cy 9531999 Human
p16 b-cell lymphoma The p16 gene is frequently mutated or deleted in many types of cancer cell lines as well as in certain types of primary tumors. p16 knockout mice are viable but predisposed to sarcoma and B-cell lymphoma. 9563903 Mouse
p16 adrenal cortical hyperplasia Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
p16 malignant tumors of the adrenal cortex Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P 9596277 Human
p16 soft tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
p16 large cell carcinomas To observe the expression of p16, pRb, cdk4 and cyclinD1 in non-small cell lung cancers, 104 cases of resected lung cancers were collected, which included squamous cell carcinomas, adenocarcinomas and large cell carcinomas. 9751261 Human
p16 plasma cell leukemia Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. 9815612 Human
p16 plasma cell leukemia (pcl) However, the frequency and significance of p16 abnormalities in multiple myeloma (MM) and the more aggressive phase of plasma cell leukemia (PCL) have not been well defined. 9815612 Human
p16 intraductal carcinomas In 33 (9%) invasive and two (4%) intraductal carcinomas, a cytoplasmic accumulation of the p16 protein was seen. 9862580 Human
p16 cystadenomas METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys 9889036 Human
p16 ovarian cystadenomas METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys 9889036 Human
p16 carcinoma in pleomorphic adenoma Results of this study suggest that two different genetic alterations, the inactivation of the p16 gene and genetic instability, play roles in the malignant transformation of carcinoma in pleomorphic adenoma. 9917133 Human
p16 invasive carcinoma In contrast, p16 expression was lost in moderate dysplasia (12%) and in CIS (30%) in patients with lung cancer. p16 loss occurred exclusively in patients who displayed loss of p16 expression in their related invasive carcinoma. 10037171 Human
p16 invasive carcinoma Our results indicate that Rb protein function can be invalidated before invasion through alteration of the Rb phosphorylation pathway, by p16 inhibition, and/or by cyclin D1 overexpression and suggest a role for p16 and cyclin D1 deregulation in progressi 10037171 Human
p16 colonic adenomas CONCLUSIONS: p16 methylation occurs frequently in human colonic adenomas and cancers and is closely associated with K-ras mutations. 10220498 Human
p16 verrucous carcinomas (vcs) In this study, the expression of the cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 were examined by immunohistochemistry in precancerous and cancerous oral lesions, including verrucous carcinomas (VCs). 10226946 Human
p16 agnogenic myeloid metaplasia (amm) P16 gene deletions and point mutations in patients with agnogenic myeloid metaplasia (AMM). 10400184 Human
p16 agnogenic myeloid metaplasia (amm) Studies of p16 alterations with homozygous deletions and mutation analysis were done in 32 patients with agnogenic myeloid metaplasia (AMM) including six patients in leukemic phase. 10400184 Human
p16 endometrial tumours The roles of the p16 and p15 inhibitor of cyclin-dependent kinase tumour suppressor genes were examined in human uterine cervical and endometrial cancers. p16 mRNA, examined by reverse transcription polymerase chain reaction (RT-PCR), was significantly re 10408854 Human
p16 cervical tumours Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. 10408854 Human
p16 cervical tumours Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours and one of 38 (3%) endometrial tumours. 10408854 Human
p16 endometrial tumours Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours and one of 38 (3%) endometrial tumours. 10408854 Human
p16 cervical tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
p16 endometrial tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
p16 uterine tumours PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). 10408854 Human
p16 uterine tumours These observations suggest that inactivation of the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours. 10408854 Human
p16 neurofibromatosis Mutations of p16 (CDKN2), p53, ras, neurofibromatosis type I gene (NF-1), bcl2 and the retinoblastoma gene have been described, but none are common. 10427507 Human
p16 basaloid carcinomas In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
p16 nsclc In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
p16 squamous cell carcinomas In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
p16 basaloid carcinoma In univariate analysis, Rb-negative adenocarcinomas at stages I-II had a significantly shorter survival than Rb-positive cases ( p = 0.04) and stages I-II p16-positive cases had a shorter survival than p16-negative cases ( p = 0.02), which was more signif 10440744 Human
p16 advanced carcinomas PATIENTS AND METHODS: The expression patterns and their possible prognostic relevance of the cell cycle regulatory proteins p53, p21(WAF/CIP1), Rb, p16(INK4A), CDK4 and Cyclin D1, MIB1 (Ki-67) and BCL-2 were analysed in pretreatment tumor biopsies from 43 10525606 Human
p16 salivary gland carcinomas Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. 10534174 Human
p16 small bowel adenocarcinomas The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). 10613343 Human
p16 neuroendocrine tumors of the lung Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. 10649246 Human
p16 acral lentiginous melanoma An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. 10657449 Human
p16 acral lentiginous melanomas These data suggest that p16 inactivation may play an important role in the development and progression of acral lentiginous melanomas. 10657449 Human
p16 high grade lymphoma With time, a fraction of follicular lymphoma accumulates mutations of p53 and of p16 and evolves into a high grade lymphoma. 10681729 Human
p16 hydatidiform mole METHODS: The expressions of p16, cyclin-dependent kinase 4 (CDK4), proliferation cell nuclear antigen (PCNA) proteins in 18 cases of trophoblastic tumors, 30 cases of hydatidiform mole and 30 cases of normal villi were studied by immunohistochemical metho 10681785 Human
p16 trophoblastic tumors METHODS: The expressions of p16, cyclin-dependent kinase 4 (CDK4), proliferation cell nuclear antigen (PCNA) proteins in 18 cases of trophoblastic tumors, 30 cases of hydatidiform mole and 30 cases of normal villi were studied by immunohistochemical metho 10681785 Human
p16 endometrial hyperplasias (eh) We analysed p16 gene alteration and p16, cyclin-dependent kinase 4 (CDK4), CDK6, cyclin D1, cyclin D2, cyclin D3 and retinoblastoma protein (pRb) expression in ten normal endometriums (PE), 18 endometrial hyperplasias (EH) and 35 endometrial cancers (EC). 10682682 Human
p16 ovarian serous cystadenocarcinomas [A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden 10683958 Human
p16 serous cystadenomas [A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden 10683958 Human
p16 ovarian serous cystadenocarcinoma These results suggested that P16 and P53 protein expressions of the ovarian serous cystadenocarcinoma might be correlated with human organs, histological type of tumor, cyclin and cyclindependent kinase. 10683958 Human
p16 9l gliosarcoma We detected homozygous deletions of the p16/Cdkn2a/Ink4a gene locus in 4 of 5 glioma cell lines (C6, F98, RG2, and RGL.3), but not in the 9L gliosarcoma cell line or in a rat primary fibroblast cell line. 10738182 Rat
p16 indolent lymphomas To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 10854221 Human
p16 hereditary cancer syndrome [Mechanism of tumorigenesis caused by tumor suppressor gene] Hereditary cancer syndrome is mainly caused by tumor suppressor genes, such as p53 gene in Li-Fraumeni syndrome and p16 gene in familial melanoma. 10879046 Human
p16 aml The p16 mRNA expression in 12 AML at diagnosis or relapse was significantly lower than that in 4 long term remission cases and normal controls. p16 mRNA expression was significantly higher in a case of AML with p53 mutation. 10921094 Human
p16 squamous cell lung carcinoma By increasing the sensitivity of a PCR approach to detect methylated DNA sequences, we now demonstrate that aberrant methylation of the p16 and/or O6-methyl-guanine-DNA methyltransferase promoters can be detected in DNA from sputum in 100% of patients wit 11085511 Human
p16 leukoplakia Immunohistochemical analysis of Rb, p16(INK4A) and cyclin D1 expression was performed on 78 oral squamous cell carcinoma (SCC), 46 leukoplakia, and 20 normal mucosa. 11098077 Human
p16 leukoplakia Rb and p16(INK4A) expression were observed in all normal mucosa and most of leukoplakia. 11098077 Human
p16 pancreatic carcinoma CONCLUSION: The alteration of p16 gene and abnormal expression of P16 protein are significantly correlated with the biological behavior and clinical staging of pancreatic carcinoma and may hence be helpful to prognostication 11110976 Human
p16 medullary thyroid carcinoma At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom 11205230 Human
p16 pediatric osteosarcomas Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. 11241308 Human
p16 pediatric osteosarcomas We examined a series of 38 pediatric osteosarcomas for abnormal expression of pRB, p16(INK4a) and cyclin D1 by immunohistochemical analysis of archival biopsy specimens. 11241308 Human
p16 metastasis There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen 11241308 Human
p16 tumor necrosis There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen 11241308 Human
p16 pediatric osteosarcomas Immunohistochemical analysis of p16(INK4a) expression in pediatric osteosarcomas may be a useful adjunctive marker of prognosis. 11241308 Human
p16 corticotroph adenomas Staining for p16 was only seen in 5 of 15 (33%) corticotroph, 3 of 13 (23%) somatotroph, 3 of 5 (60%) plurihormonal, and 1 of 19 (5%) null cell adenomas. p16 immunonegativity without CDKN2A methylation or deletion occurred in 22 tumours, including most so 11276008 Human
p16 corticotroph adenomas The mechanisms of p16 down-regulation probably involve CDKN2A methylation in most types, but remain to be determined in somatotroph and corticotroph adenomas. 11276008 Human
p16 acute promyelocytic leukemia (apl) PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. 11283136 Human
p16 mrd It is possible that p16 methylation is acquired during clonal evolution. p15 methylation is a potential marker of MRD and might be of prognostic significance. 11283136 Human
p16 cin ii In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
p16 intraepithelial neoplasm In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
p16 invasive cervical cancers In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 11291057 Human
p16 invasive ductal carcinoma of the breast Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. 11329139 Human
p16 uveal melanoma Treatment of uveal melanoma cell lines with 5-aza-2'-deoxycytidine results in demethylation of p16(INK4a) and in reexpression of p16(INK4a) mRNA, which is maintained upon withdrawal of the 5-aza-2'-deoxycytidine. 11431374 Human
p16 neurofibroma CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. 11433531 Human
p16 hcl The latter DNA probes and probes hybridizing to chromosomal regions, which are frequently deleted in other subtypes of non-Hodgkin lymphomas (NHL), namely 9p21/ P16(INK4A), 13q14/D13S25, and 17p13/P53 were subsequently applied to all 14 cases of HCL, but 11463458 Human
p16 lymphoid tumors Interestingly, whereas p53 mutations or loss of heterozygosity did not account for the accelerated development of lymphoid tumors in UV-irradiated p53(+/-) mice, deletions in the p16(INK4a) gene were quite common. 11481437 Mouse
p16 adult acute myeloid leukemia In this study, we used sodium bisulfite sequencing to obtain a complete map of the 5-methylcytosine status of 80 CpGs covering approximately 900 bp in the 5' p15 CpG island, and 53 CpGs covering approximately 700 bp in the 5' p16 CpG island in t 11532526 Human
p16 hepatic tumor Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). 11568971 Mouse
p16 vulvar epidermoid carcinoma To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and 11593424 Human
p16 metastatic cancers Homozygous deletions of the p16 gene were observed in 2 of the 5 primary colorectal carcinomas and in 1 of the matching liver metastatic cancers. 11677769 Human
p16 barrett's esophagus Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the 11719461 Human
p16 esophageal adenocarcinoma We conclude that most Barrett's metaplasia contains genetic and/or epigenetic p16 lesions and has the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to esophageal adenocarcinoma. 11719461 Human
p16 metaplasia We conclude that most Barrett's metaplasia contains genetic and/or epigenetic p16 lesions and has the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to esophageal adenocarcinoma. 11719461 Human
p16 parotid tumor CONCLUSIONS: When p16 multiple tumor suppressor gene is lost and oncogene p21 is mutated, the tumor's contiguous acini maybe in the condition of "paraneoplasm" after parotid tumor removal, and it has a strong ability of preliferation, which 11769651 Human
p16 atypical hyperplasia METHODS: Methylation status of p16 gene was determined by methylation-sensitive restriction enzymes, PCR and p16 mRNA expression was evaluated by RT-PCR in a series of 8 specimens with normal endometrium(NE), 6 with simple and complex hyperplasia(SCH), 6 11778238 Human
p16 sch In 1 of the 6 AH and 13 of the 38(34.21%) EC, there was methylation of p16 exon 1; 5 of the 6 SCH showed overexpression of p16 mRNA, 4 of the 6 AH and 27 of the 38 (71.05%) EC exhibited decrease or loss of p16 mRNA expression. 11778238 Human
p16 extrahepatic bile duct carcinomas We investigated their role in the pathogenesis of 9 bile tract cancer cell lines and 21 primary sporadic extrahepatic bile duct carcinomas. p53 and p16 protein expression was examined by Western blot analysis and immunohistochemistry. 11802210 Human
p16 extrahepatic bile duct cancers In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. 11802210 Human
p16 recurrent breast carcinoma Fourteen patients (12.2%) of 114 patients whose tumors did not show p16 expression died of recurrent breast carcinoma, whereas 18 patients (23.1%) of 78 patients with p16 expressing tumor died during the follow-up period. 11804184 Human
p16 signet ring cell carcinoma The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 11819820 Human
p16 transitional cell carcinoma of bladder [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. 11831985 Human
p16 bladder cancer CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
p16 transitional cell carcinoma of urinary bladder CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
p16 agnogenic myeloid metaplasia(amm) Hypermethylation of p15 and p16 genes was determined in 32 patients with agnogenic myeloid metaplasia(AMM), also known as idiopathic myelofibrosis (MF). 11849214 Human
p16 differentiated carcinoma The p16 positive rate was negatively correlated to the degree of tumor histological differentiation, and the rate difference between the high differentiated carcinoma and the low differentiated one was significant (P < 0.05). bcl-2 protein positive expres 11853608 Human
p16 endometrioid carcinomas Endometrioid carcinomas frequently show microsatellite instability (MIN), PTEN and K-ras mutation but infrequently p53 mutations, loss of p16 expression and her2/neu amplification, respectively. 11873308 Human
p16 serous carcinomas In contrast, serous carcinomas show a high frequency of p53 mutations and often loss of p16 expression whereas MIN and PTEN and K-ras mutations are uncommon. 11873308 Human
p16 atypical endometrial hyperplasia During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar 11873308 Human
p16 endometrioid carcinoma During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar 11873308 Human
p16 macroglobulinemia MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma 11920239 Human
p16 macroglobulinemia RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s 11920239 Human
p16 malignant eyelid tumors CONCLUSIONS: The expression of the P16 protein was related to the occurrence and degree of differentiation of malignant eyelid tumors. 11930651 Human
p16 invasive ductal adenocarcinoma Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. 12010891 Human
p16 angiosarcomas In vivo, mice doubly deficient for p16(INK4a) and p53 showed an increased rate of tumor formation with particular susceptibility to aggressive angiosarcomas. 12019151 Mouse
p16 relapsed childhood acute lymphoblastic leukemia Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia. 12036898 Human
p16 teratomas Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
p16 yolk sac tumor Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
p16 liver tumor On the other hand, circulating liver tumor DNA such as p16 and p15 methylation and mitochondrial mutations in the plasma and serum of liver cancer patients might be useful for monitoring, similar to the tumor markers. 12094698 Human
p16 thyroid tumors Additionally, we analyzed the methylation frequency of the CpG island of cell cycle inhibitor p16(INK4a) in the same thyroid tumors. 12097277 Human
p16 hereditary breast-ovarian cancer syndrome Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
p16 hereditary pancreatic cancer Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
p16 inherited cancer syndromes Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
p16 polyposis Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
p16 nerve sheath tumors Hemizygous or homozygous p16 deletions were detected in 75% of MPNSTs, but not in benign nerve sheath tumors (p < 0.001). 12152785 Human
p16 idiopathic pulmonary fibrosis MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. 12169206 Human
p16 oral cancer We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and t 12183435 Human
p16 mds We examined p15 and p16 methylation status in bone marrow mononuclear cells from patients with high-risk MDS during treatment with decitabine, using a methylation-sensitive primer extension assay (Ms-SNuPE) to quantitate methylation, and denaturing gradie 12351408 Human
p16 pleomorphic adenomas To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. 12375265 Human
p16 liver angiosarcoma Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D 12378512 Human
p16 common neoplasms Loss of p16(INK4a) expression has also been frequently observed in more common neoplasms such as lung cancer as well. 12399123 Human
p16 mesothelioma This methylation in these mesothelioma cells could be reversed, resulting in re-expression of p16(INK4a) protein, following the treatment of the cells with cytidine analogs, which are known inhibitors of DNA methylation. 12399123 Human
p16 lobular carcinomas Oestrogen and progesterone receptors, tumour proliferative activity, the expression of cyclin A, p16(ink4A), p27(kip1), p21(waf1), p53, bcl-2, and levels of vascular endothelial growth factor and hypoxia-inducible factor-1alpha (HIF-1alpha) were evaluated 12402149 Human
p16 human erythroleukemia Changes of biophysical behavior of k562 cells for p16 gene transfer. p16 gene was transferred into human erythroleukemia cell line K562 that had been subjected to p16 deletion. 12454374 Human
p16 vulvar carcinoma Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. 12454817 Human
p16 vulvar carcinoma (vc) Three different alterations in the p16/pRb/cyclin-D1 pathway (p16(INK4a)-promoter hypermethylation and expression of pRb and cyclin-D1) were investigated in a series of 38 cases of vulvar carcinoma (VC), 13 cases of vulvar intraepithelial neoplasia (VIN), 12454817 Human
p16 oral cancer In an attempt to model oral cancer in a human cell-based system, we analyzed normal oral epithelial keratinocytes with the pRB pathway dysregulated by loss of expression of the cyclin-dependent kinase (cdk) 4/cdk6 inhibitor p16(INK4A) and/or ectopic expre 12543805 Human
p16 cervical glandular intraepithelial neoplasia A total of 45 surgical specimens, including 18 cases of invasive carcinoma, 8 cases of adenocarcinoma in situ, 4 cases of endocervical glandular atypia (cervical glandular intraepithelial neoplasia), and 15 reactive lesions of the endocervical glands were 12548164 Human
p16 large cell carcinoma METHODS: p16 and p53 expression were detected by immunohistochemical analysis of 90 paraffin specimens of resected NSCLC, including 35 squamous cell carcinoma, 47 adenocarcinoma, and eight large cell carcinoma, between stages I and IV. 12559346 Human
p16 mouse tumor Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. 12573439 Mouse
p16 aggressive fibromatosis Importantly, exogenous p16(INK4a) introduced by cotransfection is sufficient to reduce GR activity in FS cells, without affecting GR activity in p16-positive aggressive fibromatosis cells. 12624188 Human
p16 adenoid cystic carcinoma Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. 12624503 Human
p16 adenoid cystic carcinomas (acc) To explore the role of p16 in the biological behavior of adenoid cystic carcinomas (ACC), we investigated the immunohistochemical expression of p16 protein in 38 ACC tumors (32 primary, 3 recurrent, and 3 metastatic tumors) and the methylation status of i 12624503 Human
p16 atypical adenomatous hyperplasia In the case of adenocarcinoma, we investigated the utility of hnRNP B1 for both detection of early adenocarcinoma and discrimination of non-invasive lesion, atypical adenomatous hyperplasia (AAH) from adenocarcinoma. hnRNP B1, cyclin D1, p16, and Ki-67 we 12660006 Human
p16 liver tumors Additionally, we analysed the methylation status of p16(INK4a) and other cancer-related genes in the same liver tumors. 12660822 Human
p16 hca In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic ba 12660822 Human
p16 gastric adenoma (ga) Five different classes of methylation behaviors were found: (a). genes methylated in GC only (GSTP1 and RASSF1A), (b). genes showing low methylation frequency (<12%) in CG, IM, and gastric adenoma (GA) but significantly higher methylation frequency in GC 12695555 Human
p16 basal cell carcinoma Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. 12702553 Human
p16 basal cell carcinomas Using immunohistochemistry and Western blotting of microdissected parts of basal cell carcinomas, we showed that p16(INK4a) was up-regulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, followed by ceas 12702553 Human
p16 laryngeal papilloma (alp) METHODS: HPV consensus primers direct in situ polymerase chain reaction (ISPCR) and immunohistochemical method were applied to detect the presence of HPV genomes (1, 6, 8, 11, 13, 16, 18, 30, 31, 32, 33, 45, 51) and the expression of p16 protein respectiv 12761910 Human
p16 neuroendocrine tumors Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancrea 12802288 Human
p16 tonsil cancers In our study 86 tonsil cancers were analysed for HPV status by sequence analysis of polymerase chain reaction products and for the expression of cell cycle proteins (p53, p21(CIP1/WAF1), pRb, p16(INK4A), cyclin D1 and p27(KIP1)) by immunohistochemistry. 12845651 Human
p16 hepatitis b virus related hepatocellular carcinoma [Effect of p16 gene on carcinogenesis of hepatitis B virus related hepatocellular carcinoma] OBJECTIVE: To investigate the relation between p16 gene expression and the carcinogenesis and progress of hepatitis B virus (HBV) related hepatocellular carcinoma 12921565 Human
p16 sporadic breast cancer [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter 12942643 Human
p16 tumors Our results suggest that abnormal expression of the p16 and/or p14ARF may be associated with a poor prognosis in these 3 tumors. 12963998 Human
p16 squamous cell carcinoma of the cervix Carcinogenesis of cervical cancer has been investigated, and p16(INK4a) overexpression in squamous cell carcinoma of the cervix has been reported as a result of infection by human papillomavirus (HPV) (eg, HPV 16), and the consequence of the retinoblastom 14506638 Human
p16 small cell carcinoma of the cervix However, to our knowledge, there have been no studies on the relation between p16(INK4a) overexpression associated with HPV and small cell carcinoma of the cervix, which behaves more aggressively clinically than squamous cell carcinoma. 14506638 Human
p16 tongue neoplasms [Expression of p15 and p16 proteins in tongue squamous cell carcinoma and their significances] BACKGROUND & OBJECTIVE: Abnormal expression of p15 and p16 were commonly found in many kinds of primary tumors, but the possible correlation between p15 and p16 14613656 Human
p16 tongue squamous cell carcinoma This study was designed to investigate the expression of p15 and p16 proteins and their possible correlation with clinicopathology and prognosis of tongue squamous cell carcinoma (TSCC). 14613656 Human
p16 papillomatosis METHODS: Immunohistochemistry was used to examine the protein expression of CyclinD1, p16, E2F-1 and Rb in 4 groups (196 cases) with mild papillomatosis (MP), moderate papillomatosis (MoP), serious papillomatosis (SP) and ductal carcinoma in situ (DCIS). 14642081 Human
p16 schwannomas EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific 14654541 Human
p16 head and neck carcinomas Due to heterozygous p16-Leiden constitution, our proband with multiple head and neck carcinomas was a suitable model for studying the type of p16 inactivation according to the Knudson-two-hit model. 14740307 Human
p16 adenoid cystic carcinoma (acc) Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 carcinoma ex pleomorphic adenoma (cepa) Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc 14747065 Human
p16 gallbladder tumors RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, 15014024 Human
p16 corticotroph adenomas EXPERIMENTAL DESIGN: Tissue from 31 corticotroph adenomas and 16 nonadenomatous pituitaries were subject to methylation-sensitive PCR to determine the methylation status of the p16 gene CpG island. 15014032 Human
p16 laryngeal cancer Our purpose was to investigate 9p21 LOH and expression of p16 protein and their possible prognostic value in laryngeal cancer. 15101277 Human
p16 transitional cell carcinomas (tcc) Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
p16 cysts Immunohistochemical staining was performed for p16(INK4a) and pRb in formalin-fixed, paraffin-embedded tissue sections of the uterine cervix using an indirect immunoperoxidase method. p16(INK4a) staining was detected in 7 of 108 sections (6.5%) of normal 15188135 Human
p16 malignant salivary gland tumors Positive rate of P16 protein expression was 76.9% (10/13) and 40.9% (9/22) in benign and malignant salivary gland tumors, respectively. 15190803 Human
p16 salivary gland tumors There was no correlation of the expression of P16 and nm23 in salivary gland tumors was found (P > 0.05). 15190803 Human
p16 malignant salivary gland tumors CONCLUSION: p16 and nm23 genes may play an important role in different sides in salivary gland tumorigenesis and the reduce of the expression of p16 and nm23 genes may contribute to the generation of malignant salivary gland tumors. 15190803 Human
p16 keratinizing squamous cell carcinoma In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). 15213596 Human
p16 verrucous carcinoma In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). 15213596 Human
p16 keratinizing squamous cell carcinomas One of the keratinizing squamous cell carcinomas positive for p16 occurred in a 25-year-old woman and the other two were associated with small foci of basaloid VIN3 adjacent to the tumor, suggesting a probable relationship with HPV. p16 was positive in 6 15213596 Human
p16 non-small cell carcinomas In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and non-small cell carcinomas. p16(INK4A) express 15309021 Human
p16 chl The aim of the present study was to assess expression of cyclin D2, Ki67, cyclin A, cyclin B1, cyclin D1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins in order to gain further insight into the proliferation profile of cHL. 15354186 Human
p16 cervical cancer The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C 15381905 Human
p16 cin The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C 15381905 Human
p16 fundic gland polyps (fgps) We studied methylation of 2 tumor suppressor genes (p14, p16) and 4 MINT (methylated in tumor) clones (MINT1, MINT2, MINT25, MINT31) among 51 fundic gland polyps (FGPs) and 27 normal gastric body biopsy samples using bisulfite treatment of genomic DNA fol 15491970 Human
p16 hydatidiform mole Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal plac 15507671 Human
p16 soft tissue sarcomas (stss) In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur 15551306 Human
p16 fibroadenoma The potential role of p16(INK4a) methylation in breast cancer is controversial whereas there are no data on fibroadenoma. 15578730 Human
p16 fibroadenoma To assess if inactivation of p16(INK4a) by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 15578730 Human
p16 lung adenocarcinoma CONCLUSIONS: Aberrant methylation of the promoter region of the p16 gene and loss of expression of its product were in accord with the multistep progression of peripheral-type lung adenocarcinoma, and these alterations were associated closely with poor pr 15612080 Human
p16 b-cell lymphoblastic leukemia [Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands 15612580 Human
p16 b-cell lymphoblastic leukemia High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. 15612580 Human
p16 benign prostatic hyperplasias (bph) EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
p16 gallbladder adenocarcinomas RESULTS: Of 38 gallbladder adenocarcinomas analyzed by IHC, 11 cases (29%) were negative for p16 protein. 15693199 Human
p16 polyposis BRAF mutation status in patients with multiple/large HPs and/or hyperplastic polyposis correlated with HPs from the same patient (odds ratio, 5.8; P = 0.0002) but associated with younger age (odds ratio, 0.83; P = 0.006 compared to older age), with a larg 15793287 Human
p16 colon cancer Loss of MGMT protein expression was associated with the MSI-L phenotype but was not a prognostic factor for overall survival in colon cancer. p16 methylation was significantly less frequent in MSI-L than in MSI-H and MSS tumors and was not associated with 15800322 Human
p16 tumors Loss of MGMT protein expression was associated with the MSI-L phenotype but was not a prognostic factor for overall survival in colon cancer. p16 methylation was significantly less frequent in MSI-L than in MSI-H and MSS tumors and was not associated with 15800322 Human
p16 signet ring cell carcinoma The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 Human
p16 leukoplakia [The p16 methylation in oral leukoplakia and oral squamous cell carcinoma] OBJECTIVE: To investigate p16 gene methylation in normal mucosa, leukoplakia with hyperplasia and dysplasia and oral squamous cell carcinoma. 15842853 Human
p16 vin 3 RESULTS: p16(INK4a) immunoreactivity was different in VIN 1, VIN 2, VIN 3, and squamous cell carcinoma. 15870532 Human
p16 vin 3 Strong expression of p16(INK4a) protein was observed in 92% (22 of 24) of VIN 2 and VIN 3 lesions and 100% (4 of 4) of invasive SCCs. 15870532 Human
p16 condyloma acuminatum No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions. 15870532 Human
p16 condyloma acuminatum CONCLUSIONS: Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) neg 15870532 Human
p16 cervical polyp METHODS: A total of 188 consecutive and unselected colposcopically directed cervical biopsies and a single contemporaneous cervical polyp were accessioned prospectively over a 3-month period, step-serially sectioned and examined by H&E and immunostained f 16028838 Human
p16 cervical polyp Diffuse strong parabasal immunostaining for p16(INK4a), suggestive of integrated high-risk HPV DNA into the host genome, was observed in 81 biopsies (42.9%, including the cervical polyp) and correlated (>90%) with HGSIL in the H&E sections. 16028838 Human
p16 immunoblastic lymphoma Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r 16053658 Human
p16 chronic myelomonocytic leukemias (cmml) To determine whether genetic alterations of p16 and p27 genes play an important role in MDS pathogenesis, we examined DNA from 51 patients classified as 17 refractory anemias (RA), four refractory anemias with ringed sideroblasts (RARS), 19 refractory ane 16104874 Human
p16 nodular melanoma To evaluate the importance of ID1 in malignant melanoma, tumour cell expression was examined by immunohistochemistry in 119 cases of nodular melanoma using tissue microarray technique, and related to multiple tumour markers including proliferation, p16 ex 16189525 Human
p16 squamous cell carcinoma of conjunctiva Expression of cell cycle-regulatory proteins, MIB-1, p16, p53, and p63, in squamous cell carcinoma of conjunctiva: not associated with human papillomavirus infection. 16328355 Human
p16 keratoacanthoma Further, the loss of MMP-19 and p16 could aid in making the differential diagnosis between well-differentiated SCC and keratoacanthoma. 16699496 Human
p16 verrucous carcinoma METHODS: Promoter hypermethylation status of p16 and MGMT genes were examined by the methylation-specific PCR (MSP) in OSCC (n = 51), verrucous carcinoma (n = 2), and carcinoma in situ (n = 2) tissues. 16791592 Human
p16 invasive ductal carcinomas (idcs) MATERIALS AND METHODS: To evaluate the biological importance of 14-3-3 sigma expression in pancreatic carcinogenesis, immunohistochemistry for 14-3-3 sigma, CDX2, MUC1, MUC2, p53, p16 and Ki-67 was carried out on 33 IPMTs and the results were compared wit 16886641 Human
p16 bowenoid papulosis Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in Bowenoid papulosis. 16919029 Human
p16 bowenoid papulosis (bp) The expression of p16 and hTERT protein in Bowenoid papulosis (BP) has not been studied. 16919029 Human
cdk4i squamous cell carcinoma of the larynx p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. 9333020 Human
cdk4i squamous cell carcinomas of larynx These findings indicate that p16MTS1/CDK4I is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. 9333020 Human
multiple tumor suppressor 1 central nervous system primitive neuroectodermal tumor The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. 7791990 Human
arf indolent lymphomas To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 10854221 Human
arf aggressive lymphomas Aggressive lymphomas with p14(ARF) inactivation and p53 wild type showed a significantly lower p53 protein expression than tumors with no alteration in any of these genes. 10854221 Human
arf neurofibroma CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. 11433531 Human
arf chondrosarcoma Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues. 11477582 Human
arf chondrosarcoma In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. 11477582 Human
arf anaplastic meningiomas Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. 11485924 Human
arf atypical meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
arf benign meningiomas We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr 11485924 Human
arf benign meningioma One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. 11485924 Human
arf hepatic tumor Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). 11568971 Mouse
arf primary central nervous system lymphoma Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. 11804283 Human
arf endometrial hyperplasia Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. 11818530 Mouse
arf prostatic intraepithelial neoplasia Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. 11818530 Mouse
arf common tumor p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t 11830494 Human
arf breast tumors Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. 12000749 Human
arf myeloproliferative disorders A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr 12032783 Human
arf neurofibromatosis The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. 12118376 Mouse
arf primary carcinomas RESULTS: Altogether inactivation (methylation, loss of heterozygosity and mutation of exon 1beta) of p14(ARF) was found in 29 of all 68 (43%) carcinomas, with a significant difference in primary [8 of 29 (28%)] relative to second primary carcinomas [21 of 12189502 Human
arf recurrent carcinomas Mutations of p53 were found in 32 of 68 HNSCCs (44%), evenly distributed among primary and recurrent carcinomas. p14(ARF) alterations showed no relationship to p53 mutations. 12189502 Human
arf recurrent carcinomas The significantly higher rate of p14(ARF) alterations in recurrent (respective second primary) carcinomas suggests a further acquired genetic aberration during the development of the recurrent carcinomas. 12189502 Human
arf liver angiosarcoma Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D 12378512 Human
arf mouse tumor Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. 12573439 Mouse
arf sporadic breast cancer [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter 12942643 Human
arf schwannomas EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific 14654541 Human
arf mec Late-passage hTERT-immortalized MEC express p53 but down-regulate p14(ARF). 14966292 Human
arf benign meningiomas We found methylation of p14(ARF) gene in five of 58 cases of benign meningiomas (8.6%), two of 10 cases of atypical meningiomas (20%), and two of four cases of anaplastic meningiomas (50%). 15073599 Human
arf odontogenic tumors BACKGROUND: To clarify the roles of the p53-MDM2-p14(ARF) cell cycle regulation system in oncogenesis and cytodifferentiation of odontogenic tumors, p53 gene status and expression of p53, MDM2, and p14(ARF) proteins was analyzed in ameloblastomas as well 15078490 Human
arf ameloblastoma Markedly decreased reactivity for p53, MDM2, and p14(ARF) was detected in keratinizing and granular cells in ameloblastoma subtypes. 15078490 Human
arf ameloblastoma Basal cell ameloblastoma showed slightly higher reactivity for p53, MDM2, and p14(ARF) as compared with other subtypes. 15078490 Human
arf ameloblastoma Immunoreactivity for p53, MDM2, and p14(ARF) in ameloblastoma variants suggests that these factors might be associated with tissue structuring and cytodifferentiation of ameloblastomas. 15078490 Human
arf b-cell lymphoblastic leukemia [Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands 15612580 Human
arf b-cell lymphoblastic leukemia High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. 15612580 Human
arf benign prostatic hyperplasias (bph) EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
arf salivary gland carcinomas (sgcs) As combinations of genetic and/or epigenetic alterations occurring during salivary gland carcinogenesis are largely unknown, we here analyzed 36 salivary gland carcinomas (SGCs) for changes in INK4a/ARF, RB1, p21, p27, PTEN, p53, MDM2 and O6-MGMT genes us 15695118 Human
arf mcl To determine the role of these genes in MCL, we have examined their gene status and expression and their relationship to INK4a/ARF and p53 gene aberrations in 69 tumors. 15781632 Human
arf scc of the tongue CONCLUSIONS: These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers. 15930346 Human
arf immunoblastic lymphoma Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r 16053658 Human
ink4 spindle cell tumor Gene deletion of the INK4 locus is associated with transformation to a highly invasive spindle cell tumor phenotype. 10341708 Human
ink4 basaloid carcinomas In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
ink4 nsclc In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
ink4 squamous cell carcinomas In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 10440744 Human
ink4 testicular germ-cell tumours Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis. p19INK4d, a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) com 10962575 Human
ink4 neurofibroma CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. 11433531 Human
ink4 idiopathic pulmonary fibrosis MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. 12169206 Human
ink4 ovarian granulosa cell tumors Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. 12203782 Human
cdkn2a plasmacytoma Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 9482902 Mouse
cdkn2a soft tissue tumors Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. 9664128 Human
cdkn2a soft tissue tumors Presumably, alterations of the CDKN2A gene do not contribute to the oncogenesis in the majority of soft tissue tumors. 9664128 Human
cdkn2a oropharyngeal squamous cell carcinoma (oscc) Loss of CDKN2A expression was demonstrated by immunohistochemistry in 87% of oral and oropharyngeal squamous cell carcinoma (OSCC) primary tumor samples. 10221335 Human
cdkn2a corticotroph adenomas Homozygous CDKN2A deletion was restricted to rare somatotroph (15%) and corticotroph adenomas (13%). 11276008 Human
cdkn2a corticotroph adenomas Staining for p16 was only seen in 5 of 15 (33%) corticotroph, 3 of 13 (23%) somatotroph, 3 of 5 (60%) plurihormonal, and 1 of 19 (5%) null cell adenomas. p16 immunonegativity without CDKN2A methylation or deletion occurred in 22 tumours, including most so 11276008 Human
cdkn2a corticotroph adenomas The mechanisms of p16 down-regulation probably involve CDKN2A methylation in most types, but remain to be determined in somatotroph and corticotroph adenomas. 11276008 Human
cdkn2a oral carcinomas In this longitudinal study, we examined changes in the CDKN2A gene locus in sequential epithelial dysplasias and oral carcinomas from 11 patients. 11289098 Human
cdkn2a teratomas Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
cdkn2a yolk sac tumor Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st 12071636 Human
cdkn2a hereditary breast-ovarian cancer syndrome Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
cdkn2a hereditary pancreatic cancer Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
cdkn2a inherited cancer syndromes Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
cdkn2a polyposis Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i 12120226 Human
cdkn2a metastatic pancreatic adenocarcinoma RESULTS: Sequence analysis confirmed a CDKN2A mutation, and immunohistochemical evaluation confirmed the diagnoses of metastatic melanoma and metastatic pancreatic adenocarcinoma. 12925390 Human
cdkn2a sporadic breast cancer [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter 12942643 Human
cdkn2a b-cell lymphoblastic leukemia [Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands 15612580 Human
cdkn2a b-cell lymphoblastic leukemia High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. 15612580 Human
cdkn2a benign prostatic hyperplasias (bph) EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b 15623627 Human
cdkn2a gallbladder adenocarcinomas MATERIAL AND METHODS: We analyzed the methylation status of the promoter region of the CDKN2A gene in gallbladder adenocarcinomas using methylation specific PCR (MSP). 15693199 Human
cdkn2a gastrointestinal stromal tumors (gist) PURPOSE: The aim of the current study was to examine the prognostic relevance of the CDKN2A tumor suppressor pathway in gastrointestinal stromal tumors (GIST). 16166437 Human
p16ink4a erythroleukemia In mouse MEL erythroleukemia cells, p16INK4a associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. 7651726 Mouse
p16ink4a hairy cell leukemia (hcl) We analyzed p16INK4A and p15INK4B genes in 178 cases of primary leukemias including 81 cases of chronic lymphocytic leukemia (CLL), seven of hairy cell leukemia (HCL), seven of chronic myelogenous leukemia (CML), 43 of acute myelogenous leukemia (AML), 27 7795238 Human
p16ink4a childhood rhabdomyosarcoma Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. p16INK4A, p15INK4B, and p18 proteins are highly specific inhibitors of cyclin-dependent serine/threonine kinase (CDK) activities required for G 8703847 Human
p16ink4a childhood rhabdomyosarcoma Our results strongly indicate that the p16INK4A (and/or p15INK4B) protein plays a key role in the development and/or progression of childhood rhabdomyosarcoma and suggest that this CDK-inhibitor protein might control proliferation and/or differentiation o 8703847 Human
p16ink4a thymoma However, inactivation of p16INK4A and RB may play a role in the progression of thymoma and thymic carcinoma. 9398039 Human
p16ink4a plasmacytoma Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 9482902 Mouse
p16ink4a cml In this disease p53, p16INK4A, p15INK4B, p57KIP2 mutations and p15INK4B/p16INK4A homo/hemizygous deletions were analyzed in the initial diagnosis phase and during the treatment phase of twelve CML cases, in order to establish whether there was a consisten 10069444 Human
p16ink4a squamous cell carcinoma of the anterior tongue These data indicate that cyclin D1 overexpression and loss of p16INK4A expression predict early relapse and reduced survival in squamous cell carcinoma of the anterior tongue. 10537346 Human
p16ink4a anaplasia P16INK4a expression was not related to anaplasia in oligodendrogliomas and ependymomas. 10564531 Human
p16ink4a thymic lymphomas (tls) Frequent chromosome 4 LOH in mouse radiation-induced (C57BL/6 x RF/J) thymic lymphomas (TLs) is associated with promoter/exon 1 region hypermethylation of the remaining p15INK4b and p16INK4a alleles, so this may be common to mouse radiation myeloid and ly 10602427 Mouse
p16ink4a colorectal adenomas In primary colorectal carcinomas, p14ARF promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. p14ARF methylation appears in the context of an adj 10646864 Human
p16ink4a adenoid cystic carcinomas (acc) In this study, the expressions of Rb, p16INK4A, and cyclin D1 alternations were analyzed by immunohistochemical assay in 5 specimens of normal salivary glands and twenty-two cases of adenoid cystic carcinomas (ACC). 10928172 Human
p16ink4a aggressive lymphomas For the aggressive lymphomas, the Kaplan-Meier estimate of overall survival for cases with disruption of either p16INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5 year survival 45% vs 35%; P= 0.85), suggesting 11021747 Human
p16ink4a skin tumors In skin tumors from (XP) patients, p16INK4a UV induced mutations occur more frequently, are often multiple, and significantly associated with the presence of p53 mutations. 11741799 Human
p16ink4a agnogenic myeloid metaplasia (amm) Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. 11849214 Human
p16ink4a primary effusion lymphoma p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. 11896614 Human
p16ink4a pel To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. 11896614 Human
p16ink4a primary effusion lymphoma To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. 11896614 Human
p16ink4a salivary gland carcinomas Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. 12684623 Human
p16ink4a adenoid cystic carcinomas A total of 5 (14%) SGCs demonstrated homozygous deletion (1 case) or methylation (4 cases) of p16INK4a, all but one being adenoid cystic carcinomas. 12684623 Human
p16ink4a seminomas To improve understanding of the role of this pathway in spermatogenesis, and its subversion in TGCTs, we examined immunohistochemical expression patterns of CDK4, p16INK4a, p15INK4b, and pRB, and established an in situ assay for cyclin D-mediated phosphor 12754735 Human
p16ink4a teratomas To improve understanding of the role of this pathway in spermatogenesis, and its subversion in TGCTs, we examined immunohistochemical expression patterns of CDK4, p16INK4a, p15INK4b, and pRB, and established an in situ assay for cyclin D-mediated phosphor 12754735 Human
p16ink4a uterine tumors An allelic loss was detected in 12 of 50 (24%) carcinomas with a higher incidence in advanced endometrial carcinomas than in early-stage uterine tumors. p16INK4A alterations were generally accompanied by gene silencing, confirmed by aberrant protein immun 12920579 Human
p16ink4a undifferentiated carcinomas The p16INK4A promotor status was compared with p16INK4A protein expression and patient-specific data. p16INK4A promotor hypermethylation was detected in 13% of non-tumorous tissue; in 33% of follicular adenomas; in 44% of papillary carcinomas; in 50% of f 12924440 Human
p16ink4a bowen's disease BACKGROUND: Progression of cutaneous squamous neoplasms from actinic keratosis (AK) to Bowen's disease (BD; squamous cell carcinoma in situ) has important implications for clinical management and treatment, thus requiring accurate diagnosis. p16INK4a 14632806 Human
p16ink4a squamous cell carcinoma in situ BACKGROUND: Progression of cutaneous squamous neoplasms from actinic keratosis (AK) to Bowen's disease (BD; squamous cell carcinoma in situ) has important implications for clinical management and treatment, thus requiring accurate diagnosis. p16INK4a 14632806 Human
p16ink4a squamous cell carcinoma in situ Expression of a paraffin-reactive p16INK4a marker has recently been shown to increase in cervical squamous neoplasms as lesions progress from low-grade dysplasia to squamous cell carcinoma in situ. p16INK4a expression in the progression of squamous cutane 14632806 Human
p16ink4a verruca vulgaris METHODS: Biopsies of 203 squamous cutaneous neoplasms with unequivocal features of AK (n = 87) and BD (n = 116) as well as a benign squamous control group (verruca vulgaris: n = 10; seborrhoeic keratosis: n = 11; scar tissue: n = 8) obtained between Janua 14632806 Human
p16ink4a osteosarcoma The growth inhibition rate was the greatest for lung adenocarcinoma cells, lacking p16INK4a expression associated with methylation-mediated gene silencing; 83% at a concentration of 300 nM for 72-h treatment; while the growth of osteosarcoma and MFH cells 15069542 Human
p16ink4a squamous cell carcinoma in situ We therefore characterized the expression of p16INK4a, Rb-phosphorylation and proliferation in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma with special reference to infiltrative behavior. 15257310 Human
p16ink4a invasive cervical cancer Serial consecutive biopsies representing normal cervical epithelium to cervical intraepithelial neoplasia and/or invasive cervical cancer were stained with immunohistochemistry for p16INK4A, p14ARF and proliferating cell nuclear antigen. 15502810 Human
p16ink4a nk cell leukemia We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. 15813917 Human
p16ink4a colorectal tumors Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? 16760277 Human
p16ink4 ampullary cancers One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. 7796400 Human
p16ink4 bile duct cancers One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. 7796400 Human
p16ink4 metastatic lung cancer Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. 7882351 Human
p16ink4 melanocytic neoplasms To clarify any role for p16INK4 and CDK4 proteins in the development of human malignant melanoma, we have examined, immunohistochemically, the expression of these two proteins in melanocytic neoplasms including 19 primary lesions of non-familial melanoma. 8746340 Human
p16ink4 esophageal squamous cancer [Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer] To evaluate the prognostic significance of gene amplification and overexpression of cyclin D1 in the patients of esophageal squamous cancer, 8920671 Human
p16ink4 thymoma p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. 9398039 Human
p16ink4 pediatric osteosarcoma CONCLUSIONS: Mutations of the TP53 and deletion of p16INK4 tumor suppressor genes seem to be involved in the development of pediatric osteosarcoma. 9586287 Human
p16ink4 bone tumors CONCLUSIONS: Alteration of TP53, p16INK4 and p21WAF1 seems to be involved in the development of pediatric bone tumors and to be an unfavourable prognostic factor in this type of tumors. 12886318 Human
p14arf thyroid tumour The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. 17117177 Human
cdkn2a nodular melanoma PURPOSE: In order to obtain better insight into the genetic background of nodular melanoma (NM), we aimed to analyse the frequency of CDKN2A and C-MYC copy number changes. 16977458 Human
p16 sporadic breast cancer CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic breast cancer and can be detected in serum DNA. 17264521 Human
cdkn2a second cancer The obtained results allow us to conclude: (i) survival times of 500 C/G carriers vs. cumulating proportion surviving was not statistically significant; (ii) CDKN2a polymorphism 500 C/G correlated with Ala148Thr; (iii) no correlation was observed between 17351674 Human
p16 sporadic breast cancer Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. 17264521 Human
cdkn2a nodular melanoma Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. 16977458 Human
p16 oropharyngeal squamous cell carcinoma (oscc) Molecular prognostic indicators for oropharyngeal squamous cell carcinoma (OSCC), including HPV-DNA detection, epidermal growth factor receptor (EGFR) and p16 expression, have been suggested in the literature, but none of these are currently used in clini 17236202 Human
cdkn2a egc CONCLUSIONS: Our study shows a high prevalence of co-inactivating mutations of p53 and/or CDKN2A genes in EGC, that seem to occur preferentially in LS-derived tumours and late in oncogenesis. 17300232 Human
p19 ganglioglioma Direct analysis demonstrated loss of p19 expression and p53 mutation in the malignant areas, highly suggestive of these alterations being involved in the malignant progression of the ganglioglioma. 17259542 Human
p14arf large b cell lymphoma All patients with follicular lymphoma (FL), myeloma or acute myeloid leukemia (AML) expressed p14ARF while nine of 23 patients with diffuse large B cell lymphoma (DLBCL) lost p14ARF expression. 10557050 Human
p14arf condyloma All condyloma acuminata except one and low-grade dysplasia with HPV infection of low risk, such as HPV 6, immunohistochemically showed completely negative staining for p14ARF, also seen in non-neoplastic and mesenchymal cells. 12100520 Human
p14arf invasive ductal breast cancers This study examined p14ARF and p53/Hdm2 expression and subcellular localisation by using immunohistochemistry in a series of invasive ductal breast cancers (IDCs) with concomitant ductal carcinoma in situ (DCIS), to evaluate whether findings in vitro were 15318938 Human
p14 serous microcystic adenomas In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c 14614047 Human
p14 serous microcystic adenomas There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. 14614047 Human
p14 ampullary tumors RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, 15014024 Human
mts1 pancreatic neuroendocrine tumors Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. 9443399 Human
mts1 pancreatic neuroendocrine tumor In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. 9443399 Human
mts1 primary bladder cancer CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
mts1 intraductal papillary mucinous tumors P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. 12749268 Human
ink4a nongerminomatous germ cell tumors To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. 10786670 Human
ink4a metastatic breast carcinomas However, primary and metastatic breast carcinomas exhibited a relative hypomethylation of p16(INK4A), which is associated with expression, compared to normal breast tissue. 11369056 Human
ink4a intraductal papillary mucinous tumours Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. 12010891 Human
ink4a primary cutaneous b cell lymphoma Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. 12060387 Human
ink4a primary cutaneous b cell lymphomas Our findings suggest that p15(INK4b) and p16(INK4a) biallelic gene abnormalities are common in primary cutaneous B cell lymphomas, most frequently as a result of promotor hypermethylation. 12060387 Human
cdkn2 advanced stage cancer CDKN2 is homozygously deleted in approximately 25% of nonsmall cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. 7478613 Human
cdkn2 familial atypical multiple mole-melanoma (fammm) We have analysed CDKN2 coding sequences in 15 Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome pedigrees, and identified a 19 basepair (bp) germline deletion in 13 of them. 7670475 Human
cdkn2 common bile duct cancers One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. 7796400 Human
p16 borderline ovarian tumor We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. 7478544 Human
p16 pancreatic neuroendocrine tumors Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. 9443399 Human
p16 mixed mesodermal tumour No p16 deletion was found, and mutations were detected in only one tumour sample and Skut1B uterine mixed mesodermal tumour cells. 10071231 Human
p16 paraffin embedded tumor METHODS: p16 and Rb pretoin were immunostained by SP immunohistochemical method in the sections of formalin fixed paraffin embedded tumor tissue from 102 patients with astrocytoma brain tumors. 10374322 Human
p16 familial atypical multiple mole melanoma (fammm) A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. 10400925 Human
p16 low grade tumors The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s 10536183 Human
p16 adenosquamous cell carcinoma (ascc) The rate of loss of P16 protein expression in adenocarcinoma (AC) was 28.47 +/- 16.33%, that in squamous cell carcinoma (SCC) was 35.95% +/- 17.36%, and that in adenosquamous cell carcinoma (ASCC) 57.88% +/- 10.18%. 10684032 Human
p16 familial atypical multiple mole melanoma Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). 10956390 Human
p16 primary brain lymphomas Recent reports indicate a high proportion of primary brain lymphomas show loss of CDKN2A/p16 gene expression. 10976700 Human
p16 familial atypical multiple mole melanoma (fammm) [From gene to disease; from p16 to melanoma] Approximately 10% of human cutaneous melanoma cases occur in families with the familial atypical multiple mole melanoma (FAMMM) syndrome, which is characterised by the familial occurrence of melanomas and atypi 11103670 Human
p16 large cell lymphoma Here, we provide the first evidence of the involvement of the tumor suppressor gene p16 in primary cutaneous large cell lymphoma. 11121148 Human
p16 metastatic breast carcinomas However, primary and metastatic breast carcinomas exhibited a relative hypomethylation of p16(INK4A), which is associated with expression, compared to normal breast tissue. 11369056 Human
p16 familial atypical multiple mole melanoma (fammm) BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro 11815963 Human
p16 hereditary cancer syndromes BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro 11815963 Human
p16 primary bladder cancer CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in 11831985 Human
p16 ii lung cancers In stage I and II lung cancers, the obvious inactivation of tumor suppressor gene p16 or Rb was examined (32.6% or 28.3%); p16 inactivation was detected mainly in non-small cell lung cancers, and Rb inactivation mainly in small cell lung cancers. 11832104 Human
p16 sebaceous carcinomas RESULTS: In the 96 cases, including 40 cases of basal cell carcinoma (BCC), 33 squamous and 23 sebaceous carcinomas, their p16 protein positive (nuclear staining) rates were 70.0%, 54.6% and 56.5% respectively. 11853608 Human
p16 sebaceous carcinoma RESULTS: Among the 96 cases, there were 40 basal cell carcinomas (BCCs), 33 squamous carcinomas and 23 sebaceous carcinoma, with P16 protein positive (nuclear staining) rates 70%, 54.6% and 56.5%, respectively. 11930651 Human
p16 intraductal papillary mucinous tumours Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. 12010891 Human
p16 intraductal papillary-mucinous tumors p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. 12021900 Human
p16 intraductal papillary-mucinous tumors CONCLUSIONS: The p16 and p53 gene alterations and accumulations observed are crucial events during the carcinogenesis and malignant progression of intraductal papillary-mucinous tumors of the pancreas. 12021900 Human
p16 primary cutaneous b cell lymphoma Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. 12060387 Human
p16 primary cutaneous b cell lymphomas We analyzed DNA from 36 cases of primary cutaneous B cell lymphomas, four systemic B cell lymphomas, and six benign B cell lymphoproliferative infiltrates for abnormalities of p15 and p16 using microsatellite markers for 9p21, methylation specific polymer 12060387 Human
p16 primary cutaneous b cell lymphomas In primary cutaneous B cell lymphomas with allelic loss or promotor hypermethylation of either p15 or p16, loss of expression in tumor cells was identified in 5 of 8 and 9 of 10 cases, respectively. 12060387 Human
p16 primary cutaneous b cell lymphomas Our findings suggest that p15(INK4b) and p16(INK4a) biallelic gene abnormalities are common in primary cutaneous B cell lymphomas, most frequently as a result of promotor hypermethylation. 12060387 Human
p16 metastatic human prostate cancers We examined the status of a cell cycle checkpoint by immunohistochemically staining for p16 and pRb using multiple tissue arrays generated from 49 primary and 23 hormone-sensitive metastatic human prostate cancers. 12169393 Human
p16 intraductal papillary-mucinous tumors Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. 12469138 Human
p16 lip cancers [Expression of VEGF, EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance] OBJECTIVE: To detect the expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), p16 protein in lip ca 12475418 Human
p16 lip cancers METHODS: Immunohistochemisty for expression VEGF, EGFR, P16 were carried out in 69 cases of lip cancers and OSCC. 12475418 Human
p16 lip cancers RESULTS: Expression of VEGF, EGFR, p16 protein in OSCC and lip cancers was respectively 71.01%, 46.37%, 28.98% and there were no significance between their positive expressions (P > 0.05) as well as in different sites of them (P > 0.05). 12475418 Human
p16 lip cancers CONCLUSIONS: The results show that there is no correlation to the expression of VEGF, EGFR and P16 protein in OSCC and lip cancers. 12475418 Human
p16 squamous cervical cancers In squamous cervical cancers, overexpression of p16 is induced by HPV and associated with the carcinogenesis of cervical epithelia. 12548164 Human
p16 digestive tract cancers PURPOSE AND EXPERIMENTAL DESIGN: To date, the presence of p16 gene promoter methylation associated with loss of protein expression has been demonstrated frequently in digestive tract cancers. 12631606 Human
p16 intraductal papillary mucinous tumors P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. 12749268 Human
p16 intraductal papillary mucinous tumors The purpose of the study was to determine the prevalence of p53-, p16/MTS1- and K-ras mutations in benign and malignant intraductal papillary mucinous tumors with intent to value their importance for tumor progression. 12749268 Human
p16 lymph node metastasis METHODS: p53 and p16 expression status, the Ki-67 LI, and int-2/cyclin D1 amplification were assessed by immunohistochemical staining and slot blot analysis in pretreatment endoscopic biopsy specimens of 41 patients with T4 or M1 Lym (distant lymph node m 12900371 Human
p16 advanced prostate cancers We investigated the prognostic significance of both pRB and p16 expression in locally advanced prostate cancers, from patients treated on the Radiation Therapy Oncology Group (RTOG) protocol 86-10. 12947069 Human
p16 seborrhoeic keratosis Enhanced expression of p16 in seborrhoeic keratosis; a lesion of accumulated senescent epidermal cells in G1 arrest. 14510989 Human
p16 cervical lymph node metastasis CONCLUSION: The expression of p15 and p16 protein are closely associated with clinical stages and cervical lymph node metastasis of TSCC. p15 deletion, or both p15 and p16 co-deletion in TSCC can also predict a poor prognosis. p15 and p16 expression can b 14613656 Human
p16 serous microcystic adenomas In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c 14614047 Human
p16 serous microcystic adenomas There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. 14614047 Human
p16 primary gastric lymphomas Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. 14976529 Human
p16 primary gastric lymphoma However, the p16 protein expression in primary gastric lymphoma has not been studied. 14976529 Human
p16 primary gastric lymphomas In this study, we characterize protein expression and promoter hypermethylation of the p16 gene in B-cell primary gastric lymphomas from China. 14976529 Human
p16 primary gastric lymphomas In conclusion, loss of p16 protein expression is frequent in those B-cell primary gastric lymphomas and approximately one-third of such loss correlated with promoter hypermethylation. 14976529 Human
p16 ampullary tumors RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, 15014024 Human
p16 squamous cell hyperplasia In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). 15213596 Human
p16 familial atypical multiple mole melanoma This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat 15264268 Human
p16 bronchioloalveolar carcinomas (bacs) OBJECTIVES: Loss of p16(INK4) has been associated with a poor cancer prognosis, but its potential significance in bronchioloalveolar carcinomas (BACs) has not been explored. 15753637 Human
p16 muscle invasive bladder cancer METHODS: Fluorescence in situ hybridisation analysis was performed to evaluate chromosomes 3, 7, 9, and 17 and the 9p21 (p16), 17p13.1 (p53), 13q14 (RB1), and 17q11.2 (HER-2) chromosomal loci in 48 muscle invasive bladder cancer specimens and the adjacent 15790699 Human
p16 malignant rhabdoid tumor Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. 15796965 Human
p16 rars To determine whether genetic alterations of p16 and p27 genes play an important role in MDS pathogenesis, we examined DNA from 51 patients classified as 17 refractory anemias (RA), four refractory anemias with ringed sideroblasts (RARS), 19 refractory ane 16104874 Human
p16 non-keratinizing carcinoma (nkc) METHODS: Immunohistochemical study for p16 protein was carried out in 90 cases of non-keratinizing carcinoma (NKC) of nasopharynx. 16185507 Human
p16 salivary adenoid cystic carcinoma [Mechanisms of p16 gene inactivation salivary adenoid cystic carcinoma] OBJECTIVE: To study the mechanism of p16 gene inactivation in salivary adenoid cystic carcinoma. 16285551 Human
p16 salivary adenoid cystic carcinomas Polymerase chain reaction (PCR) and single-stranded conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP) were used to detect deletion and mutation of p16 gene in salivary adenoid cystic carcinomas. 16285551 Human
p16 salivary adenoid cystic carcinomas RESULTS: The homozygous deletion, mutation and hypermethylation of p16 gene were noted in 16 cases (30.2%), 4 cases (7.5%) and 26 cases (49.1%) respectively in 53 cases of salivary adenoid cystic carcinomas. 16285551 Human
p16 salivary adenoid cystic carcinoma CONCLUSION: The main inactivation mechanisms of p16 gene in salivary adenoid cystic carcinoma were hypermethylation and homozygous deletion. 16285551 Human
p16 salivary adenoid cystic carcinoma The mutation p16 gene was rare in salivary adenoid cystic carcinoma. 16285551 Human
arf nongerminomatous germ cell tumors To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. 10786670 Human
ink4 bronchioloalveolar carcinomas (bacs) OBJECTIVES: Loss of p16(INK4) has been associated with a poor cancer prognosis, but its potential significance in bronchioloalveolar carcinomas (BACs) has not been explored. 15753637 Human
cdkn2a large b cell lymphoma Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. 10086736 Human
cdkn2a somatotrophinoma In contrast, a single invasive methylated somatotrophinoma failed to express the CDKN2A protein. 10092131 Human
cdkn2a primary brain lymphomas Recent reports indicate a high proportion of primary brain lymphomas show loss of CDKN2A/p16 gene expression. 10976700 Human
cdkn2a inherited cancer syndrome Usually this occurs in the setting of a known inherited cancer syndrome caused by mutations in genes such as BRCA1/2 and CDKN2A. 11291558 Human
cdkn2a neuroendocrine (merkel cell) carcinoma CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. 11433400 Human
cdkn2a familial atypical multiple mole melanoma (fammm) BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro 11815963 Human
cdkn2a hereditary cancer syndromes BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro 11815963 Human
cdkn2a familial atypical multiple mole melanoma This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat 15264268 Human
p16ink4a digestive cancers Point mutations of p16ink4a have also been sequenced, especially in familial melanomas and digestive cancers but preferential mechanism of p16ink4a/p15ink4b inactivation seems to be biallelic deletion. 8724524 Human
p16ink4a cholangiocellular carcinomas We examined the genomic status of the p16INK4A (inhibitor of cyclin-dependent kinase 4 A) and cyclin-dependent kinase 4 (CDK4) genes in 62 human hepatocellular carcinomas (HCCs), 5 cholangiocellular carcinomas and 6 cell lines derived from human liver can 8760583 Human
p16ink4a metastatic breast carcinomas We show here that primary and metastatic breast carcinomas demonstrate hypomethylation of p16INK4a which is associated with expression of p16INK4a mRNA, as compared to normal breast tissue which demonstrates a relative hypermethylation of p16INK4a associa 9652738 Human
p16ink4a oral squamous cell carcinoma Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16ink4a in response to treatment with a demethylating agent. 10030668 Human
p16ink4a large b cell lymphoma Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. 10803523 Human
p16ink4a epidermoid tumors P16INK4a UV induced mutations (CC:GG > TT:AA tandem transition or C:G > T:A transition at dipyrimidic site) are found in 12% of sporadic skin carcinomas, mainly in epidermoid tumors, and seem to occur independently of p53 mutations. 11741799 Human
p16ink4a large cell lymphoma We investigated the response of SUDHL-1 and L428 cells, derived from t(2;5)-anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD), respectively, to recombinant adenoviruses expressing cyclin-dependent kinase inhibitors (CDKIs) p27Kip1 (Adp 12153002 Human
p16ink4a malignant rhabdoid tumor P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. 14604992 Human
p16ink4a seborrhoeic keratosis METHODS: Biopsies of 203 squamous cutaneous neoplasms with unequivocal features of AK (n = 87) and BD (n = 116) as well as a benign squamous control group (verruca vulgaris: n = 10; seborrhoeic keratosis: n = 11; scar tissue: n = 8) obtained between Janua 14632806 Human
p16ink4a salivary adenoid cystic carcinoma Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. 15959912 Human
p16ink4 ampullary tumor CONCLUSIONS: The disruption of the pRb-p16NK4 pathway plays an important role in ampullary carcinogenesis, the absence of p16INK4 protein expression might be involved in ampullary tumor progression. 15782994 Human
p14arf papillary carcinomas In all histological types, except papillary carcinomas, we observed a statistically significant relationship between p14ARF and E2F1 (r=0.64 to 1, P<0.05). 17117177 Human
arf follicular lymphoma These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma. 17374722 Human
p16 cancerous lesions Point mutations of p16(CDKN2A) exon 1 were found in all of the precancerous and cancerous lesions. 17091472 Human
p16 tumour infiltrating lymphocytes Methylation of the MLH1, P16, TIMP3 and P14 genes was associated with tumour infiltrating lymphocytes (p < 0.05), microsatellite instability (p < 0.001), BRAF mutation (p < 0.0001) and elevated concentrations of the methyl group carriers tetrahydrofolate 16981189 Human
p14arf sporadic breast carcinomas Since our earlier studies have shown lack of genetic alterations such as missense mutations and deletions in the tumor associated genes-p16, ras and p14ARF in sporadic breast tumors, the epigenetic alterations of the two genes reported in the present stud 16480176 Human
p14arf melanoma CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, S 16778180 NA
p14arf ovarian serous tumors We studied the immunoexpression of p14ARF, MDM2, and p53, in addition to relationships between those protein expressions and estrogen receptor (ER)alpha in ovarian serous tumors including benign (n= 23), borderline (n= 41), and malignant (n= 94). 16803476 Human
p14arf borderline tumors The expression of MDM2 was significantly higher in borderline tumors compared to benign (P= 0.04) and malignant (P < 0.01) tumors. p53 expression in borderline tumors was uncommon, and p14ARF expression loss was mainly observed in carcinomas. 16803476 Human
p19 lung adenomas Lung adenomas exhibited a 50% decrease and a 35-fold increase in expression of Rb and p19/ARF mRNA, respectively. 16424006 Human
p14 childhood ependymomas PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
p14 ependymoma PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
p14 ependymomas PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
p14 round cell liposarcoma Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. 16177957 Human
p14 anaplastic lymphoma To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, an 16185764 Human
p14 neuroendocrine tumors We therefore compared methylation of the RAS-association domain family 1, isoform A (RASSF1A), p14, p16 and O6-methyl-guanine methyltransferase genes in neuroendocrine tumors from 47 patients including 16 pancreatic, 15 nonileal and 16 ileal neuroendocrin 16258509 Human
p14 mpnst We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. 16510576 Human
p14 round cell liposarcoma Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. 16622896 Human
p14 supratentorial pnet High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. 16623784 Human
p14 squamous cell carcinoma of the endometrium p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. 16844559 Human
p14 malignant pleural mesothelioma p53-Induced Apoptosis Occurs in the Absence of p14(ARF) in Malignant Pleural Mesothelioma. 16867217 Human
p14 malignant pleural mesotheliomas Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. 16867217 Human
p-16 choriocarcinoma Numerous works on this subject are published and some recent important discoveries underline the roles of genes HOX, Tim P3, E-cad and p-16, and the recurrent chromosome anomalies 7q21+and 8p21- in the mole to choriocarcinoma processing. 16005675 Human
mts1 rectal carcinoma [The expression of MTS1 gene product in transitional mucosa adjacent to rectal carcinomas and its clinical significance] OBJECTIVE: To study the property of transitional mucosa (TM) adjacent to rectal carcinoma and the clinical significance of MTS1 gene d 11829899 Human
mts1 rectal carcinoma CONCLUSIONS: The inactivation of MTS1 gene is relative to the occurrence of rectal carcinoma, suggesting that the TM adjacent to rectal carcinoma possess as certain potential malignancy. 11829899 Human
ink4a tumors Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val 16152615 Human
ink4a hsil There was a higher mean number of p16(INK4A) and MIB-1 immunoreactive cells/1,000 cells in HSIL (4.06 +/- 1.93 and 11.13 +/- 2.83, respectively) compared to other cytological categories. 16161049 Human
ink4a keratoacanthoma As the phenotype worsens, with increasing hyperplasia and vascularization leading to keratoacanthoma, p16(INK4a) and matrix metalloproteinase 9 expression is induced. 16204053 Mouse
ink4a nasopharyngeal carcinoma These data are consistent with the cooperative effects seen between LMP1 and loss of the INK4a locus in transgenic mice and with the frequency of loss of this locus in EBV-associated nasopharyngeal carcinoma. 16204053 Mouse
ink4a hepatocellular carcinomas In contrast, strong induction of HSP90, CDC37, and E2F4 was paralleled by P16(INK4A) downregulation and high levels of HSP90-CDK4 and CDC37-CDK4 complexes in hepatocellular carcinomas with poorer prognosis. 16317707 Human
ink4a low-grade lymphomas To examine whether methylation of p16(INK4A) and p57(KIP2) is involved in the development and progression of gastric MALT lymphomas, 24 gastric low-grade lymphomas of MALT, 11 diffuse large B-cell lymphomas, and 10 each case of gastric lymphoid follicles 16357845 Human
ink4a mpnst We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. 16510576 Human
ink4a skin tumors Induction of Nevi and Skin Tumors in Ink4a/Arf Xpa Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures. 16510579 Mouse
ink4a xeroderma pigmentosum Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. 16510579 Human
ink4a skin tumors Ink4a/Arf(-/-) mice developed most skin tumors faster, but surprisingly developed nevi slower than their heterozygous counterparts especially after neonatal UV exposure. 16510579 Mouse
ink4a nevus Hence, although our experiments did not effectively emulate human melanoma, they provided clear evidence that intermittent UV overexposure strongly stimulates and the Ink4a/Arf(-/-) genotype may actually impair nevus development. 16510579 Mouse
ink4a pancreatic ductal adenocarcinoma Activating KRAS mutations and p16(Ink4a) inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC). 16585505 Human
ink4a head and neck cancer The frequency and precise loss of CDKN2B(INK4b), CDKN2A(ARF, INK4a), and MTAP in the prognosis of 9p21-deleted HNSCC may provide impetus for use of these targets as therapeutic biomarkers in head and neck cancer. 16618910 Human
ink4a histiocytic sarcoma The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. 16697958 Human
ink4a breast tumor These results demonstrate a causal role of p16(INK4A) disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression. 16766534 Human
ink4a malignant pleural mesotheliomas Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. 16867217 Human
p16 lung cancer CONCLUSION: p16 gene mutation and abnormal expression may play an important role in the occurrence and development of lung cancer, and it is relative to CT appearances of lung cancer. p16 gene may be used as a predicting index for clinical diagnosis and p 15898427 Human
p16 tumors Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val 16152615 Human
p16 squamous cell carcinoma of the skin Samples of basal cell carcinoma and squamous cell carcinoma of the skin with either functional or non-functional Rb also exhibited at least two forms of p16. 16161044 Human
p16 hsil There was a higher mean number of p16(INK4A) and MIB-1 immunoreactive cells/1,000 cells in HSIL (4.06 +/- 1.93 and 11.13 +/- 2.83, respectively) compared to other cytological categories. 16161049 Human
p16 anaplastic lymphoma To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, an 16185764 Human
p16 cutaneous t-cell lymphoma Extensive methylation of the p16 promoter was seen in six out of 10 cutaneous T-cell lymphoma patient samples and corresponded with lack of p16 protein expression in the cases examined. 16185764 Human
p16 keratoacanthoma As the phenotype worsens, with increasing hyperplasia and vascularization leading to keratoacanthoma, p16(INK4a) and matrix metalloproteinase 9 expression is induced. 16204053 Mouse
p16 hyperplastic polyps Two benign gastric hyperplastic polyps also had intact p16 and MTAP. 16224217 Human
p16 neuroendocrine tumors Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. 16258509 Human
p16 neuroendocrine tumors We therefore compared methylation of the RAS-association domain family 1, isoform A (RASSF1A), p14, p16 and O6-methyl-guanine methyltransferase genes in neuroendocrine tumors from 47 patients including 16 pancreatic, 15 nonileal and 16 ileal neuroendocrin 16258509 Human
p16 hepatocellular carcinomas In contrast, strong induction of HSP90, CDC37, and E2F4 was paralleled by P16(INK4A) downregulation and high levels of HSP90-CDK4 and CDC37-CDK4 complexes in hepatocellular carcinomas with poorer prognosis. 16317707 Human
p16 colorectal tumors p16 Gene Methylation in Colorectal Tumors: Correlation with Clinicopathological Features and Prognostic Value. 16352895 Human
p16 low-grade lymphomas To examine whether methylation of p16(INK4A) and p57(KIP2) is involved in the development and progression of gastric MALT lymphomas, 24 gastric low-grade lymphomas of MALT, 11 diffuse large B-cell lymphomas, and 10 each case of gastric lymphoid follicles 16357845 Human
p16 keratoses DESIGN: We studied the expression of p16 by immunohistochemistry in 24 KAs, 24 infiltrating SCCs of the skin, 4 histologically indeterminate lesions, and 8 nonmalignant keratoses. 16390241 Human
p16 keratoses No significant difference in measures of p16 expression was identified among the KAs, the SCCs, the indeterminate lesions, or the benign keratoses. 16390241 Human
p16 anal intraepithelial neoplasia The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively. 16404747 Human
p16 dlbcl CONCLUSIONS: Our results suggest that hypermethylation of the p16 promoter indicates a poor prognosis in high-intermediate-risk and high-risk DLBCL patients, and may be a useful marker for selection of appropriate treatment when used in conjunction with t 16406514 Human
p16 carcinomatosis We assessed the correlation of the clinicopathologic variables (previous surgical score, age, sex, performance status, previous systemic chemotherapy, carcinomatosis extension, completeness of cytoreduction, IPHP drug schedule, mitotic count [MC], nuclear 16444562 Human
p16 smooth muscle neoplasms In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied. 16462152 Human
p16 mucinous adenocarcinoma Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary o 16462152 Human
p16 ovarian adenocarcinomas Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary o 16462152 Human
p16 sporadic breast carcinomas We have employed a novel restriction digestion based multiplex PCR assay to analyse the methylation status of promoter regions of tumor suppressor genes (p16, hMLH1, MGMT and E-cadherin) in sporadic breast carcinomas of Indian women. 16480176 Human
p16 undifferentiated carcinomas Hypermethylation of tumor suppressor and tumor-related genes, including APC, CHFR, DAP-kinase, DCC, E-cadherin, GSTP1, hMLH1, p16, PTEN, RASSF1A, RUNX3, and TSLC1, can be detected in both differentiated and undifferentiated carcinomas at varying frequenci 16482617 Human
p16 mpnst We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. 16510576 Human
p16 xeroderma pigmentosum Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. 16510579 Human
p16 cervical squamous intraepithelial lesions BACKGROUND/AIM: It is generally assumed that similar pathways are involved in human papillomavirus (HPV) induced pathogenesis of cervical squamous intraepithelial lesions (SILs) and cancers and a subset of conjunctival intraepithelial neoplasm (CIN)-that 16540490 Human
p16 pleural mesotheliomas Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. 16540645 Human
p16 villous adenomas METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30). 16575619 Human
p16 colorectal neoplasms CONCLUSIONS: Despite both p16 and p53 having been detected in colorectal neoplasms, they were not related to the different histologic variables nor to the expression of p63. 16575619 Human
p16 pancreatic ductal adenocarcinoma Activating KRAS mutations and p16(Ink4a) inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC). 16585505 Human
p16 stage i non-small cell lung cancer Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer. 16618724 Human
p16 stage i nsclc In conclusion, the present study suggests that cohypermethylation of p16 and FHIT genes in patients with stage I NSCLC may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease. 16618724 Human
p16 atypical endometrial hyperplasia MATERIALS AND METHODS: Hypermethylation in the promoter region of the p16 gene and the expression of the p16 protein in 51 specimens, including 8 endometrial cancer cell lines, 7 normal endometrial tissues, 12 atypical endometrial hyperplasia tissues and 16619479 Human
p16 carcinosarcoma In total, 92% of serous carcinomas expressed p16 strongly compared to weak-to-moderate expression of p16 in 7-67% of other tumors (FIGO grades 1 and 2 carcinoma and carcinosarcoma, respectively). 16648864 Human
p16 serous carcinomas In total, 92% of serous carcinomas expressed p16 strongly compared to weak-to-moderate expression of p16 in 7-67% of other tumors (FIGO grades 1 and 2 carcinoma and carcinosarcoma, respectively). 16648864 Human
p16 breast tumor These results demonstrate a causal role of p16(INK4A) disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression. 16766534 Human
p16 cin 3 There was no observed association of methylation of the p16INK4a gene with either CIN grading (P=0.0698) or HPV status (P=0.2811): specifically 42.9% (3/7) was found in CIN 1, 57.1% (8/14) in CIN 2, and 52.9% (9/17) in CIN 3. 16778587 Human
p16 leukoplakia of buccal mucosa RESULTS: The methylation of p16 gene was found in 15 of 30 cases SCC and 1 of 10 cases of leukoplakia of buccal mucosa (P < 0.05). 16784614 Human
p16 scc of buccal mucosa Methylation of p16 gene in SCC of buccal mucosa was not related with age, sex, cell differentiation and clinical stage. 16784614 Human
p16 scc of buccal mucosa CONCLUSIONS: The methylation of p16 gene leaded to the inactivation of p16 gene and was related with the carcinogenesis and progress of SCC of buccal mucosa. 16784614 Human
p16 monocytic leukemia Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. 16786142 Human
p16 tumors of the uterus Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus. 16803529 Human
p16 mmmt Five cases of recurrent uterine MMMT were examined by paraffin immunohistochemistry for the expression of p53, p16, P-cadherin, and Cerb-B2. 16803529 Human
p16 common tumor P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. 16803529 Human
p16 mmmt P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. 16803529 Human
p16 oral tumour As proof of principle, we illustrate MEP using assays of p16 and cyclin A1 promoters in a methylated DNA dilution matrix and also in a clinical setting using paired saliva and oral tumour specimens. 16807314 Human
p16 condylomas After discrepancies were resolved and concurrence was achieved by at least 2 of 3 reviewing pathologists, the diagnoses were as follows: 37 negative, 12 condylomas without overt dysplasia, 14 AIN I, 25 AIN II, and 16 AIN III. p16 and Ki67 expression was e 16819320 Human
p16 condylomas None of the condylomas and only 1 of the negative cases showed a band of p16 positive staining. 16819320 Human
p16 adenomatous polyps We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human non-neoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon. 16820927 Human
p16 squamous cell carcinoma of the endometrium p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. 16844559 Human
arf childhood ependymomas PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
arf ependymoma PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
arf ependymomas PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet 16086408 Human
arf round cell liposarcoma Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. 16177957 Human
arf lung adenomas Lung adenomas exhibited a 50% decrease and a 35-fold increase in expression of Rb and p19/ARF mRNA, respectively. 16424006 Human
arf skin tumors Induction of Nevi and Skin Tumors in Ink4a/Arf Xpa Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures. 16510579 Mouse
arf round cell liposarcoma Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. 16622896 Human
arf supratentorial pnet High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. 16623784 Human
arf histiocytic sarcoma The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. 16697958 Human
arf malignant pleural mesothelioma p53-Induced Apoptosis Occurs in the Absence of p14(ARF) in Malignant Pleural Mesothelioma. 16867217 Human
arf malignant pleural mesotheliomas Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. 16867217 Human
ink4 cervical squamous intraepithelial lesions BACKGROUND/AIM: It is generally assumed that similar pathways are involved in human papillomavirus (HPV) induced pathogenesis of cervical squamous intraepithelial lesions (SILs) and cancers and a subset of conjunctival intraepithelial neoplasm (CIN)-that 16540490 Human
cdkn2a recurrent carcinoma The results showed that a considerable frequency (35%, 7 of 20) of CDKN2A methylation was present in histologically negative margins, and methylation pattern analysis might be valuable for studying the cellular origin of recurrent carcinoma. 16269133 Human
cdkn2a acute promyelocytic leukaemia Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide. 16351640 Human
cdkn2a pleural mesotheliomas Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. 16540645 Human
cdkn2a urothelial cell carcinoma (ucc) The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. 16619045 Human
cdkn2a advanced cancers Comparative mutational profiling for different genomic loci [1p36(CCM = cutaneous malignant melanoma], 3p26(OGGI = 8 oxoguanine DNA glycosylase), 5q23 (APC, MCC = mutated in colorectal cancer), 9p21(p16/CDKN2A = cyclin-dependent kinase 2A), 10q23(PTEN = p 16719202 Human
cdkn2a supratentorial primitive neuroectodermal tumor In addition, one supratentorial primitive neuroectodermal tumor had lost both copies of the tumor-suppressor genes CDKN2A and CDKN2B. 16783165 Human
cdkn2a adenomatous polyps We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human non-neoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon. 16820927 Human
p16ink4a cervical intraepithelial neoplasia grade 1 We evaluated the expression of HSP40, HSP60, HSP70, and HSP90 in normal tissues (N=30), in cervical intraepithelial neoplasia grade 1 (CIN1)(synonymous with productive HPV infections) (N=32), and in CIN3 (cervical precancer)(N=25) by immunohistochemistry 16112431 Human
p16ink4a neuroendocrine tumor Of all seven markers tested for, p16INK4A methylation was observed in both components of one composite carcinoma and hMLH1 was methylated in the neuroendocrine tumor component within the same tumor. 16218931 Human
p16ink4a rhabdoid tumor Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. hSNF5, the smallest member of the SWI/SNF chromatin remodeling complex, is lost in most malignant rhabd 16288006 Human
p16ink4a squamous cervical cancer It was shown that the expression of p16ink4a in the squamous cervical cancer was induced by HPV. 16637315 Human
p16ink4 cervical squamous intraepithelial lesion Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion. 16540490 Human
p14 primary endometrial squamous cell carcinoma The purpose of this study was to evaluate the role of p14, p16, p53, cyclin D1, steroid hormone receptors, and human papillomaviruses (HPV) infection in the pathogenesis of primary endometrial squamous cell carcinoma. 16844559 Human
ink4a early lung cancer Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val 16152615 Human
ink4a nevi and melanomas Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. 16510579 Human
ink4a nonsmall cell lung carcinoma The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. 16598757 Human
p16 ii lung cancer In stage I and II lung cancer, the obvious inactivation rate of the tumor suppressor gene p16 or RB was 32.6% or 28.3%. 11832187 Human
p16 salivary adenoid cystic carcinoma p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83. 15953919 Human
p16 salivary adenoid cystic carcinoma (sacc) OBJECTIVE: This study aimed to determine the growth inhibitory effects of transfecting the wild-type p16 gene into human salivary adenoid cystic carcinoma (SACC) cells in vitro. 15953919 Human
p16 salivary adenoid cystic carcinoma CONCLUSION: The study confirmed the reversal effect of wild-type p16 on malignant phenotype of the salivary adenoid cystic carcinoma and provides valuable data for further clinical trial of gene therapy with p16. 15953919 Human
p16 early lung cancer Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val 16152615 Human
p16 cardiac carcinomas Results: The C/G genotype of p16 was identified in 10.4% of esophageal carcinomas, 13.3% of cardiac carcinomas, and in 14.1% of gastric carcinomas, compared to 17.4% in the healthy control group. 16163549 Human
p16 early invasive cervical cancers Methods: Peripheral blood samples and cervical tissues, from 36 cervical tissues from high-grade squamous intraepithelial lesions (HSIL) and 31 early invasive cervical cancers (EICC), were analyzed for HPV 16/18 DNA and HPV 16/18 E7 mRNA expression, as we 16289504 Human
p16 nevi and melanomas Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. 16510579 Human
p16 nonsmall cell lung carcinoma The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. 16598757 Human
p16 condyloma Spotty p16 immunoreactivity was observed in 8.1% negative, 8.3% condyloma, 14.3% AIN I, 12.0% AIN II, and 12.5% AIN III cases. 16819320 Human
p16 primary endometrial squamous cell carcinoma The purpose of this study was to evaluate the role of p14, p16, p53, cyclin D1, steroid hormone receptors, and human papillomaviruses (HPV) infection in the pathogenesis of primary endometrial squamous cell carcinoma. 16844559 Human
p16ink4a malignant rhabdoid tumors (mrt) Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. hSNF5, the smallest member of the SWI/SNF chromatin remodeling complex, is lost in most malignant rhabd 16288006 Human
p16ink4a breast cancer metastases Expression of Retinoblastoma Protein in Breast Cancer Metastases to Sentinel Nodes: Evaluation of its Role as a Marker for the Presence of Metastases in Non-Sentinel Axillary Nodes, and Comparison to p16INK4a. 16540733 Human
p16ink4a nevi and melanomas Atypical nevi have been clinically considered to be precursors of melanoma, and recently, biochemical abnormalities have been found that are present in both nevi and melanomas, including inactivation of the p16INK4a tumor suppressor gene and mutations in 16924053 Human
mts1 solid tumors Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. 8521382 Human
cdkn2 solid tumors Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. 8521382 Human
p16 npc These findings suggest that complete inactivation of the p16 gene may play a role in the development of NPC. 7743498 Human
p16 npc In the NPC xenograft (xeno-666) and its newly derived cell line (cell-666), both showing hypermethylation of the p16 gene, no p16 gene expression was found. 8665502 Human
p16 pre-cancerous lesions In the pre-cancerous lesions, Waf1p21 and pRb were detected in cells surrounding the top of the lesioned region, p16-positive cells were scattered in the basal cell hyperplastic and dysplastic lesions and p53-positive cells existed in 2 distinct patterns: 9311588 Human
p16 mantle cell lymphoma Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. 9377576 Human
p16 diffuse large cell lymphomas All but 3 of the RB- and p16-negative cases were diffuse large cell lymphomas, for an abnormality rate of 55% in this category. 9620022 Human
p16 nodular melanomas Eighteen of 26 (69%) superficial spreading melanomas, 17 of 28 (61%) nodular melanomas, all of three lentigo maligna melanomas, and all of five melanoma metastases were found to harbor less than 10% p16-positive tumor cells. 9694617 Human
p16 lentigo maligna melanomas Eighteen of 26 (69%) superficial spreading melanomas, 17 of 28 (61%) nodular melanomas, all of three lentigo maligna melanomas, and all of five melanoma metastases were found to harbor less than 10% p16-positive tumor cells. 9694617 Human
p16 neuroblastoma We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. 9872329 Human
p16 invasive breast carcinomas Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. 9990866 Human
p16ink4a erythroleukemia In mouse MEL erythroleukemia cells, p16INK4a associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. 7651726 Mouse
p16ink4a tumor-specific antigen These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a. 7652577 Human
p16ink4a solid tumors Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. 8521382 Human
cdkn2a cancerous lesions Point mutations of p16(CDKN2A) exon 1 were found in all of the precancerous and cancerous lesions. 17091472 Human
p14arf stage i adenocarcinoma of the lung In this pathway, the immunohistochemical profile of p14ARF-negative/MDM2-positive/p53-negative is characteristic of stage I adenocarcinoma of the lung. 11940214 Human
p14arf renal carcinoma It has recently been suggested that p53 function is unusually compromised in renal carcinoma cells by a novel dominant, MDM2/p14ARF-independent mechanism. 16061625 Human
p14arf round cell liposarcoma Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. 16622896 Human
p14arf common tumor Knowledge of the roles of proteins that are abnormally suppressed or activated due to mutation in the DNA sequences of the common tumor suppressor genes, p14ARF and p53, is critical to the understanding the pathogenesis of breast cancer. 16919268 Human
p14 tumor antigens These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)gene 15192787 Human
p14 colorectal tumours The MethyLight assay was used to provide quantitative estimates of MLH1, P16, TIMP3, P14, DAPK and APC methylation levels in 199 unselected colorectal tumours. 16981189 Human
p14 nervous system tumors Alterations in the p14(ARF) tumor suppressor are frequent in many human cancers and are associated with susceptibility to melanoma, pancreatic cancer, and nervous system tumors. 17035234 Human
p14 papillary carcinomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14 follicular adenomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14 oncocytic adenomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14 follicular carcinomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
p14 papillary carcinomas In all histological types, except papillary carcinomas, we observed a statistically significant relationship between p14ARF and E2F1 (r=0.64 to 1, P<0.05). 17117177 Human
mts1 carcinogenesis Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
mts1 invasive breast cancers [Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance] OBJECTIVE: The purpose of the present study was to explore the expr 17147116 Human
mts1 primary invasive breast cancers METHODS: Flow cytometry was used to analyze the expression level of MTS1 and COX-2 in cancer tissues and corresponding para-cancer tissues from 66 cases of primary invasive breast cancers. 17147116 Human
ink4a xeroderma pigmentosum Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients. 11078762 Human
ink4a xeroderma pigmentosum (xp) We examined the frequency of INK4a-ARF, p53, and CDK4 mutations in skin carcinomas from patients with xeroderma pigmentosum (XP), a rare autosomal disease that is associated with a defect in DNA repair and that predisposes patients to skin cancer. 11078762 Human
ink4a hepatocarcinogenesis The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis. 11704835 Human
ink4a rms Here we show that simultaneous loss of Ink4a/Arf function and disruption of c-Met signaling in Ink4a/Arf(-/-) mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. 12368906 Mouse
ink4a rms Our data indicate that human c-MET and INK4a/ARF, situated at the nexus of pathways regulating myogenic growth and differentiation, represent critical targets in RMS pathogenesis. 12368906 Human
ink4a pleomorphic adenoma of the parotid gland Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. 12375265 Human
ink4a angiosarcoma of the liver This study was done to investigate the contribution of the INK4a-ARF locus in tumorigenesis of angiosarcoma of the liver. 12378512 Human
ink4a angiosarcoma of the liver In conclusion, our data indicate that the INK4a-ARF locus is frequently inactivated in angiosarcoma of the liver and occurs independently of p53 mutations. 12378512 Human
ink4a xeroderma pigmentosum group c Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. 12485439 Human
ink4a xeroderma pigmentosum An elevated proportion of tumors from xeroderma pigmentosum patients harbor ultraviolet-induced mutations (CC:GG > TT:AA tandem transitions) of the p53 and/or the INK4a-ARF genes. 12485439 Human
ink4a atypical fibroxanthoma Single strand conformation polymorphism and sequencing analysis of the p53 and INK4a-ARF genes were carried out in DNA from normal skin and different tumors (four actinic keratosis, two microinvasive squamous cell carcinomas, one basal cell carcinoma, and 12485439 Human
ink4a xeroderma pigmentosum After characterization of the xeroderma pigmentosum C complementation group, we found unexpectedly that this patient also carried a germline mutation of the INK4a-ARF locus affecting the p16INK4A reading frame. 12485439 Human
ink4a xeroderma pigmentosum Furthermore, this study confirms that concomitant somatic mutations of INK4a-ARF and p53 occur in some xeroderma pigmentosum associated tumors, and seem to accumulate during tumor progression rather than the initiation step. 12485439 Human
ink4a rms We used cDNA microarray analysis of RMS cell lines, derived from Ink4a/Arf-deficient mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF), to identify a set of genes whose expression was significantly different between highly and poorly me 14704789 Mouse
ink4a skin tumors This study demonstrates for the first time UV-induced mutations of INK4a-ARF that occur in a small percentage in late stages skin tumors. 15057871 Human
ink4a carcinogenesis Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de 15161057 Human
ink4a barrett's adenocarcinoma INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. 15185075 Human
ink4a tumor antigens These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)gene 15192787 Human
ink4a skin tumor In conclusion, molecular analysis using a combination of p53 and INK4a-ARF mutation analysis can identify the corresponding primary skin tumor in case of CSCC metastases in the majority of cases. 15613867 Human
ink4a skin tumors The high level of ras oncogene activation, Ink4a-Arf and p53 tumor suppressor gene modifications as well as alterations of the different partners of the mitogenic sonic hedgehog signaling pathway (patched, smoothened and sonic hedgehog), characterized in 15748637 Human
ink4a cancerous lesions The aim was to investigate in biopsies the expression of p16(INK4a) of normal uterine cervical tissue, pre-cancerous and cancerous lesions, and their relation with human papilloma virus (HPV) and HIV status. 16376485 Human
ink4a uterine cervical cancers [Study of p16(INK4A) expression and DNA ploidy in HPV-negative cervical cancers and precursors] OBJECTIVE: To investigate the clinicopathological significance of p16(INK4A) expression and DNA ploidy status in HPV-negative uterine cervical cancers and thei 17069677 Human
ink4a colorectal adenomas Here, we show that, in a series of human colorectal adenomas, those with deregulation of cyclin D1 and/or p16(Ink4a) showed little evidence of constitutive DNA damage response (DDR), contrary to cyclin E-overexpressing higher-grade cases. 17079443 Human
ink4a oncocytic adenomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
ink4a follicular carcinomas Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. 17117177 Human
tp16 schwannomas METHODS: The methylation status of 16 tumor-related genes including RASSF1A, RAR-B, VHL, PTEN, HMLH1, RB1, TP16, CASP8, ER, TIMP3, MGMT, DAPK, TP73, GSTP1, TP14, and THBS1 was examined in a series of 22 vestibular schwannomas.The bisulfite modification of 16983315 Human
cdkn2 childhood chronic myeloid leukemia Here we report th